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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease 
characterized by a loss of voluntary movement over time, leading to paralysis 
and death. While 10% of ALS cases are inherited or familial (FALS), the majority 
of cases (90%) are sporadic (SALS) with unknown etiology. Approximately 20% 
of FALS cases are genetically linked to a mutation in the anti-oxidizing enzyme, 
superoxide dismutase (SOD1). SALS and FALS are clinically indistinguishable, 
suggesting a common pathogenic mechanism exists for both types. Since such a 
large number of genetic mutations in SOD1 result in FALS (>170), it is 
reasonable to suspect that non-genetic modifications to SOD1 induce structural 
perturbations that result in ALS pathology as well. In fact, misfolded SOD1 
lacking any genetic mutation was identified in end stage spinal cord tissues of 
SALS patients using misfolded SOD1-specific antibodies. In addition, this 
misfolded WT SOD1 found in SALS tissue inhibits axonal transport in vitro, 
supporting the notion that misfolded WT SOD1 exhibits toxic properties like that 
of FALS-linked SOD1.  Indeed, aberrant post-translational modifications, such as 
oxidation, cause WT SOD1 to mimic the toxic properties of FALS-linked mutant 
SOD1. Based on these data, I hypothesize that modified, misfolded forms of WT 
SOD1 contribute to SALS disease progression in a manner similar to FALS-
linked mutant SOD1 in FALS. The work presented in this dissertation supports 
this hypothesis. Specifically, one common misfolded form of SOD1 is defined and 
exposure of this toxic region is shown to enhance SOD1 toxicity. Preventing 
vii
exposure, or perhaps stabilization, of this “toxic” region is a potential therapeutic 
target for a subset of both familial and sporadic ALS patients. Further, the 
possibility of exploiting this misfolded SOD1 species as a biomarker is explored. 
For example, an over-oxidized SOD1 species was identified in peripheral blood 
mononuclear cells (PBMCs) from SALS patients that is reduced in controls. 
Moreover, 2-dimensional gel electrophoresis revealed a more negatively charged 
species of SOD1 in PBMCs of healthy controls greatly reduced in SALS patients. 
This species is hypothesized to be involved in the degradation of SOD1, further 
implicating both misfolded SOD1 and altered protein homeostasis in ALS 
pathogenesis.  
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1CHAPTER I: INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) 
Clinical Overview 
  Amyotrophic Lateral Sclerosis (ALS) is a debilitating neurodegenerative 
disease with 5,000 new cases diagnosed each year in the United States 
(http://wwwn.cdc.gov/ALS/). Conditions begin mildly, with onset occurring either 
as bulbar or limb with a slight male preference (1.5:1, (Yoshida et al. 1986)).
Bulbar onset starts with difficulty swallowing and/or chewing as where limb onset 
tends to be realized when the patient trips and/or falls from muscle weakness in 
the legs (Kiernan et al. 2011). The mild muscle weakness quickly progresses to a 
gross loss of voluntary muscle movement (e.g., walking, speaking, breathing). 
Like Alzheimer’s disease, ALS primarily effects the aging population with an 
average onset of 60, but there are also earlier documented cases with an onset 
as young as 25 years of age. Some patients can live for decades with this 
disease, but typically ALS progresses fast, with death occurring within 3-5 years 
of diagnosis.  
An overlooked aspect of the disease is the intense pain that the majority of 
patients experience during progression. This pain is a side effect of the neuronal 
death and muscle wasting known to occur in ALS pathogenesis and is caused by 
such symptoms as joint inflammation and muscle cramping (Handy et al. 2011). 
Medication directed at calming muscle spasms, such as Baclofen are prescribed 
in some cases. Unfortunately, even though medications are prescribed to deal 
2with many of the symptoms associated with ALS, such as depression, sialorrhea, 
muscle cramping and stiffness, studies directed at finding better treatments for 
these symptoms are lacking (Radunovic et al. 2007, Nakamura et al. 2012). The 
only FDA approved drug aimed directly at slowing the progression of ALS is 
Riluzole, extending survival by a mere 3 months (Miller et al. 2012). The ALS 
community is starving for more effective treatments of this devastating disease. 
Genetic and Environmental Factors 
  Approximately 10% of cases are inherited, or familial (FALS), while the 
remaining 90% are sporadic (SALS), the majority with unknown etiology. 
However, the genetic causes of FALS cases are largely known. These FALS-
linked genetic mutations are found in genes such as C9ORF72 (40%, (Dejesus-
Hernandez et al. 2011, Renton et al. 2011)), SOD1 (15%, (Rosen et al. 1993)), 
TARDBP (4%,(Sreedharan et al. 2008)), and FUS (4%, (Kwiatkowski et al. 2009, 
Vance et al. 2009, Renton et al. 2014)). The first genetic link to ALS, discovered 
in 1993, were mutations in SOD1 on chromosome 21. Currently, the most 
prevalent genetic mutation that results in FALS pathology is hexanucleotide 
expansions in C9ORF72, which is thought to contribute to ~40% of FALS cases 
(Dejesus-Hernandez et al. 2011, Renton et al. 2011). This mutation is an intronic 
repeat with multiple modes of disease pathogenicity proposed, such as an 
unknown loss of function mechanism, unconventional repeat associated non-
ATG (RAN) translation of the expansion and toxicity of the dipeptide product, and 
RNA toxicity via RNA foci sequestering RNA binding proteins (Rohrer et al. 
32015). C9orf72 hexanucleotide expansions are also the cause of a subset of 
frontotemporal lobar dementia (FTLD) cases. Why in some cases this expansion 
results in ALS, some FTLD, and some both is unknown at this time (Cruts et al. 
2013). Even within the same family, some members can develop FTLD while 
others present with ALS, highlighting the complexity of disease pathogenesis. 
A “two hit” hypothesis has been put forward for the development of both 
SALS and FALS. This hypothesis proposes that some individuals have a 
predisposition to develop ALS, but require a “second hit” such as brain injury, 
environmental toxins, etc. to develop disease. A debated issue in the field is 
whether or not traumatic brain injury increases the likelihood of developing ALS 
in the future (Pearce et al. 2015). Multiple studies have shown a link between 
repeated brain injury in sports, e.g., football, soccer and boxing, and the 
development of ALS (Lehman et al. 2012, Kuwahara and Sato 2013). There have 
also been contradicting reports that show no correlation between brain injury and 
ALS (Beghi et al. 2010, Turner M. R. et al. 2010). In fact, it has been postulated 
that the link between professional athletes and ALS may be more tightly linked to 
the performance enhancing drugs frequently used among them and not the head 
injury itself (Pearce et al. 2015). 
Supporting the “two hit” hypothesis, there are subpopulations with higher 
frequency of ALS occurrence, likely due to exposure to environmental chemical 
toxins. One such example is the Gulf War veterans deployed in the Gulf Region 
4who had a 2-fold increase in the likelihood of developing ALS (Haley 2003a, 
Horner et al. 2003). The increased susceptibility of Gulf War veterans to develop 
disease extended far beyond ALS, with 21% experiencing some type of military-
linked disease (Haley 2003b). One theory proposed for this increase is exposure 
to chemical warfare agents such as sarin, an organophosphate nerve agent 
(Haley et al. 1999, Haley 2003b). This theory has been supported by data 
showing altered concentrations of paraoxanases in sera of these veterans, which 
are a group of enzymes involved in hydrolysis of organophosphates (Haley et al. 
1999).  
Insights into Disease Pathogenesis and Mechanism 
  ALS is a multifaceted disease involving among others, mitochondrial 
dysfunction, protein aggregation, protein clearance deficits, chronic inflammation, 
oxidative stress and excitotoxicity (Barber and Shaw 2010, Sreedharan and 
Brown 2013). Pinpointing the aspects that are causative in disease, and not 
simply a byproduct or coping mechanism, has proved challenging. ALS is 
characterized by severe neuronal loss in the spinal cord and motor cortex 
(Kawamata et al. 1992).  Ubiquitinated inclusions are typically found in end-stage 
neuronal tissue, specifically in neurons and surrounding glia (Nakano et al. 2004, 
Mackenzie and Feldman 2005, Mendonca et al. 2006). P62, a ubiquitin binding 
protein, localizes to these inclusions as well (Nakano et al. 2004, Maekawa et al. 
2009, Braak et al. 2010). The presence of both ubiquitin and p62 implicate 
defective protein clearance mechanisms in disease, as both proteins are 
5associated with targeting proteins for degradation. Another common component 
of these inclusions found in ALS is TDP-43 (Maekawa et al. 2009). TDP-43-
containing inclusions are not unique to ALS, but are also found in the closely 
linked FTLD. In fact, approximately 5% of ALS patients have FTLD as well 
(Neumann et al. 2006, Maekawa et al. 2009), with evidence of some level of 
cognitive impairment seen in 50% of ALS patients (Ringholz et al. 2005, Rusina 
et al. 2010, Rohrer et al. 2015).  
A chronic state of inflammation is evident both in biofluids, such as CSF 
and blood (Zhang R. et al. 2005, Kuhle et al. 2009, Zhang R. et al. 2009, Fiala et 
al. 2010) as well as in the CNS of patients (Turner M. R. et al. 2004). For 
example, spinal cord tissue from end-stage ALS patients show enhanced 
microglia activation (Kawamata et al. 1992). In fact, PET imaging technologies 
are able to detect an increase in microglial activation in the brain of living ALS 
patients (Turner M. R. et al. 2004). Further, CD4+ and CD8+ lymphocytes are 
increased in the brain of ALS patients (Kawamata et al. 1992). In the CSF, the 
proinflammatory cytokines MCP-1 and IL-8 are upregulated (Kuhle et al. 2009). 
In sera, the proinflammatory cytokine IL-17A is upregulated (Fiala et al. 2010). 
The cause of this state of chronic inflammation is unknown, but there is evidence 
for an increase in the endotoxin level in the plasma of ALS patients (Zhang R. et 
al. 2009), which is a potent activator of the immune system. Interestingly, the 
chronic injection of endotoxin decreases survival in an ALS mouse model 
(Nguyen et al. 2004), suggesting the presence of endotoxin in ALS patients may 
6exacerbate disease. Moreover, FALS-linked proteins are prone to misfold and 
aggregate which, in turn, induces pro-inflammatory responses both in vitro and in 
ALS mouse models (Di Giorgio et al. 2008, Zhao et al. 2010, Haidet-Phillips et al. 
2011, Butovsky et al. 2012). These data suggest that FALS-linked proteins may 
directly induce the chronic neuroinflammation observed in patients.  
ALS mouse models show increased survival when treated with 
inflammatory modulators, arguing for a link between chronic inflammation and 
ALS progression (Tikka et al. 2001, Drachman et al. 2002, Kriz et al. 2002, Van 
Den Bosch et al. 2002). Minocycline, for example, inhibits microglia activation 
and proliferation and extends survival in ALS mouse models (Tikka et al. 2001, 
Kriz et al. 2002, Van Den Bosch et al. 2002). Disheartening clinical trials of 
minocycline treatment in patients, however, failed to recapitulate the mouse 
models and, in contrast, seemed to exacerbate disease (Gordon et al. 2007). 
Nonetheless, glial cells, such as astrocytes and microglia, activated by ALS-
linked proteins have proved toxic to motor neurons in vitro (Di Giorgio et al. 2008, 
Zhao et al. 2010, Haidet-Phillips et al. 2011), supporting the notion that gliosis is 
involved in pathogenesis. Alternatively, the state of neuroinflammation in ALS 
could be a protective mechanism. Astrocytes are involved in supporting and 
maintaining the extracellular environment of the CNS (Rothstein et al. 1996). 
Microglia are thought of as the “macrophage” of the CNS, where they protect the 
neuronal network through constant perusal and clearance of cellular debris 
and/or foreign material through phagocytosis. In their activated state, microglia 
7function as antigen-presenting cells that jumpstart the immune response and 
even promote repair of neuronal tissue in their post-inflammatory state (Graeber 
2010). In support of this, wild-type bone marrow transplanted into ALS mouse 
models lacking myeloid and lymphoid cell lineages extends survival by providing 
functional microglia (Beers et al. 2006). In fact, it is quite likely that the initial state 
of neuroinflammation is protective and switches to neurotoxic at later stages of 
disease (Liao et al. 2012).  
It is becoming increasingly clear that ALS occurs via a non-cell 
autonomous mechanism where non-neuronal cell types, such as glia, are 
implicated in pathogenesis. Transgenic mouse models with selective expression 
of ALS-linked SOD1 in different cell types elucidate the non cell-autonomous 
nature of ALS pathogenesis. A huge limit of developing mouse models with cell 
type-specific expression, however, is the dynamic nature of SOD1. SOD1 is a 
secreted protein, and as such, expression in a single cell type does not translate 
to mutant SOD1 being present only in that cell type (Mondola et al. 1996, 
Mondola et al. 1998, Cimini et al. 2002, Mondola et al. 2003). Conversely, 
excluding a specific cell type from SOD1 expression does not necessarily mean 
that the cell type is not exposed to SOD1. In the case of SOD1, this is 
exceedingly clear since multiple cell types have the ability to both secrete and 
uptake extracellular SOD1 (Mondola et al. 1996, Mondola et al. 1998, Cimini et 
al. 2002, Mondola et al. 2003, Turner B. J. et al. 2005, Grad et al. 2011, Munch 
et al. 2011, Sundaramoorthy et al. 2013). This could be one reason exclusive 
8expression in the skeletal muscle, for example, is adequate for inducing muscle 
atrophy, neuron degeneration and oxidative stress (Dobrowolny et al. 2008, 
Wong M. and Martin 2010). However, sole expression of ALS-linked mutant 
SOD1 in astrocytes of transgenic mice does not induce an ALS-like phenotype, 
although mild astrogliosis is observed (Gong et al. 2000). In contrast, when ALS-
linked SOD1 expression is reduced in the astrocytes of ALS mouse models, 
survival is extended by 60 days (Yamanaka et al. 2008). The protection observed 
appears to be through the reduction of microgliosis, as astrogliosis is unaltered in 
this model. Astrocytes and microglia expressing ALS-linked proteins have been 
shown to be toxic to cultured neurons in vitro (Di Giorgio et al. 2007, Nagai et al. 
2007). These data support that glia are not the only culprit in this complex 
disease, but are actively involved in disease progression (Rossi et al. 2008, 
Yamanaka et al. 2008).  
 In the healthy CNS, a protective role for astrocytes in neuronal survival 
has been well established (Rothstein et al. 1996). Astrocytes are actively 
involved in protection from neuronal death by excitotoxicity (Rothstein et al. 1996, 
Schousboe and Waagepetersen 2005, Yi and Hazell 2006), a function that might 
be lacking in ALS-linked astrocytes. Excitotoxicity, which is a toxic calcium influx 
caused by the overstimulation of cells by excessive glutamate, is heavily 
implicated in ALS pathogenesis. GLT-1 (a.k.a. EAAT2), a glutamate transporter 
preferentially expressed by astrocytes in the CNS that is responsible for the 
majority of glutamate uptake (Danbolt et al. 1992, Rothstein et al. 1995), is 
9involved in maintaining neuronal integrity and survival (Rothstein et al. 1996, 
Tanaka et al. 1997). Animal models lacking GLT-1 have severe neurological 
deficits (Rothstein et al. 1996, Tanaka et al. 1997). Reduced levels and activity of 
GLT-1 are seen in ALS patients, likely through a mechanism involving aberrant 
RNA processing (Rothstein et al. 1992, Rothstein et al. 1995, Lin et al. 1998). 
Moreover, an increase of glutamate, a side effect of reduced GLT-1 expression, 
has been found in the CSF of a subset of ALS patients (Shaw P. J. et al. 1995, 
Spreux-Varoquaux et al. 2002), supporting the notion that excitotoxicity is 
involved in disease. 
Cu, Zn-Superoxide Dismutase (SOD1) 
Structure and Function of the SOD1 Holoenzyme 
Long before SOD1 was identified as a causative factor in FALS (Rosen et 
al. 1993), the anti-oxidizing and catalytic properties of native SOD1 were being 
investigated (McCord and Fridovich 1969).  While the role of SOD1 as an anti-
oxidizing enzyme is well known and accepted, the role of SOD1 as a signaling 
molecule has been relatively underappreciated.  Herein we discuss what is 
known regarding the normal functions of SOD1 in the context of both anti-
oxidation and signaling. The normal physiological properties of SOD1 are 
discussed in order to establish a foundation for the following sections that 
describe how both FALS-linked mutations and post-translational modifications 
alter the structure and function of the protein.  
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Copper,zinc- superoxide dismutase-1 (SOD1) is a member of the human 
SOD family of proteins, which also includes SOD2 and SOD3.  While all three 
proteins function as anti-oxidizing enzymes that catalyze the dismutation of 
superoxide radicals (O2•-) to hydrogen peroxide (H2O2), they are distinct proteins 
with unique characteristics (Zelko et al. 2002).  SOD1 is highly abundant, 
comprising ~1% of total protein in the cell (Pardo et al. 1995), and resides mainly 
in the cytosol with some degree of localization in the mitochondrial inner 
membrane space (Fukai and Ushio-Fukai 2011).  The mitochondrion is also 
home to SOD2, which is localized to the mitochondrial matrix.  In contrast to both 
SOD1 and SOD2, SOD3 is predominately located outside the cell in the 
extracellular matrix.  Other key differences amongst the SOD proteins include 
their quaternary structures and mechanism of superoxide dismutation:  SOD1 is 
a homodimer while SOD2 and SOD3 are homotetrameric proteins; SOD1 and 
SOD3 catalyze the dismutation of O2•- through the alternate reduction and 
reoxidation of Cu2+, whereas SOD2 utilizes manganese (Mn) as a redox active 
transition metal for this purpose.  The role of SOD in FALS, which will be 
discussed in detail below, is specific to the SOD1 isoform as there is no 
compelling evidence supporting the involvement of either SOD2 or SOD3 in 
FALS pathogenesis (Tomkins et al. 2001). 
Normal Post-translational Modifications of SOD1 
While coordination of copper to SOD1 is required for dismutation of O2•-, other 
post-translational modifications, such as Zn2+ coordination (Kayatekin et al. 2008) 
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and disulfide oxidation, help create a mature and structurally stable protein.  The 
32 kDa homodimeric SOD1 protein adopts an eight-stranded Greek key beta-
barrel structural motif (Fig. I-1).  Two functional loops are present in SOD1: the 
electrostatic loop that guides superoxide into the redox active site where Cu2+ is 
located and the zinc-binding loop. All told, each SOD1 molecule coordinates two 
copper and two zinc atoms, one of each per subunit.  A unique functional feature 
of SOD1 is the presence of an intrasubunit disulfide bond between Cys57 and 
Cys146 (C57-C146), which is unusual for proteins that reside in the highly 
reducing environment of the cytosol.  Both copper coordination and formation of 
C57-C146 is facilitated by the cytosolic copper carrier protein CCS (copper 
chaperone for SOD1) (Furukawa et al. 2004, Seetharaman et al. 2009).  A recent 
study utilizing both electrospray ionization mass spectrometry (ESI-MS) and 
nuclear magnetic resonance (NMR) spectroscopy support a step-wise model for 
SOD1 maturation: i) SOD1 is loaded with Zn, ii) heterodimerization between 
SOD1 and CCS, iii) Cu is transferred from CCS to SOD1, iv) C57-C146 is formed 
and v) SOD1 homodimerization (Banci et al. 2012b).  Together these post-
translational modifications produce a highly stable protein, as evidenced by a 
high melting temperature (Tm) of ~92°C and resistance to denaturation in both 6 
M GdmCl and 4% SDS (Forman and Fridovich 1973, Bartnikas and Gitlin 2003, 
Chattopadhyay and Valentine 2009). Demetallation of SOD1 and/or reduction of 
C57-C146 destabilizes the protein and drastically decreases the melting  
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Figure I-1. Structural features of SOD1. (A,B) SOD1 is a homodimer with 1 
copper (orange sphere) and one zinc (blue sphere) per subunit (PDB:2C9V). 
SOD1 consists of 8 beta sheets that form the beta barrel core. An intramolecular 
disulfide bond (C57-C146; green) stabilizes the protein structure. (A) The major 
functional loops are the zinc binding loop (purple; residues 49-81) and 
electrostatic loop (yellow; residues 124-139). (B) Additional modifications that 
have been identified within native human WT SOD1 include phosphorylation 
(yellow), deamidation (blue), and cysteinylation/glutathionylation (red). 
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temperature (Forman and Fridovich 1973, Potter and Valentine 2003, Furukawa 
and O'Halloran 2005, Chattopadhyay and Valentine 2009). As will be discussed 
below, these post-translational modifications (PTMs) are compromised by both 
FALS-linked mutations and oxidation, which in turn destabilize SOD1 in the 
context of disease. 
In addition to PTMs that are directly linked to a mature, functional protein, 
other modifications have been observed within subpopulations of wild-type 
SOD1, although their functional importance has not been well established. These 
PTMs include phosphorylation, glutathionylation, cysteinylation, and deamidation 
(Fig. I-1B). Phosphorylation, a modification typically involved in switching a 
protein from an  “active” to “inactivate” state, or vice versa, has been observed in 
SOD1 isolated from erythrocytes (Wilcox et al. 2009). Although the downstream 
effects of this modification have yet to be established, the history of 
phosphorylation events in the context of other proteins suggests a functional role.  
Evidence supports a destabilization effect with the introduction of 
glutathionylation onto the side-chain of Cys111 of SOD1 (Wilcox et al. 2009). 
Glutathionylation promotes monomerization, which is thought to be a precursor of 
aggregation (Rakhit et al. 2004, Svensson et al. 2010, Redler et al. 2011). 
Nonetheless, it is found on WT SOD1 isolated from human erythrocytes from 
non-diseased individuals (Wilcox et al. 2009). In contrast, cysteinylation of 
Cys111, a modification identified within SOD1 isolated from human spinal cord 
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homogenates, protects SOD1 from subsequent oxidation (Auclair et al. 2013b). 
Although the effect of cysteinylation on inducing SOD1 aggregation has yet to be 
determined, the seemingly protective effects of cysteinylation are likely due to the 
smaller size of cysteine (121 Da), compared to the larger glutathione (307 Da) 
that impedes the beta-barrel fold and/or the dimer interface.  
A Role for SOD1 in Cell Signaling 
The physiological relevance of SOD1 catalysis extends beyond oxidative 
stress protection (as discussed in (Rotunno and Bosco 2013)).  In a zinc deficient 
environment, for example, SOD1 is implicated in regulating the ER stress 
response through a mechanism involving Derlin-1 (Homma et al. 2013). 
Moreover, SOD1 catalysis plays a key role in signal transduction, a function that 
is largely underappreciated compared to its role as an anti-oxidizing enzyme 
(Fig. I-2, Reviewed in (Rotunno and Bosco 2013)).  For instance, H2O2 
generated by SOD1 can reversibly and specifically react with proteins, generally 
by oxidizing Cys residues.  Cys oxidation in turn alters the biochemical and 
functional properties of those proteins in a redox dependent manner (Georgiou 
2002).  A variety of signal transduction pathways are modulated by H2O2, 
including but not limited to gene expression, cell proliferation, differentiation and 
death (Rhee 2006, Brown D. I. and Griendling 2009), implicating SOD1 in these 
pathways as well.  NADPH oxygenases (Nox) function as upstream regulators of 
these signal transduction pathways through the production of O2•-, which is either 
converted to H2O2 spontaneously or catalytically by SOD1.  SOD1 comes into  
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Figure I-2. The putative normal function of the native WT SOD1 protein. (1) 
SOD1 is responsible for converting the toxic superoxide anion (O2•-) into oxygen 
(O2) and hydrogen peroxide (H2O2), the latter of which is involved in the 
modulation of multiple pathways through oxidation of exposed thiols. (2) SOD1 
binds and stabilizes Rac1 in its active, GTP bound state, resulting in Nox2 (Nox) 
activation and superoxide production. The hydrogen peroxide by-product of the 
dismutase reaction of SOD1 and superoxide anion promotes the disassociation 
of SOD1 from the Rac1 complex, resulting in Nox inactivation. (3) Secreted 
SOD1 plays a role in extracellular signaling processes. The presence of 
extracellular SOD1 leads to an increase in intracellular calcium via a mechanism 
involving the phospholipase C/protein kinase C pathway. (4) In a zinc deficient 
environment, SOD1 is involved in activating the ER Stress response (reviewed in 
(Rotunno and Bosco 2013)). 
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close proximity with Nox2-derived O2•- at the surface of endosomes in response 
to proinflammatory cytokines (Harraz et al. 2008).   A report by Harraz et al. 
demonstrated that SOD1 not only acts downstream of Nox2 but can also 
modulate Nox function through an interaction with Rac1 (Harraz et al. 2008).  
SOD1 directly binds and stabilizes the active form of Rac1 in its GTP-bound 
state, leading to Nox2 activation and O2•- production. Interestingly, H2O2 
generated by SOD1 serves as a negative feedback of Nox2 activity: H2O2 
induces the dissociation of the SOD1/Rac1 complex, thereby inactivating Rac1 
and Nox2 (Harraz et al. 2008).  The mechanism for how H2O2 disrupts the 
interaction between SOD1 and Rac1 has not been elucidated. One possibility is 
that the H2O2 generated by SOD1, which is in close proximity to Rac1, oxidatively 
modifies Cys residues within Rac1 in such a way that disrupts the SOD1/Rac1 
binding interaction.   
Mechanisms of SOD1 in Familial ALS 
Evidence of Misfolding in FALS-linked Mutant SOD1  
Mutations in the SOD1 gene, located on chromosome 21, are linked to an 
estimated 20% of FALS and 3% of SALS cases. Amino acid substitutions in the 
translated protein, Cu/Zn superoxide dismutase (SOD1) are the most common 
consequence of these genetic mutations (http://alsod.iop.kcl.ac.uk/). Since the 
majority of ALS-linked mutant-SOD1 proteins maintain their dismutase activity, 
disease is thought to develop through a gain of a toxic function as opposed to 
loss of normal function. Support of this hypothesis is evident in mouse models 
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overexpressing mutant SOD1 that develop ALS-like phenotype in the presence 
of endogenous mouse SOD1 (Gurney et al. 1994, Dal Canto and Gurney 1995, 
Bruijn et al. 1997, Dal Canto and Gurney 1997, Watanabe et al. 2001). Moreover, 
mouse models lacking SOD1 do not develop an ALS-like phenotype, but do 
show signs of excessive sensitivity to neuronal damage (Reaume et al. 1996), 
reduced fertility (Ho et al. 1998), and liver cancer (Elchuri et al. 2005).   
Currently, more than 170 mutations in SOD1 have been identified as 
causative in FALS pathology (http://alsod.iop.kcl.ac.uk/).   These point mutations 
span the entire primary sequence of the SOD1 protein arguing for a global 
susceptibility of SOD1 to cause disease. The gain of toxic function involved in 
disease pathogenesis remains to be determined, but is likely a result of its 
inclination to misfold and aggregate due to the destabilization ALS-linked 
mutations impose on the protein. Molecular mechanisms involving the 
proteasome system and HDAC6 compete with accumulating aggregates in vivo, 
and in their absence, enhanced aggregation is detected (Gal et al. 2013, 
Kitamura et al. 2014).  
Supporting the notion that FALS-linked SOD1 is destabilized, a reduction 
in Tm relative to WT SOD1 is observed (Stathopulos et al. 2006, Vassall et al. 
2006).  In fact, FALS-linked SOD1 mutants are further destabilized when normal 
post-translational modifications such as Cu/Zn coordination and C57-C146 
oxidation are impaired (Furukawa and O'Halloran 2005, Rodriguez et al. 2005, 
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Kayatekin et al. 2010, Svensson et al. 2010), demonstrating interconnection 
between normal post-translational modifications and the stability of SOD1. 
Additionally, mutant SOD1 exhibits an altered tertiary structure, evidenced by 
enhanced hydrophobicity compared to WT SOD1 (Tiwari et al. 2005, Munch and 
Bertolotti 2010). While X-ray crystallography has failed to reveal significant 
structural differences between WT- and mutant-SOD1 proteins, (Hart et al. 1998, 
Elam et al. 2003, Hough et al. 2004, Cao et al. 2008, Galaleldeen et al. 2009), 
solution-based structural studies indicate that FALS-linked mutations induce 
some degree of SOD1 unfolding, or “misfolding” within the electrostatic and/or 
zinc loops. For example, NMR relaxation experiments reveal an overall increase 
in protein dynamics for SOD1 G93A compared to WT SOD1 (Shipp et al. 2003).  
The region proximal to the G93A mutation, termed the “β-barrel plug”, as well as 
residues within the zinc-binding loop exhibited the greatest increase in mobility, 
whereas the dynamics within the electrostatic loop were comparable between 
SOD1 G93A and WT (Shipp et al. 2003).  Similarly, β-strands 3 and 4, which 
contain the β-barrel plug, displayed high deuterium exchange rates as assessed 
by mass spectrometry for several demetallated mutant forms of SOD1 (Durazo et 
al. 2009). In a separate study using similar methodology but with metallated 
forms of SOD1, only 1 out of the 13 mutants exhibited relatively high deuterium 
exchange rates in the β-barrel plug (Molnar et al. 2009). However, this study 
detected a 10-31% increase in deuterium exchange within the electrostatic loop 
for 7 out of 8 “WT-like” ALS-linked SOD1 mutants (i.e., mutant-SOD1 proteins 
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that coordinate Cu and Zn), including G93A.  Deuterium exchange increased 
within both the electrostatic and zinc binding loops for those SOD1 mutants with 
impaired metal binding (Molnar et al. 2009). 
Toxic Functions of FALS-linked SOD1 
The structural perturbations present in FALS-linked SOD1 have been 
hypothesized to induce a more promiscuous protein, promoting aberrant protein-
protein interactions. In fact, multiple proteins have been identified that uniquely 
bind or demonstrate enhanced binding for FALS-linked SOD1 variants over WT 
SOD1.  These “toxic” interactions result in altered signaling pathways, 
neuroinflammation, apoptosis, axonal transport inhibition, ER stress, and calcium 
dysregulation.  
As discussed above in “A Role for SOD1 in Cell Signaling”, WT SOD1 is 
involved in the regulation of Nox2 function (Harraz et al. 2008). Altered regulation 
of Nox2 is a consequence of FALS-linked SOD1 variants. SOD1 FALS-linked 
mutants (L8Q, G93A) interfere with this process by exhibiting a tighter 
association with Rac1-GTP thereby preventing GTP hydrolysis.  The prevention 
of GTP hydrolysis results in constitutively activated Rac1 and an increase in 
Nox2 activation (Harraz et al. 2008). In turn, the cellular response to 
proinflammatory cytokines (Harraz et al. 2008) that utilizes this regulation 
mechanism, may be compromised. 
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Throughout the course of disease in SOD1 G93A transgenic mice, there is 
an increase in SOD1 associated with Bcl-2, an anti-apoptotic protein (Pasinelli et 
al. 2004). Moreover, overexpression of Bcl-2 in SOD1 G93A transgenic mice 
extends survival (Kostic et al. 1997). A study by Pedrini et al. demonstrated 
mutant SOD1-mediated mitochondrial damage only in the presence of Bcl-2 
through exposure of the toxic BH3 domain (Pedrini et al. 2010). When the BH3 
domain is exposed, Bcl-2 switches from its normal anti-apoptotic function to pro-
apoptotic, an effect likely washed out by the presence of excess anti-apoptotic 
Bcl-2 as seen in the overexpressing rescue in the G93A mouse model (Kostic et 
al. 1997).   
Transgenic mice expressing SOD1 G93A also exhibit alterations in axonal 
transport. These models have diminished fast (FAT) and slow axonal transport 
(SAT) with cargo specificity (Zhang B. et al. 1997, Williamson and Cleveland 
1999, Kieran et al. 2005, Shi P. et al. 2010). These axonal transport defects are 
seen at very early stages, as early as 13 days of gestation (Kieran et al. 2005) 
arguing for an active role of transport inhibition in the neurodegeneration 
observed during disease progression. One study utilized time lapse microscopy 
to analyze FAT in motor neurons derived from SOD1 G93A transgenic mice and 
found an 80% increase in retrograde axonal transport of mitochondria along with 
a corresponding decrease in anterograde axonal transport. Additionally, the 
study showed an inhibition of FAT of membrane bound organelles in both 
anterograde and retrograde axonal transport (De Vos et al. 2007). The dynein 
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complex, responsible for retrograde transport, was found to interact with FALS-
linked SOD1, and not the wild-type protein (Zhang F. et al. 2007).  Moreover, 
isolated squid axoplasm perfused with mutant SOD1 (H46R, G93A, G85R) 
inhibits anterograde FAT through a mechanism involving p38 kinase (Morfini G. 
A. et al. 2013). An increase in phosphorylated p38 is evident in axoplasms 
exposed to mutant SOD1 (G93A, G85R) compared to normal WT SOD1 (Morfini 
G. A. et al. 2013). This phosphorylated p38 directly inhibits Kinesin-1, a motor 
known to be involved with anterograde transport (Morfini G. A. et al. 2013).  
Neuronal cultures from SOD1 G93A transgenic mice show signs of UPR 
activation, a pathway activated in response to ER stress. These signs of UPR 
activation include activated ATF6α and spliced XBP1 (Prell et al. 2012).  In 
addition, mammalian cells expressing mutant SOD1 (A4V, G93A, G85R) in vitro 
induce ER stress via an enhanced interaction with Derlin-1 and direct inhibition of 
ER-associated degradation (ERAD). This interaction traps protein substrates 
headed for degradation by the UPS in a complex with Derlin-1, which prevents 
both ubiquitination and translocation to the cytosol (Nishitoh et al. 2008). It 
should be noted that intracellular expression of mutant SOD1 is not required to 
cause ER Stress. Another study showed extracellular WT SOD1 and SOD1 
G93A are taken up by cultured cells, the latter resulting in ER stress (Munch et 
al. 2011, Sundaramoorthy et al. 2013). The combination of mutant-SOD1 uptake 
and intracellular expression in neurons could exacerbate ER stress, thereby 
causing a switch from the UPR coping pathway to apoptosis in vivo (Mondola et 
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al. 1998, Turner B. J. et al. 2005, Urushitani et al. 2006, Polazzi et al. 2012).   
Another adverse side effect of misfolded, FALS-linked mutant SOD1 is 
altered calcium homeostasis. WT SOD1 has been shown to participate in 
calcium modulation in multiple cell culture models, even acting as a 
neuroprotectant in some instances (Carri et al. 1997, Mondola et al. 2004, Allen 
et al. 2011, Polazzi et al. 2012). Neuroblastoma cells exposed to FALS-linked 
SOD1 results in a greater increase in intracellular calcium levels compared to 
cells exposed to WT SOD1 (Carri et al. 1997, Allen et al. 2011). FALS-linked 
SOD1 has been proposed to modulate intracellular calcium by binding to the 
membrane surface and forming aberrant ion channels (Mondola et al. 2004, Allen 
et al. 2011). Moreover, in SOD1 G93A transgenic mice, spinal cord motor 
neurons have a higher level of intracellular calcium compared to non-effected 
neurons, such as oculomotor neurons (Siklos et al. 1998). Motor neurons are 
more sensitive to increased calcium levels in part because of their low cytosolic 
calcium buffering capacity coupled with a decrease in calcium binding proteins 
compared to neurons not affected throughout disease (reviewed in (von Lewinski 
and Keller 2005)). Since motor neurons are more sensitive to changes in calcium 
levels, and FALS-linked SOD1 alters these levels to a greater extent than  WT 
SOD1, loss of calcium homeostasis could be responsible for the select 
vulnerability of motor neurons in ALS.   
FALS-linked SOD1 has been implicated in inducing chronic 
neuroinflammation. Direct activation of microglia, the macrophage of the CNS, 
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via extracellular mutant SOD1 has been observed in vitro (Urushitani et al. 2006, 
Ezzi et al. 2007, Zhao et al. 2010).  The mechanism of activation involves binding 
of mutant-SOD1 to the CD14/TLR receptor, the same pathway used by a known 
proinflammatory microglia activator, LPS (Zhao et al. 2010). This activation 
results in a proinflammatory activation state (i.e. increased levels of TNFα and IL-
1β), and toxicity toward cultured motor neurons (Urushitani et al. 2006, Zhao et 
al. 2010).  
SOD1 and Sporadic ALS 
Evidence for a Role of SOD1 in SALS 
Sporadic ALS has no known etiology and is likely caused by a complex 
interplay of both genetic and environmental factors. Familial (FALS) and 
Sporadic (SALS) ALS are clinically indistinguishable, a fact that could be 
explained by a similar toxic mechanism shared between them. Evidence in other 
neurodegenerative disease supports the crossover of familial linked proteins to 
sporadic cases such as phosphorylation of α-synuclein in Parkinson’s (Beyer and 
Ariza 2013) and phosphorylation of tau in Alzheimer’s disease (Mandelkow et al. 
1996). 
Since mutations in SOD1 account for such a large portion of FALS, 20% 
of cases, we hypothesize that SOD1 plays an active role in sporadic ALS 
pathology as well. The causative role of SOD1 in FALS has been well 
established, but its role in sporadic ALS remains controversial. Accumulating 
evidence from human patient samples, however, supports a role for WT SOD1 in 
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disease. SOD1 purified from spinal cord tissue of SALS patients, for example, 
inhibits axonal transport in vitro (Bosco et al. 2010). SOD1 is also implicated by 
the presence of a hyperoxidized SOD1 species in patient derived lymphoblast 
cell lines (Guareschi et al. 2012). Further, elevated levels of antibodies toward 
anti-SOD1ox, have been detected in sera from a subset of SALS cases that 
directly correlates with survival (van Blitterswijk et al. 2011). Antibodies directed 
at aberrant forms of SOD1 would be expected to have a beneficial effect by 
neutralizing its toxic properties. Moreover, misfolded SOD1 has been detected in 
a subset of post-mortem spinal cord tissue slices from SALS patients lacking a 
mutation in SOD1 using misfolded-SOD1 specific antibodies (Table I-1, (Bosco 
et al. 2010, Forsberg et al. 2010, Pokrishevsky et al. 2012)). Many of these 
antibodies also recognize misfolded SOD1 induced by FALS-linked SOD1 
mutations, suggesting a similar misfolded conformation is shared amongst them. 
Multiple antibodies have been developed that selectively react with an 
altered tertiary structure present in misfolded SOD1 and not exposed in WT 
SOD1 (Fig. I-3, Table I-1). Such antibodies include C4F6 (Urushitani et al. 
2006), SEDI (Rakhit et al. 2007), MS785 (Fujisawa et al. 2012), and D3H5 (Gros-
Louis et al. 2010), the latter of which has extended survival in the G93A 
transgenic mouse model. Passive immunization therapies targeting select 
regions of SOD1 exposed upon misfolding have been shown to decrease the  
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Table I-1. Antibodies that recognize misfolded conformations of SOD1.  
Antibody SOD1 
epitope 
(aa) 
Reactive 
for FALS 
SOD1 
Reactive for SALS SOD1 Therapeutic 
Benefits 
Reference 
Patient 
Tissue 
Modified 
SOD1 
B8H105 57-781 + nd 2 nd Nd (Gros-Louis et al. 2010, Pickles 
et al. 2013) 
C4F65 80-118 + + + (ox) Nd (Urushitani et al. 2007, Bosco et 
al. 2010, Prudencio and 
Borchelt 2011, Brotherton et al. 
2012, Pickles et al. 2013) 
MS785 6-16 + nd +3 Nd (Fujisawa et al. 2012) 
D3H5 24-551 + nd + (apo) + (Gros-Louis et al. 2010) 
A5C35 80-1181 + nd nd - (Gros-Louis et al. 2010) 
SEDI 143-151 + - + (ox) +4 (Rakhit et al. 2007, Liu et al. 
2009, Kerman et al. 2010, 
Prudencio and Borchelt 2011, 
Liu et al. 2012, Mulligan et al. 
2012) 
USOD 42-48 + - - (ox) Nd (Kerman et al. 2010, Mulligan et 
al. 2012) 
DSE2 (3H1) 125-142 + + nd Nd (Vande Velde et al. 2008, Grad 
et al. 2011, Pokrishevsky et al. 
2012) 
4-20Ra-ab 4-20 + + nd Nd (Jonsson et al. 2004, Forsberg 
et al. 2010) 
57-72Ra-ab 57-72 + + nd Nd (Stewart et al. 2006, Forsberg 
et al. 2010, Forsberg et al. 
2011) 
131-153Ra-ab 131-153 + + nd Nd (Jonsson et al. 2004, Forsberg 
et al. 2010, Forsberg et al. 
2011) 
1Determined using similar methodology as in C4F6 epitope mapping (Bosco et al. 2010) (unpublished data, Bosco DA). 
2 nd: Not Determined 
3 Serum starvation in cultured cells results in SOD1 reactivity with antibody 
4Benefits observed from active immunization with SOD1 peptide recognized by SEDI  
5Commercially available  
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Figure I-3. Conformation specific antibodies highlight regions exposed in 
SOD1 upon misfolding. The primary sequence for WT SOD1 is shown with the 
secondary structure displayed below. The binding regions of 11 antibodies 
specific for misfolded SOD1 are depicted above the sequence (See Table I-1 for 
antibody details). 
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level of misfolded SOD1 present in the spinal cord of ALS mouse models and 
enhance survival (Gros-Louis et al. 2010). Understanding the binding interaction 
between such antibodies and SOD1 will further our understanding of how 
aberrant SOD1 is causative in disease by painting a clearer picture of the 
misfolded, toxic conformation. Further, the misfolded SOD1 species itself, once 
identified, has the potential to be a powerful biomarker for ALS. In fact, there is 
evidence that soluble misfolded WT SOD1 mimics the toxic functions and toxic 
conformation of FALS-linked SOD1 as discussed further below. 
Loss of native SOD1 PTMs Results in WT SOD1 Misfolding  
As discussed above, coordination of Zn, oxidation of the C57-C146 
intrasubunit disulfide bond and homodimerization of SOD1 contribute to the 
structural stability of the molecule. A loss in integrity of any one of these normal 
post-translational modifications compromises the stability of WT SOD1 and 
contributes to its misfolding and aggregation (Fig. I-1).   For example, a reduction 
of WT SOD1 stability upon demetallation is a widely documented observation 
(Stathopulos et al. 2003, Lynch et al. 2004, Furukawa and O'Halloran 2005, Ding 
and Dokholyan 2008). Interestingly, demetallation of WT SOD1 induces similar 
conformational perturbations within the zinc binding and the electrostatic loops 
(loops IV and VII, respectively; Fig. I-1) as do FALS-linked SOD1 mutations 
(Strange et al. 2003, Strange et al. 2007, Ding and Dokholyan 2008, Durazo et 
al. 2009, Molnar et al. 2009). A direct comparison of NMR backbone chemical 
shifts for apo dimeric WT SOD1 versus holo dimeric WT SOD1 revealed the 
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largest structural variations within the electrostatic loop (Banci et al. 2009). These 
structural alterations were accompanied by pronounced changes in backbone 
dynamics that further support demetallation-induced misfolding (Banci et al. 
2009).  Molecular dynamics (Ding and Dokholyan 2008) and H/D exchange by 
mass spectrometry (Durazo et al. 2009) also report enhanced flexibility within the 
aforementioned loops of apo WT SOD1 compared to holo SOD1, but in addition 
these studies also detect misfolding within the beta barrel of SOD1 upon 
demetallation (Ding and Dokholyan 2008, Durazo et al. 2009).  Furthermore, the 
misfolding of WT SOD1 induced by demetallation leads to aggregation of the 
protein (Banci et al. 2007), which may be driven by the exposure of hydrophobic 
regions within misfolded SOD1 that are otherwise buried in the native protein 
(Tiwari et al. 2009).   
In addition to demetallation, reduction of the C57-C146 disulfide bond also 
has a destabilizing effect on WT SOD1 that can lead to protein misfolding and 
aggregation in a manner similar to FALS-linked mutant SOD1 (Furukawa et al. 
2008, Chan et al. 2013).  Several studies have demonstrated that a reduction of 
C57-C146 in apo-SOD1 shifts the monomer-dimer equilibrium towards the 
monomeric state. Addition of zinc or oxidation of C57-C146 shifts the equilibrium 
back to the dimeric state, demonstrating interdependence between Zn 
coordination, C57-C146 bond integrity, and dimerization on the structural stability 
of SOD1 (Arnesano et al. 2004, Lindberg et al. 2004, Hornberg et al. 2007).  
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Aberrant Post-Translational Modifications Induce WT SOD1 Misfolding 
In addition to alterations of the normal post-translational modifications of 
SOD1, WT SOD1 misfolding and aggregation can be induced by the formation of 
aberrant modifications.  Oxidation of SOD1 side chains represents one such 
modification that has been postulated to play a significant causal role in both 
FALS and SALS (Kabashi et al. 2007).  However, Shaw et al. demonstrated that 
FALS-linked SOD1 transgenic mouse models have miniscule amounts of 
modified SOD1 present in the spinal cord (Shaw B. F. et al. 2008). It should be 
noted that the high amount of DTT used in the analysis would likely preclude 
detection of certain modifications present on cysteine residues, such as 
cysteinylation, oxidation and glutathionylation (Shaw B. F. et al. 2008). In the 
context of WT SOD1, which has relevance to SALS, metal catalyzed oxidation 
with CuCl2 and ascorbic acid leads to oxidative modification of SOD1 histidine 
residues and subsequent SOD1 aggregation (Rakhit et al. 2002, Rakhit et al. 
2004).  This mode of oxidation-induced SOD1 aggregation proceeds by way of 
SOD1 dimer dissociation/ monomer formation, demonstrating interdependence 
between aberrant and normal SOD1 post-translational modifications (Rakhit et al. 
2004).  Cys111 within SOD1 is particularly susceptible to H2O2 induced oxidation 
(Fig. I-1B). Prolonged exposure of SOD1 to H2O2 results in the irreversible 
conversion of the Cys111 sulfhydryl group to sulfonic acid (Fujiwara et al. 2007, 
Bosco et al. 2010, Auclair et al. 2013b), which may be detrimental since WT 
SOD1 oxidized by H2O2 (hereafter referred to as SOD1ox) exhibits an enhanced 
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propensity to misfold and aggregate (Ezzi et al. 2007, Fujiwara et al. 2007, Bosco 
et al. 2010, Chen X. et al. 2012b). Glutathionylation on Cys111 has a similar 
destabilizing effect (McAlary et al. 2013). Interestingly, modifications such as β-
mercaptoethanol (Fujiwara et al. 2007), persulfide (de Beus et al. 2004) and 
cysteinylation (Auclair et al. 2013b) on cysteine 111 protect SOD1 against 
oxidation and possibly against subsequent misfolding.  
Misfolded WT SOD1 Proteins are Toxic and Mimic FALS-linked SOD1   
In recent years, several reports have demonstrated a toxic effect of  
misfolded WT SOD1 in the context of ALS relevant pathways and processes 
(Fig. I-4).  The observation that zinc depleted WT SOD1 exerts a toxic effect onto 
motor neurons by a mechanism involving nitric oxide provided one of the first 
clues that modified WT SOD1 species are toxic and may contribute to SALS 
pathogenesis (Estevez et al. 1999, Beckman et al. 2001).  The fact that oxidation 
damages the zinc binding site of SOD1 and aging is known to result in increased 
protein oxidation, it is reasonable to suspect that zinc-deficiency plays a role in 
pathology (Smith C. D. et al. 1991, Sampson and Beckman 2001). In fact, zinc 
supplements extend survival in ALS mouse models (Ermilova et al. 2005). More 
recently, zinc- deficient SOD1 was shown to exhibit a toxic effect related to 
mitochondrial dysfunction in Drosophila (Bahadorani et al. 2013).  That metal 
deficient WT SOD1 can be induced to misfold and exhibit a toxic nature 
analogous to FALS-linked SOD1 is supported by the immunization trial in ALS 
mice  reported  by  Takeuchi  et  al.   Low  copy   SOD1 G93A   transgenic   mice  
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Figure I-4. The toxic properties shared by ALS-linked mutant SOD1 and 
modified WT SOD1. As shown, misfolded SOD1, resulting from mutations or 
aberrant post-translational modifications, causes the protein to engage in 
aberrant interactions. (1) Misfolded SOD1 is both secreted, possibly through 
chromogranins, and taken up from the extracellular environment. (2) Extracellular 
misfolded SOD1 activates microglia by binding to the CD14/TLR4 receptor, 
thereby elevating nitric oxide synthase (iNOS) activity as well as secretion of 
superoxide anion ((O2•-)) and proinflammatory cytokines (e.g., TNFα). (3) 
Expression and uptake of misfolded SOD1 leads to ER stress, which elevates 
the pro-apoptotic CHOP protein and induces mitochondrial damage. (4) The 
presence of misfolded SOD1 in the axon results in axonal transport inhibition 
through a mechanism involving the phosphorylation of p38 and the kinesin motor.  
All these aberrant functions compromise the integrity of the motor neuron, and 
potentially contribute to both FALS and SALS pathogenesis. 
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vaccinated with the apo WT SOD1 immunogen exhibited delayed disease onset 
and prolonged survival compared to control mice injected with saline/adjuvant, 
and  importantly,  to  a  similar  degree  as mice vaccinated with apo SOD1 G93A 
(Takeuchi et al. 2010).  This study also implicates WT SOD1 as a viable 
therapeutic target for SALS.   
SOD1ox also acquires aberrant protein-interactions that are observed for 
FALS-linked SOD1 mutants.  For example, SOD1ox interacts with the heat shock 
protein Hsc70 that plays a role in refolding misfolded proteins (Ezzi et al. 2007), 
the secretory protein chromogranin B that actively secretes misfolded forms of 
SOD1 (Urushitani et al. 2006, Ezzi et al. 2007), and the anti-apoptotic protein 
Bcl-2 in a manner that induces mitochondrial damage (Pasinelli et al. 2004, 
Guareschi et al. 2012).  SOD1ox was also shown to mimic FALS-linked SOD1 
mutants in the inhibition of anterograde fast axonal transport (FAT) in squid 
axoplasm.  These studies demonstrated that the inhibitory effect of SOD1ox and 
mutant SOD1 was mediated by activated p38 MAPK, indicating that misfolded 
SOD1 can trigger kinase-dependent signaling cascades (Morfini G. A. et al. 
2009, Bosco et al. 2010, Morfini G. A. et al. 2013, Song et al. 2013).  
Extracellular derived WT SOD1 can also induce a toxic effect onto cells.  
SOD1ox applied to cell culture media activates immortalized microglia (Ezzi et al. 
2007), which in turn may cause motor neuron death (Ezzi et al. 2007, Zhao et al. 
2010).  Furthermore, uptake of aggregated WT SOD1 species by 
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macropinocytosis in neuronal cells caused ER stress and seeded the 
aggregation of intracellular, endogenous SOD1 (Sundaramoorthy et al. 2013).   
Studies in various SOD1 transgenic ALS mouse models have provided 
direct evidence for WT SOD1 mediated toxicity in vivo.  Intriguingly, an ALS-like 
phenotype was only observed in transgenic mice expressing the human SOD1 
A4V variant, a mutation that corresponds to an aggressive ALS phenotype in 
humans, when these mice expressed the human WT version of SOD1 (Deng et 
al. 2006).   This paradoxical result may be explained by heterodimerization of WT 
and A4V subunits, affording a ‘stabilized’ and thus more toxic version of SOD1 
A4V that would otherwise be degraded (Witan et al. 2008, Witan et al. 2009).  A 
similar phenomenon was observed in double-transgenic mice expressing human 
SOD1 WT and G85R, where disease onset was hastened relative to single-
transgenic SOD1 G85R mice (Wang L. et al. 2009).  Recently, a transgenic 
mouse model was developed that over-expresses human WT SOD1 at similar 
levels to the established high-copy SOD1 G93A mouse model (Gurney et al. 
1994, Graffmo et al. 2013).  Compared to transgenic mice expressing fewer 
copies of the human WT SOD1 gene, the mice generated by Graffmo et al 
exhibit an ALS-like phenotype that includes significant weight loss, SOD1 
aggregation, neurodegeneration, gliosis, and a shortened life-span of 
approximately 360 days (Graffmo et al. 2013). The authors posit that the ALS-like 
phenotype is not a general effect of SOD1 overexpression per se, but rather a 
direct consequence of a substoichiometric population of misfolded SOD1.  
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Although the exact mechanism for WT SOD1 mediated toxicity is not well 
understood in these models, and the extent to which WT SOD1 is post-
translationally modified has not been addressed, these studies clearly 
demonstrate a link between WT SOD1 and motor neuron degeneration 
characteristic of ALS.   
Summary 
Misfolding of SOD1 induced by post-translational modifications and FALS-
linked mutations converge in a common pathway with overlapping toxic 
downstream events. These similarities support the hypothesis that misfolded WT 
SOD1 plays a causative role in a subset of sporadic ALS cases. In the following 
chapters, I will present one common, toxic misfolded conformation shared by 
FALS-linked SOD1 and PTM-linked SOD1 variants that I have identified using 
cross-linking and mutagenesis techniques. I have also identified a species of 
SOD1 that is present in control peripheral blood mononuclear cells (PBMCs), but 
underrepresented in SALS-derived PBMCs. Further, an over-oxidized form of 
SOD1 was identified in SALS-derived PBMCs that was less abundant in controls. 
Together, these data implicate misfolded WT SOD1 in disease, suggesting 
therapeutics that target FALS-linked SOD1 may prove beneficial to sporadic 
patients lacking a genetic mutation in SOD1 as well.  
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CHAPTER II:  IDENTIFICATION OF A MISFOLDED REGION IN SOD1 THAT 
IS EXPOSED IN ALS 
Introduction 
ALS is a fast-progressing, fatal neurodegenerative disorder that primarily 
targets motor neurons.  The complex nature of ALS represents a hurdle in 
developing effective therapies for this incurable disease. A growing list of genes 
have been linked to ALS, where mutations in SOD1, TDP-43, FUS, C9orf72 
account for >50% of inherited, or familial ALS (FALS) (Sreedharan and Brown 
2013).  However, much less is known about the cause(s) of sporadic ALS (SALS) 
that account for the majority (90%) of ALS cases (Sreedharan and Brown 2013). 
FALS and SALS are clinically indistinguishable, suggesting similar mechanisms 
are at play for both forms of this disease.  
SOD1 (Cu,Zn-superoxide dismutase) represents a factor that is common 
to FALS and SALS.  Mutations in SOD1 likely cause FALS through a gain-of-
toxic mechanism induced by a misfolded conformation of the protein (Rotunno 
and Bosco 2013). Importantly, aberrant post-translational modifications cause 
wild-type (WT) SOD1 to adapt a similar misfolded conformation (Arnesano et al. 
2004, Ezzi et al. 2007, Fujiwara et al. 2007, Ding and Dokholyan 2008, Banci et 
al. 2009, Durazo et al. 2009, Bosco et al. 2010, Chen X. et al. 2012b, Auclair et 
al. 2013b).  These observations support an emerging, albeit controversial, 
hypothesis that WT SOD1 plays a pathogenic role in a subset of SALS, 
analogous to the role of mutant-SOD1 in FALS (Rotunno and Bosco 2013).  Over 
the past several years, conformation specific antibodies have been generated 
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that are selective for misfolded SOD1 variants over the native, WT SOD1 protein 
(Rakhit et al. 2007, Urushitani et al. 2007, Vande Velde et al. 2008, Forsberg et 
al. 2010, Gros-Louis et al. 2010, Fujisawa et al. 2012), suggesting the epitopes 
for these antibodies represent pathogenic motifs within misfolded SOD1.  C4F6 
is one such conformation specific monoclonal antibody, which is reactive for 
several ALS-linked SOD1 variants (Urushitani et al. 2007, Prudencio and 
Borchelt 2011, Brotherton et al. 2012) including an oxidized form of WT SOD1 
(SOD1ox) that serves as a model protein for SALS (Bosco et al. 2010).  
Importantly, C4F6 detected misfolded SOD1 species within human post-mortem 
FALS and SALS spinal cord tissues (Bosco et al. 2010, Brotherton et al. 2012) 
and C4F6 reactivity correlated with disease progression in the spinal cords of 
SOD1 G93A transgenic mice (Brotherton et al. 2012).  That C4F6 blocked the 
inhibitory effect of misfolded SOD1 on fast axonal transport in squid axoplasm 
supports the notion that the C4F6 epitope with SOD1 confers toxicity (Bosco et 
al. 2010). Collectively, these observations indicate that the C4F6 antibody is a 
reliable reporter of pathogenic SOD1 species in ALS.  
Despite the evidence that C4F6 is selective for pathogenic SOD1 species, 
very little is known about the amino acids and structural elements that comprise 
this epitope. Therefore, we developed a chemical cross-linking, site-directed 
mutagenesis and mass spectrometry approach to define the potentially toxic 
C4F6 epitope within misfolded SOD1 proteins.  Our analyses reveal that the zinc 
binding (loop IV) and electrostatic (loop VII) loops within SOD1 mask the C4F6 
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epitope, and support a model where ALS-linked mutations destabilize loop IV 
and VII (Shipp et al. 2003, Molnar et al. 2009) thereby exposing the C4F6 
epitope. In support of this model, WT SOD1 lacking loops IV and VII 
(SOD1ΔIV/ΔVII) exhibits high reactivity with C4F6 while maintaining a relatively 
stable tertiary-fold (Danielsson et al. 2011, Danielsson et al. 2013). Exposure of 
the C4F6 epitope within SOD1ΔIV/ΔVII directly correlates with SOD1-mediated 
microglia activation, indicative of enhanced SOD1 toxicity (Ezzi et al. 2007, Zhao 
et al. 2010). These findings put forth loops IV and VII as well as the C4F6 epitope 
itself as therapeutic targets for SOD1-mediated ALS. 
Results 
C4F6 is selective for misfolded forms of SOD1 over native wild-type SOD1 
The C4F6/SOD1 binding interaction was quantified in non-denaturing conditions 
using the OCTET system, which utilizes Bio-Layer Interferometry technology to 
accurately determine binding affinities (Broering et al. 2013). No binding 
interaction was detected between C4F6 and WT SOD1; thus, the apparent 
dissociation constant (Kd) is below the limit of detection (Table II-1).  C4F6 
exhibited the tightest binding affinity for SOD1 G93A (Kd = 0.40 ± 0.29 µM), the 
immunogen for this antibody (Urushitani et al. 2007). C4F6 also recognized 
SOD1 A4V and G85R with Kd values of 1.46 ± 0.41 µM and 3.00 ± 3.83 µM, 
respectively.  Oxidation of native WT SOD1 at Cys 111 (SOD1ox) was also 
sufficient to produce a tight binding interaction with C4F6 (Kd =1.13 ± 0.60 µM). 
These  data  suggest  that  C4F6   recognizes  an  aberrant  conformation shared  
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amongst multiple misfolded SOD1 variants. 
Hot-spots for C4F6 cross-linking are located within the electrostatic and 
zinc binding loops of misfolded SOD1 variants 
We employed a chemical cross-linking strategy with native SOD1 proteins 
and C4F6 to identify the C4F6 epitope within misfolded SOD1.  Both 
dithiobis[succinimidyl propionate] (DSP; cross-links lysines and has a 12Å 
spacer) and 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC; 
cross-links lysines with glutamic or aspartic acid residues and has a 0Å spacer) 
were used independently to cross-link SOD1 proteins to the Fab fragment of 
C4F6. In the presence of DSP (Fig. II-1A) and EDC (Fig. II-1B), C4F6 cross-
linked to all tested ALS-associated SOD1 variants and SOD1ox, but not to WT 
SOD1. Although the sites of ALS-linked point mutations (e.g., A4V, G85R and 
G93A) and oxidation (e.g., C111) are in different regions of the tertiary structure 
(Fig. II-2), C4F6 binding indicates that these SOD1 variants are misfolding in a 
similar manner. 
To identify the amino acids involved in SOD1/C4F6 binding, the band 
corresponding to the cross-linked species (SOD1/C4F6*) was excised from a 
Coomassie-stained SDS-PAGE gel and subjected to tryptic digestion followed by 
mass spectrometry (MS).  The amino acid sequence for the C4F6 Fab fragment 
was   determined  using  both  mass   spectrometry  and  RNA  sequencing   (see 
Methods). To aid in DSP cross-link identification, samples were prepared with 
deuterium-labeled DSP (d8-DSP) in parallel, resulting in cross-linked peptides  
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Figure II-1. C4F6 specifically cross-links to misfolded SOD1 in the presence 
of DSP or EDC. (A) A non-reducing western analysis with pan-SOD1 (red) and 
anti-Fab (green) antibodies demonstrates the specific cross-linking with DSP 
between misfolded SOD1 variants and C4F6 Fab (SOD1/C4F6; yellow band at 
66 kDa denoted by *). HC, heavy chain; LC, light chain. (B) A band 
corresponding to the SOD1/C4F6 complex cross-linked with EDC (denoted by *) 
was detected at ~70kDa for SOD1 (G93A, G85R, ox), but not wild-type (WT) 
SOD1.  A similar SDS-PAGE and western analysis was performed as in (A), 
except a 12% gel was employed under reducing conditions. (C,D) 
Representative cross-linked peptides from a pooled (d8-DSP + DSP) sample 
where a 4.03 m/z shift was observed between the monoisotopic peaks (C, 
inset;16.13 Da mass shift/+4 charge state = 4.03 m/z) 708.07 m/z (DSP) and 
712.10 m/z (d8-DSP). Both parent ions, 712.10 m/z (C, d8-DSP) and 708.07 m/z 
(D, DSP), were subjected to MS/MS analysis and identified as residues 70-79 of 
SOD1 and residues 39-50 of C4F6. 
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Figure II-1 continued. C4F6 specifically cross-links to misfolded SOD1 in 
the presence of DSP or EDC. (C,D) Representative cross-linked peptides from 
a pooled (d8-DSP + DSP) sample where a 4.03 m/z shift was observed between 
the monoisotopic peaks (C, inset;16.13 Da mass shift/+4 charge state = 4.03 
m/z) 708.07 m/z (DSP) and 712.10 m/z (d8-DSP). Both parent ions, 712.10 m/z 
(C, d8-DSP) and 708.07 m/z (D, DSP), were subjected to MS/MS analysis and 
identified as residues 70-79 of SOD1 and residues 39-50 of C4F6. (E) Exemplar 
MS/MS data (59% sequence coverage) for an EDC cross-linked peptide 
comprised of C4F6 (residues 1-15) and SOD1 G93A (residues 123-136). (C-E) 
C4F6 (green) and SOD1 (blue) ions are depicted with the corresponding 
sequence displayed above.  Peaks with identical ions in both C4F6 and SOD1 
peptides are shown in red, where -18 corresponds to a loss of a water molecule 
for y1.  
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with an increased mass of 8.06 Da. Pooling both DSP and d8-DSP samples 
allowed for further validation of cross-linked peptides due to a charge-state 
dependent shift in the observed m/z of the parent ions. A representative cross-
linked peptide from a pooled (d8-DSP + DSP) SOD1 G93A/C4F6 sample is 
illustrated in Figure II-1C (inset) where a 4.03 m/z shift was observed between 
the monoisotopic peaks 708.07 m/z (DSP) and 712.10 m/z (d8-DSP). This mass-
shift corresponds to the theoretical mass shift of a cross-linked peptide 
containing two cross-linkers, one hydrolyzed dead-end cross-linker and one 
directly joining the peptides, with DSP compared to d8-DSP (16.13 Da mass 
shift/+4 charge state = 4.03 m/z).  Both parent ions, 712.10 m/z (d8-DSP) and 
708.07 m/z (DSP) were subjected to MS/MS analysis and identified as residues 
70-79 of SOD1 and residues 39-50 of C4F6 (Fig. II-1C,D). A representative 
cross-linked SOD1 G93A/C4F6 peptide from an EDC treated sample is illustrated 
in Figure II-1E.  
In total, 10 amino acids in SOD1 G93A were found to cross-link to C4F6, the 
majority of which fall in the zinc binding (loop IV, residues 49-81) and 
electrostatic (loop VII, residues 124-139) loops of SOD1 (Fig. II-2, Table II-2). 
Both DSP and EDC cross-link these loop regions within SOD1 G93A to C4F6 
(Fig. II-2B,C, Table II-2), demonstrating that these cross-linkers detect “hot-
spots” of C4F6 binding to SOD1 G93A.  Interestingly, C4F6-binding hot-spots 
within loops IV and VII are also detected for other misfolded SOD1 proteins, 
including apo-SOD1 and SOD1 (G85R, A4V, ox) variants (Fig. II-2C, Table II-2). 
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Misfolding of loops IV and VII within ALS-linked SOD1 variants exposes the 
C4F6 epitope 
Since loops IV and VII within SOD1 harbor the majority of amino acids 
involved in C4F6 binding (Fig. II-2), we hypothesized that the C4F6 epitope is 
located within these loops.  It follows that removal of loops IV and VII within 
misfolded SOD1 should eliminate the C4F6/SOD1 interaction.  Loop-deletion 
constructs were engineered to test this hypothesis. SOD1ΔIV represents WT 
SOD1 with loop IV replaced by a Gly-Ala-Gly linker. The SOD1ΔIV/ΔVII construct 
lacks loops IV and VII, both of which were replaced by Gly-Ala-Gly linkers (Fig. 
II-2C, ΔIV/ΔVII). SOD1ΔIV and SOD1ΔIV/ΔVII are both apo- (Fig. II-3) and 
monomeric proteins (Danielsson et al. 2011).  SOD1ΔIV/ΔVII is a well-folded protein 
as determined by X-ray crystallography (Fig. II-4A) (Danielsson et al. 2013), 
NMR, protein stability (Danielsson et al. 2011, Danielsson et al. 2013) and 
circular dichroism (CD)  (Fig. II-4B) analyses.  
Surprisingly, removal of loops IV and VII within SOD1 strengthened the 
C4F6/SOD1 interaction.  Octet (Table II-1) and native western (Fig. II-4C) 
analyses demonstrated that removal of these loops promoted a binding 
interaction between WT SOD1 and C4F6.  WT SOD1ΔIV and WT SOD1ΔIV/ΔVII 
bound C4F6 with a Kd of 0.72±0.24 and 0.46±0.24 (µM), respectively. Moreover, 
the affinity of SOD1ox for C4F6 increased 3-fold, from 1.13 ± 0.60 to 0.32 ± 0.03, 
upon deletion of loops IV and VII.  Therefore, C4F6 affinity for SOD1 proteins 
lacking  loops  IV and VII is  increased relative to the respective full-length protein  
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Figure II-3. Metal analyses reveal deficient metal coordination in ALS-linked 
and loop-deletion SOD1 variants. The metal content of as-isolated SOD1 
variants determined by ICP-OES. Full-length SOD1 (G93A, G85R, A4V, ox) 
contain lower levels of zinc compared to WT SOD1.  SOD1 (apo,  WT ΔIV , 
G93A ΔIV, WT ΔIV/ΔVII, and ox ΔIV/ΔVII)  are deficient in both copper and zinc. 
(apo refers to demetallated (see methods); ΔIV, deletion of loop IV; ΔIV/ΔVII 
deletion of loops IV and VII). 
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Figure II-4. Deletion of loops IV and VII exposes the C4F6 epitope. (A) The 
structure of SOD1ΔIV/ΔVII (PDB: 4BCZ; loop IV, blue; loop VII, green; Lys122, red).  
(B) CD spectra of WT SOD1 revealed a minimum ellipticity at 208 nm, indicative 
of a mixture of both β-sheets and α-helices within the secondary structure as 
previously reported (Greenfield 2006, Svensson et al. 2006). A similar trend is 
seen for SOD1ΔIV.  Due to the omission of alpha-helices within loops IV and VII, 
the minimum ellipticity is shifted towards a longer wavelength for SOD1ΔIV/ΔVII 
relative to WT SOD1 and SOD1ΔIV. (C) The indicated recombinant SOD1 protein 
(FL, full-length; ΔIV, deletion of loop IV; ΔIV/ΔVII deletion of loops IV and VII) 
was subjected to a native PAGE western analysis with C4F6 (top), revealing that 
C4F6 reactivity is enhanced when the functional loops are removed. A 
denaturing SDS-PAGE (stained with Coomassie) serves as a loading control. (D) 
WT SOD1ΔIV/ΔVII cross-links to C4F6 Fab through Lys122 in the presence of DSP 
(as described for Figure II-2). 
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(Table II-1). This trend is supported by native western analyses, which show a 
robust increase in C4F6 reactivity for SOD1 G93A when loop IV is removed 
(G93A SOD1ΔIV/ΔVII could not be sufficiently expressed) and for both WT SOD1 
and SOD1ox upon removal of loops IV and VII (Fig. II-4C).  WT SOD1ΔIV/ΔVII also 
cross-linked with C4F6 in the presence of DSP (Fig. II-4D). Despite there being 7 
potential lysines available for cross-linking with DSP (Fig. II-2C, 4A), cross-links 
were only identified at Lys122 (residue number corresponds to full-length SOD1).  
Lys122 is the only residue that cross-linked C4F6 in the context of full-length 
SOD1 G93A but was not removed by deletion of loops IV and VII (Fig. II-2C, 4A).  
These results indicate that i) the remaining 6 Lys residues in WT SOD1ΔIV/ΔVII are 
either not proximal to the C4F6 epitope or are not sufficiently positioned for 
cross-linking by DSP, ii) the C4F6 epitope is not within, but rather is proximal to, 
loops IV and VII, iii) deletion of loops IV and VII within WT SOD1 creates and/or 
unmasks the C4F6 epitope and iv) deletion of loops IV and VII in the context of 
misfolded ALS-linked variants further exposes the C4F6 epitope.  The latter two 
hypotheses seem likely given that enhanced flexibility of loop VII has been 
observed in a subset of FALS-linked SOD1 variants (Molnar et al. 2009). 
Exposure of the C4F6 epitope within SOD1 correlates with microglial 
activation 
If the C4F6 epitope does indeed confer toxicity, then SOD1ΔIV/ΔVII proteins 
are expected to exhibit heightened toxicity.  Chronic activation of microglia is 
evident in both ALS patients and mouse models (Turner M. R. et al. 2004, Liao et 
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al. 2012) and is tightly linked to motor neuron death (Block et al. 2007, Zhao et 
al. 2010). Recombinant SOD1 G93A has been shown to activate microglia in 
vitro and, in turn, confer toxicity to cultured motor neurons (Zhao et al. 2010). We 
utilized this sensitive assay to determine whether exposure of the C4F6 epitope 
exerts a disease-relevant effect onto microglia. Cultured primary murine microglia 
(>95% pure, as determined by CD11b/c positive cells) were exposed to SOD1 for 
48h, and their activation was assessed by both cellular morphology and TNFα 
secretion.  Treatment with all misfolded SOD1 variants employed in this study, 
but not WT SOD1, resulted in a similar morphological change from 
ramified/resting microglia to amoeboid, indicative of activation (Graeber 2010) 
(Fig. II-5A).  Consistent with these observations, elevated levels of secreted 
TNFα was detected in the media of microglia exposed to misfolded SOD1 
proteins, but not WT SOD1, with the highest levels induced by WT SOD1ΔIV/ΔVII 
(Fig. II-5B,C).  Consistent with previous studies using FALS-linked SOD1 
proteins (Zhao et al. 2010), the addition of an anti-CD14 antibody that competes 
with misfolded SOD1 for the CD14/TLR4 receptor in microglia partially 
suppressed SOD1-induced microglia activation for all SOD1 variants tested here 
(Fig. II-5). We note that suppression of SOD1 G93A and WT SOD1ΔIV by the 
CD14 antibody did not achieve statistical significance, however, that an 
attenuation in TNFα signal was observed for all misfolded SOD1 proteins studied 
here indicates these proteins activate microglia through a common mechanism. 
Based on these data,  we  propose  a  model  whereby the enhanced flexibility of  
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Figure II-5. Exposure of the C4F6 epitope correlates with elevated SOD1-
mediated microglial activation. Primary murine microglia were incubated with 
the indicated SOD1 protein (2.5 µM) for 48h prior to analysis. (A) 
Immunofluorescence imaging with an anti-α tubulin antibody reveals the 
activation status of microglia (active: closed arrows; inactive: open arrows). Pre-
incubation with anti-CD14 (+ anti-CD14) attenuated microglial activation (scale= 
50 microns).  
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Figure II-5 continued. Exposure of the C4F6 epitope correlates with 
elevated SOD1-mediated microglial activation. (B) Media harvested from cells 
treated as in (A) were probed for TNFα by western analysis (n=4); the highest 
signal was observed for WT SOD1ΔIV/VII treated cells. TNFα secretion was 
attenuated for the + anti-CD14 condition. SOD1 proteins added to the media 
were assessed by western analysis with a pan-SOD1 antibody (bottom) to 
ensure wells were exposed to equal amounts of protein; this antibody was less 
reactive for the loopless constructs.  (C) Densitometry analysis of (B), all SOD1 
variants are significantly increased compared to WT SOD1 (p<0.05) for the -anti-
CD14 condition; statistically significant comparisons with SOD1ΔIV/VII (*, p<0.05) 
for the -anti-CD14 condition are indicated; SOD1 variants that exhibit a significant 
attenuation in microglia activation in the presence of CD14 compared to the -anti-
CD14 condition are indicated (#, p<0.05).  
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loops IV and VII within ALS-linked variants (Shipp et al. 2003, Cao et al. 2008, 
Molnar et al. 2009) partially exposes a toxic domain that is recognized by C4F6, 
and this domain becomes fully exposed when these loops are removed. 
Enhancing the metal occupancy of SOD1 reduces exposure of the C4F6 
epitope 
To gain further insight into the relationship between the functional loops of 
SOD1 and the C4F6 epitope, we assessed the effect of SOD1 metal binding on 
C4F6 reactivity.  Inductively coupled plasma optical emission spectroscopy (ICP-
OES) was used to quantify the metallation status of our recombinant SOD1 
proteins (Fig. II-3).  The WT SOD1 dimer contained approximately 1.9 
equivalents of zinc and only 0.2 equivalents of copper, consistent with previous 
measurements (Hayward et al. 2002). SOD1 variants exhibited a relatively 
reduced metallation status with respect to zinc, especially SOD1 G85R (Hayward 
et al. 2002) (Fig. II-3). The dynamics within loops IV and VII are severely 
perturbed in metal-free SOD1 variants (Elam et al. 2003, Molnar et al. 2009), 
whereas coordination of copper and especially zinc stabilizes the tertiary and 
quaternary structures of SOD1 (Banci et al. 2003, Stathopulos et al. 2003, 
Arnesano et al. 2004, Lynch et al. 2004). Since the metallation status of SOD1 
correlates with its propensity to misfold, it may also influence C4F6 reactivity. In 
the absence of excess copper and zinc, a native western analysis of as-isolated 
recombinant SOD1 variants demonstrate C4F6 reactivity in the following rank 
order: SOD1 G85R> G93A> A4V~SOD1ox (Fig. II-6A, left).  The relatively weak  
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Figure II-6. The metallation status of SOD1 inversely correlates with C4F6 
reactivity. SOD1 incubated for 24 h without  (-) or with (+) 4-fold molar excess 
copper and zinc (Cu2+/Zn2+) and subjected to a native-PAGE western analysis 
with the C4F6 antibody. A denaturing western blot probed with a pan-SOD1 
antibody (bottom) serves as a loading control. (A) C4F6 reactivity is reduced for 
SOD1 G93A, G85R and A4V when these proteins are incubated with excess 
metals. (B) Removing metals from WT SOD1, thereby generating apo-SOD1, 
confers reactivity with C4F6.  C4F6 reactivity is attenuated when apo-SOD1 is 
incubated with excess Cu2+/Zn2+. (C)  Apo-WT SOD1 activates primary microglia 
as indicated by the TNFα western analysis (gels, bottom panels; quantification, 
top; n=2, performed as described in Figure II-5). Statistically significant 
comparisons are indicated (*, p<0.05). 
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reactivity of C4F6 for SOD1ox and A4V is consistent with the binding affinities 
measured by the OCTET, which showed a relatively tight binding interaction for 
the C4F6 antigen, SOD1 G93A (Table II-1).  The strong reactivity for SOD1 
G85R may stem from the low metallation status of this protein (Fig. II-3), as an 
apo-form of SOD1 G93A was used to create C4F6 (Urushitani et al. 2007).  
Although the binding of C4F6 for SOD1ox and A4V is weaker than SOD1 G93A 
and G85R, this antibody can still be used to detect these misfolded species with 
selectivity over the normally folded WT SOD1 protein (Table II-1, Figs. II-1 and 
II-6).  In addition, C4F6 may exhibit enhanced reactivity for SOD1 A4V when this 
protein adopts a self-associated or aggregated form (Brotherton et al. 2012, 
Redler et al. 2014).  
Upon incubation with excess copper chloride (II) and zinc sulfate 
(Cu2+/Zn2+) (Auclair et al. 2010), a change in the migration patterns of SOD1 
variants (G93A, G85R, A4V) was observed, consistent with an increased positive 
charge and change in conformation for these proteins (Tiwari et al. 2009).    A 
robust decrease in C4F6 reactivity was also observed by native western 
analyses when misfolded SOD1 species were incubated with metals (Fig. II-6A, 
right). Addition of excess metals did not have an effect on SOD1ox, and therefore 
an alternative strategy is necessary to “repair” this protein.    
As expected, C4F6 did not recognize WT SOD1 in the absence or 
presence of excess Cu2+/Zn2+. However, the C4F6 epitope was exposed in full- 
length WT SOD1 when this protein was demetallated (Fig. II-6B).  As observed 
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for the loopless constructs (Fig. II-4), exposure of the C4F6 epitope in apo WT 
SOD1 correlated with microglia activation (Fig. II-6C). C4F6 reactivity was 
attenuated when apo-SOD1 was incubated with excess metals (Fig. II-6B), 
however this attenuation was not sufficient to abolish SOD1-induced microglia 
activation (data not shown). Because the microglia assay is sensitive, even 
residual amounts of misfolded SOD1 that may have escaped remetallation are 
expected to induce microglia activation.  An additional technical caveat of this 
experiment was that higher molarities of copper and zinc were used to 
remetallate apo-SOD1 for the microglia assay compared to the native gel 
analysis, potentially causing toxicity to the cells and/or causing aberrant 
modifications to the SOD1 protein itself (Steinebach and Wolterbeek 1993, 
Rakhit et al. 2002, Lemire et al. 2008).  Nonetheless, the behavior of apo WT 
SOD1 in these experiments suggests that both C4F6 reactivity and SOD1-
induced microglia activation can be modulated to some extent by the metallation 
status of SOD1. 
Identification of key SOD1 residues required for C4F6 binding 
The results of our crosslinking experiments revealed an important role for 
loops IV and VII in masking the C4F6 epitope, although the exact amino acids 
that comprise this epitope remained elusive.  Therefore, a comprehensive site-
directed mutagenesis strategy was employed to identify key residues within 
SOD1 that are involved in C4F6 binding.  A series of amino acid substitutions 
were engineered throughout and proximal to the region corresponding to exon 4, 
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which was suggested to contain the C4F6 epitope in a previous study (Bosco et 
al. 2010).  Experiments were initially performed in the SOD1ΔIV/ΔVII background, 
as this protein exhibits the strongest interaction with C4F6 (Fig. II-4C and Table 
II-1).  Partially purified recombinant SOD1 mutants were assessed for C4F6 
binding by native and denaturing (i.e. SDS) western analyses with pan-SOD1 
and C4F6 antibodies (Fig. II-7).  Of interest were those constructs that exhibited 
reactivity with the pan-SOD1 antibody, but little or no reactivity with C4F6. 
Initially, multiple mutations were engineered to efficiently target the region within 
SOD1 that mediated C4F6 binding.  The triple mutations V97A/I99A/D101A, 
D90A/D92A/V94A and D96A/S98A/D101A abolished C4F6 reactivity under both 
denaturing and native conditions (Fig. II-7A). Next, single mutations were 
engineered into SOD1ΔIV/ΔVII to pinpoint residues that are required for the 
SOD1/C4F6 interaction. D92A and D96A mutations prevented C4F6 binding 
under both denaturing and native conditions for SOD1ΔIV/ΔVII, whereas V97A 
prevented binding only under native conditions (Fig. II-7B).  However, circular 
dichroism (CD) spectroscopy indicated that the V97A mutation severely altered 
the secondary structure of SOD1ΔIV/ΔVII (Fig. II-7C). Conversely, the secondary 
structures as determined by CD were comparable for SOD1ΔIV/ΔVII WT, D92A and 
D96A (Fig. II-7C).  Further, V97A- SOD1ΔIV/ΔVII  appeared severely destabilized 
based on the melting profile acquired by differential scanning flourimetry (DSF, 
Fig. II-7D), and thus the loss of C4F6 reactivity likely reflects a significant 
structural perturbation arising from this mutation. In contrast, D92A and D96A 
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increased the melting temperature (Tm) of SOD1ΔIV/ΔVII by at least 10 °C, 
indicative of a stabilizing effect for these mutations (Fig. II-7D).  That these 
mutations abolish the interaction between C4F6 and mutant-SOD1 under 
denaturing conditions suggests residues D92 and D96 are directly involved in the 
binding between these proteins.  For example, aspartic acid residues are 
charged and therefore have the potential to form ionic bonds between SOD1 and 
C4F6, whereas these bonds are eliminated by alanine substitutions. 
Strikingly the activation of an immortalized BV-2 microglia cell line by 
SOD1ΔIV/ΔVII was eliminated by the D92A and D96A point mutations (Fig. II-7E). 
In contrast, a variant that did not exhibit altered C4F6 reactivity (e.g., D101A, Fig. 
II-7B) was still able to activate microglia. One possibility is that the D92A and 
D96A mutations alter the conformations of beta strands 5 and 6 within 
SOD1ΔIV/ΔVII, thereby reducing the exposure of these strands and thus the toxic 
effects they mediate (Richardson and Richardson 2002, Elam et al. 2003, 
Valentine and Hart 2003).  
The D92A and D96A mutations also prevented C4F6 binding under both 
denaturing and native conditions in the context of full-length ALS-linked SOD1 
variants (G93A, G85R, and A4V) (Fig. II-8A).  To assess the role of these 
residues in SOD1-induced microglia activation in the context of the full-length 
protein, the D96A mutation was introduced into ALS-linked SOD1 (G93A, G85R, 
A4V) proteins.  All of the D96-containing variants maintained the ability to  
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activate primary microglia (Fig. II-8B), indicating there is still a misfolded 
conformation within SOD1 despite abolishing the binding interaction between 
SOD1 and C4F6. This misfolded conformation is likely within the zinc binding and 
electrostatic loops themselves, since the truncated variant, SOD1ΔIV/ΔVII, lacking 
these loops no longer induces toxicity in the presence of the D96A mutation (Fig. 
II-7E). In fact, the D96A mutation may worsen the misfolded nature of full-length 
mutant SOD1 as indicated by the higher levels of TNFα for ALS-linked proteins 
with this mutation (Fig. II-8B), increased aggregation propensity (Fig. II-8C) and 
an alteration in the melting profiles as indicated by DSF (Fig. II-8D).  While native 
SOD1 must be misfolded for C4F6 to bind, a loss of C4F6 binding does not 
require SOD1 to be properly folded.  These data demonstrate that a single amino 
acid substitution is not sufficient to restore a wild-type like conformation in an 
ALS-linked SOD1 protein.  Alternatively, strategies aimed at developing chemical 
chaperones to stabilize misfolded SOD1 and/or mask the C4F6 epitope could be 
pursued.  
Discussion 
The structural conformation(s) within misfolded SOD1 that trigger toxic 
events in ALS have not been defined.  Based on the following observations, we 
posit that the C4F6 epitope represents a misfolded conformation that confers 
toxicity.  First, C4F6 reactivity has been demonstrated in both SALS- (Bosco et 
al. 2010) and FALS-human spinal cord sections (Brotherton et al. 2012). Second, 
C4F6 preferentially binds both FALS-linked SOD1 (Urushitani et al. 2007, Bosco 
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et al. 2010, Prudencio and Borchelt 2011, Brotherton et al. 2012) and aberrantly 
modified WT SOD1 (Bosco et al. 2010) proteins (Table II-1). Third, C4F6 blocks 
the toxic effect of SOD1 derived from SALS-human spinal cord tissues in an 
axonal transport assay (Bosco et al. 2010).   Fourth, C4F6 reactivity within spinal 
cord sections of SOD1 G93A transgenic mice directly correlates with disease 
progression (Brotherton et al. 2012).   
In the present study, we quantified the disassociation constants between 
C4F6 and FALS-linked SOD1 mutants and demonstrated binding for all FALS-
linked SOD1 variants tested. While C4F6 exhibited the lowest relative affinity for 
SOD1 A4V (Table II-1 and Fig. II-6), this antibody is still able to detect this 
variant, which is both aggressive and common in North America, with clear 
selectivity over normally folded WT SOD1. Further, Brotherton et al. detected 
C4F6-positive inclusions in human FALS spinal cord tissues expressing SOD1 
A4V (Brotherton et al. 2012), suggesting that C4F6 reactivity is enhanced for 
aggregated forms of SOD1 A4V. Information regarding the residues and 
structural elements that comprise the C4F6 epitope have been lacking (Bosco et 
al. 2010). Unfortunately, attempts to assess the SOD1/C4F6 complex by H/D 
exchange and to gain high-resolution information from X-ray crystallography 
have been unsuccessful. We attempted to co-crystallize the SOD1 G93A/C4F6 
Fab complex, but crystals repeatedly contained solely the SOD1 protein (data not 
shown). For H/D exchange of the C4F6/SOD1 complex, the amount of antibody 
required to shift the majority of SOD1 molecules to the bound state resulted in an 
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overlapping of SOD1 and C4F6 spectra. Differentiating the spectra of SOD1 and 
C4F6 is pivotal for the data interpretation, and therefore prohibited the analysis 
(data not shown). Both of these approaches were likely hindered by the low 
binding affinity of SOD1 and C4F6 (Table II-1). Alternatively, our chemical cross-
linking and mass spectrometry strategy developed here was employed to define 
the C4F6 epitope, leading us first to loops IV and VII within SOD1 (Fig. II-2).  To 
our surprise, all loop-less constructs tested herein exhibited significantly 
enhanced binding affinity for C4F6 relative to their full-length SOD1 counterparts 
(Fig. II-4C).  These results demonstrate that DSP and EDC report on SOD1 
residues proximal to, but not directly in, the C4F6 epitope.  Nonetheless, using 
site-directed mutagenesis we were able to pin-point residues D92 and D96 as 
being critical for the SOD1/C4F6 binding interaction (Fig. II-7). These residues 
are likely engaged in chemical bonding with C4F6, such that their mutagenesis 
precludes a C4F6/SOD1 interaction but yet retains the misfolded nature of ALS-
linked SOD1. The model that emerges from these studies is one where loops IV 
and VII modulate the exposure of the C4F6 epitope.  FALS-linked mutations, 
oxidation and demetallation (Fig. II-1, II-2, and II-6) alter the stability and 
conformation of these loops (Elam et al. 2003, Molnar et al. 2009).  These events 
contribute to the formation of the C4F6 epitope, and removal of these loops 
allows full exposure to this region (Fig. II-4).   
While the toxicity of misfolded SOD1 proteins is well documented in the 
context of different assays and model systems (Rotunno and Bosco 2013), the 
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current study provides insight into one region within misfolded SOD1 that may 
confer toxicity.  We demonstrate a direct correlation between exposure of the 
C4F6 epitope and SOD1-induced microglial activation (Fig. II-5).  Chronic 
microglia activation is a hallmark of ALS pathogenesis, and SOD1-induced 
microglia activation leads to motor neuron death (Zhao et al. 2010).  We also 
note that elements of β-strands 5 and 6, including residue D96, comprise the 
C4F6 epitope (Figs. II-2B and II-8E).  Exposure of β-strands 5 and 6 mediate 
oligomerization of SOD1 and similar β-strands have been shown to mediate 
aberrant protein-interactions (Richardson and Richardson 2002, Elam et al. 
2003, Valentine and Hart 2003).  This is primarily because edge strands are 
poised and readily available to interact with other exposed edge strands 
(Richardson and Richardson 2002, Elam et al. 2003). Thus, these strands may 
contribute to the mechanism of toxicity induced by the C4F6 epitope.  Other 
conformation specific antibodies with SOD1 epitopes overlapping with and 
unique to C4F6 have been described, indicative of additional misfolded regions 
within ALS-linked SOD1 proteins (Rakhit et al. 2007, Vande Velde et al. 2008, 
Forsberg et al. 2010, Gros-Louis et al. 2010, Fujisawa et al. 2012, Pokrishevsky 
et al. 2012, Pickles et al. 2013).  Thus, it is plausible that other misfolded regions 
within SOD1 confer toxicity as well.  It will be important to determine which 
epitope is most relevant to the toxic ALS-phenotypes induced by misfolded 
SOD1 in vivo.  
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Importantly, we show it is possible to convert the properly folded WT 
SOD1 to a microglia-activating, misfolded conformation recognized by C4F6 by 
stripping SOD1 of both copper and zinc (Fig. II-6). We further show the ability to 
revert the misfolded conformation of SOD1 to a more “WT-like” structure, as 
demonstrated by the reduced accessibility of the C4F6 epitope in misfolded 
SOD1 upon incubation with excess metals (Fig. II-6). A similar outcome could 
potentially be achieved with chemical chaperones, which have been used to 
mitigate the misfolding and toxicity of other amyloidogenic proteins (Coelho et al. 
2013). Either with small molecules or alternative approaches, our results 
advocate for concealing the C4F6 epitope and/or stabilizing loops IV and VII as 
rational therapeutic strategies for SOD1-mediated ALS.  
Materials and Methods 
SOD1 protein expression and purification- The pET3d vectors containing 
human SOD1 and SOD1ΔIV/ΔVII (amino acid substitutions: C6A, C111S, and 
C146A) were generous gifts from Dr. Jill Zitzewitz (UMMS). This vector was used 
to construct WT SOD1ΔIV/ΔVII used in this study (amino acid substitutions: A6C, 
S111C and C146A). The SOD1ΔIV construct was generated by Genscript and 
inserted into the pET3d vector using standard cloning techniques.  All mutations 
in this study were generated using standard site directed mutagenesis methods. 
pET3d-SOD1 was expressed in BL21(DE3) PlysS cells and protein expression 
was induced with 1 mM IPTG (Sigma) in the presence of 200 µM copper (II) 
chloride (Sigma) and 200 µM zinc chloride (Sigma) when the culture reached an 
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optical density (OD 600) between 0.6 and 0.8. The bacterial culture was induced 
for 3 h at 37°C (wild-type SOD1) or 30°C (FALS-linked SOD1 and SOD1ΔIV/ΔVII 
variants). Cells were harvested and SOD1 proteins fully purified as previously 
described (Hayward et al. 2002).  Apo SOD1 and SOD1ox were generated from 
purified wild-type SOD1 as previously described (Svensson et al. 2006, Bosco et 
al. 2010). Protein concentrations for all subsequent analyses were quantified with 
the Pierce BCA Protein Assay kit (Thermo) and/or A280 using the appropriate 
extinction coefficients for monomeric SOD1.  
For the mutagenesis screen in Figure II-7, SOD1ΔIV/ΔVII proteins were 
“partially purified” by ammonium sulfate precipitation of the post-sonication 
supernatant (Hayward et al. 2002).   Ammonium sulfate precipitation was 
accomplished by adding 0.16 g ammonium sulfate per 500 µl of bacterial lysate, 
agitating the mixture on a rotating platform for 15 min at 4°C, and then pelleting 
the precipitate by centrifugation at 13,000 rpm for 15 min. The supernatant was 
collected and used as the source of SOD1 protein.  The samples were subjected 
to a denaturing western analysis (see Immunoblots below) and probed with a pan 
anti-SOD1 antibody.  
Circular Dichroism- SOD1 variants were analyzed at 10 µM for full-length 
proteins and 20 µM for loop-deletion constructs in phosphate buffered saline, pH 
7.4. Circular Dichroism (CD) spectra were acquired from 195-260 nm using a 0.1 
cm cuvette at 25°C. CD spectra of SOD1 variants (WT SOD1, SOD1ΔIV and 
SOD1ΔIV/ΔVII) were acquired with a Jasco J-810 spectrophotometer (5 scans). CD 
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spectra of SOD1 Variants (D92A- SOD1ΔIV/ΔVII, D96A- SOD1ΔIV/ΔVII and V97A- 
SOD1ΔIV/ΔVII) were acquired with an AVIV Model 400 Spectrophotometer (10 
scans). Mean residue ellipticity (MRE) was calculated as follows: MRE=(θ * 
100,000)/(A * [SOD1] * L), where θ represents raw data in millidegrees with 
buffer blank subtraction, A represents the number of amino acids in the SOD1 
variant, and L represents the path length in cm.  
Metal Analysis- SOD1 variants were prepared for quantitative metal analysis by 
dialysis with LC-MS grade water (Pierce) overnight at 4°C. SOD1 samples at 
concentrations ranging from 40 to 110 µM were then subjected to an elemental 
analysis in technical duplicate for copper and zinc using ICP-OES (Center for 
Applied Isotope Studies, University of Georgia). Post-dialysis LC-MS grade water 
was analyzed as a buffer control and subtracted from the SOD1 samples prior to 
analyses. 
Incubation of SOD1 proteins with excess copper and zinc- SOD1 proteins 
(10.75 µM) were incubated in the presence of 4-fold molar excess copper (II) 
chloride and zinc sulfate for 24 h at 4°C prior to native and denaturing western 
analysis (see Immunoblots below for details).  
Immunoblots- For denaturing western analyses, samples were diluted in 6x 
sample buffer (Boston Bioproducts, BP-111R). Samples were separated by 
PAGE with 15% Tris-acrylamide gels (unless otherwise noted) in 1% SDS, 25 
mM Tris, 192 mM glycine and transferred to PVDF membrane (Millipore) in 25 M 
Tris, 192 mM glycine. Membranes were blocked for 1 h in Odyssey blocking 
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buffer (LI-COR). Primary antibodies were incubated at 4°C overnight at the 
following dilutions: (pan-SOD1(Taylor et al. 2007), 1:500; C4F6, 0.3 µg/ml; anti-
TNFα, 1:200 (Santa Cruz, sc-1351); and anti-Fab fragment, 1:1000 (Sigma, 
B0529)). The blots were incubated for 1h with fluorophore-conjugated secondary 
antibodies (LI-COR) prior to visualization by the Odyssey Infrared Imaging 
System (LI-COR). The Odyssey infrared imaging software (LI-COR) was used for 
densitometry calculations. For native western analysis, samples were diluted 1:1 
with Native Sample Buffer (Bio-Rad, 161-0738), electrophoresed with a 7.5% 
Tris-acrylamide gel and transferred to PVDF in 25M Tris, 192 mM glycine at 4°C. 
Blots were processed as described above for denaturing western analyses. 
C4F6 expression, purification and Fab generation- A hybridoma cell line 
expressing the C4F6 monoclonal antibody was a generous gift from Dr. Jean-
Pierre Julien (Laval University)(Urushitani et al. 2007).  C4F6 was purified with a 
Protein A agarose column (Pierce) according to the manufacturer’s instructions. 
Purified C4F6 was buffer exchanged into 0.85% NaCl with PD10 G25 desalting 
columns (GE Healthcare). Fab fragments of C4F6 were generated from purified 
C4F6 antibody using immobilized papain (Thermo Scientific) in the presence of 
cysteine according to the manufacturer’s instructions. 
OCTET binding studies- Using the OCTET QK automated system (ForteBio) in 
a 96-well format at ambient temperature, C4F6 was immobilized onto anti-mouse 
IgG Fc Capture Biosensor tips (ForteBio). The extent to which SOD1 bound to 
C4F6 was determined using curves generated by Bio-layer Interferometry, which 
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is based on light interference on the biosensor tip in the presence of SOD1 
compared to an internal reference. To generate binding curves, the C4F6-coated 
tips were immersed into wells containing 12, 15 or 25 µM of the respective SOD1 
variant in phosphate buffered saline (PBS, pH 7.4) until the binding reached 
equilibrium (~120s) followed by immersion into PBS-containing wells for 
dissociation as described (Broering et al. 2013).  Dissociation constants (Kd) 
were determined by fitting the generated curves using the Forte Bio software with 
a “1:1” binding model.  At least two independent experiments were averaged for 
each SOD1 variant.  
Sequencing the C4F6 antibody by mass spectrometry and RNA/DNA 
analysis- For mass spectrometry sequencing of the C4F6 protein, tryptic 
fragments of C4F6 for mass spectrometry analyses were prepared as previously 
described (Shevchenko et al. 2006) and subjected to matrix-assisted laser 
desorption/ionization (MALDI) Time-of-Flight (TOF) and liquid chromatography 
tandem mass spectrometry (LC-MS/MS) analyses.  For MALDI-TOF/TOF, the 
digested peptide samples prepared above were further purified using C18 Zip 
Tips (Millipore) according to the manufacturer’s instructions.  Samples were co-
applied to the MALDI sample target with alpha-cyano-4-hydroxycinnamic acid 
matrix (5 mg/ml).  Samples were analyzed with an Axima-TOF2 MALDI mass 
spectrometer (Shimadzu Scientific Instruments) following external calibration.  
Data were acquired in the positive ion reflectron mode using both collision 
induced dissociation (CID) and post-source decay (PSD) fragmentation modes. 
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All spectra were processed and subjected to database search using Mascot 
(Matrix Science). For MS searches, the Peptide Mass Fingerprint program was 
used with a peptide mass tolerance of 100 ppm.  For CID and PSD spectra the 
MS/MS Ion Search program was used with a Precursor tolerance of 100 ppm 
and a fragment tolerance of 1.5 Da.  
For LC-MS/MS analysis, tryptic peptides were reconstituted in 25 µl 0.1% 
(v/v) TFA and a 3 µl aliquot was directly loaded onto a 100 µm ID custom packed 
trap column packed with 2 cm of 200Å, 5µ C18AQ particles (Michrom 
Bioresources).  
Peptides were then separated on a 75 µm ID analytical column packed 
with 25 cm 100Å, 5µ C18AQ (Michrom) to a gravity-pulled tip.  Peptides were 
eluted using a Proxeon Easy nanoLC (Thermo Scientific) with a linear gradient 
from 100% solvent A (0.1% (v/v) formic acid in 5% (v/v) acetonitrile) to 35% 
solvent B (0.1% formic acid in acetonitrile) over 35 min at a flow rate of 300 
nl/min. Data were acquired in positive ion electrospray mode using a Thermo 
Scientific LTQ Orbitrap Velos Pro mass spectrometer operating in the data 
dependent mode over the range m/z 350-2000. MS scans were acquired in the 
Orbitrap at a resolving power of 60,000 followed by 10 MS/MS spectra acquired 
in the LTQ ion trap. Raw data files were processed with Extract_MSN (Thermo 
Scientific) and were searched against the mammalian index of the NCBInr 
database using Mascot (ver. 2.3).  Parent mass tolerances were set to 10 ppm 
and fragment mass tolerances were set to 0.5 Da, and variable modifications of 
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acetyl (protein N-term), pyroglutamic for N-terminal glutamine, 
carbamidomethylation of cysteine and oxidation of methionine were considered.   
Further sequencing of C4F6 was accomplished by extracting total RNA 
from C4F6 hybridoma cells using RNeasy kit (Qiagen) and PCR amplifying C4F6 
Fab RNA for both heavy and light chains. PCR primers were designed by 
comparing the partial C4F6 Fab sequence obtained through mass spectrometry 
analyses (described above) with known antibody sequences for the same 
isotype, IgG2a, as C4F6 (http://www.imgt.org/). These primers were used in a 
OneStep RT-PCR Kit (Qiagen) reaction to generate corresponding cDNA, which 
was subjected to gel purification followed by DNA sequencing (Genewiz). 
Cross-linking of SOD1 proteins with C4F6 Fab- For the DSP 
(dithiobis[succinimidulpropionate]; Thermo Scientific) and d8-DSP (ProteoChem) 
reaction, the respective SOD1 protein (20 µM) and the Fab fragment of C4F6 (5 
µM) were combined in PBS and cross-linked according to the manufacturer’s 
instructions. The samples were then mixed 1:5 with 6x non-reducing SDS loading 
buffer (Boston Bioproducts), heated at 90°C for 5 min and subjected to SDS 
PAGE with a 10% Tris-acrylamide gel followed by coomassie blue staining (50 µl 
reaction/well) or western analysis (as described above; 15 µl reaction/well). 
Tryptic (Promega) in-gel digest was performed essentially as described 
(Shevchenko et al. 2006). Extracted peptides were concentrated to 30 µl and 
combined 1:1 (DSP:d8-DSP) prior to mass spectrometry analysis (as described 
below). For EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride; 
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Thermo Scientific) SOD1 and the Fab fragment of C4F6 were combined to a final 
concentration of 100 µM and 9 µM, respectively. EDC cross-linking was 
performed according to the manufacturer’s instructions. The reaction was 
quenched by mixing samples 1:5 (v/v) with 6x reducing loading buffer and 
heating at 90ºC for 5 min. Samples were analyzed as described above for DSP 
cross-linking.  
Identification of DSP and EDC SOD1/C4F6 Fab cross-linked peptides by 
mass spectrometry- Tryptic digests were analyzed by LC-MS/MS as described 
above for sequencing the C4F6 antibody with several noted modifications. During 
the 120 minute gradient elution, data dependent acquisition acquired full MS 
scans from m/z 350-2000 in the Orbitrap Velos Pro (resolution 60000) followed 
by higher-energy collisional dissociation (HCD) scans on the 10 most intense 
parent ions acquired in the Orbitrap. Parent ions with charge states of 1+, 2+ or 
3+ were excluded from the analysis. For database searching, a concatenated 
peptide database was generated by xComb (Panchaud et al. 2010) containing all 
possible EDC or DSP linked tryptic peptides (allowing up to 2 missed cleavages) 
of the intermolecular interactions of SOD1 and C4F6. The raw data was 
searched in Proteome Discoverer 1.3 against the concatenated database, with 
parent tolerance of 15 ppm and fragment ion tolerance of 0.05 Da. Additionally, 
spectra were verified manually with the use of GPMAW 8.20 software 
(Lighthouse Data, Denmark). To minimize false positives, only cross-linked 
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peptides with >50% sequence coverage were included in the list of identified 
cross-links.  
Microglial activation assays- Primary Microglia were isolated from mouse 
embryonic cerebral cortices and maintained as previously described (Suzumura 
et al. 1987, Sasabe et al. 2007). Microglia were plated at 100,000 cells/ml  in a 
non-tissue culture treated 96-well plate (Costar).  Microglia were allowed to 
adhere to the plate for 48 h prior to treatment with SOD1 proteins. Purified 
recombinant SOD1 variants were added directly to culture medium of microglia at 
a concentration of 2.5 µM for 48 h prior to immunofluorescence and 
immunoblotting analyses. Where indicated, the anti-CD14 antibody (Cell 
Sciences, CPC401A) was added to wells at 1:200 dilution 24 h prior to SOD1 
treatment. The animal protocol was approved by IACUC at the University of 
Massachusetts Medical Center in compliance with the Animal Welfare Act, U.S. 
Public Health Service Policy and the National Institute of Health guidelines. All 
statistics were determined with an unpaired, two-tailed T-test with Welch’s 
correction.  
Immunofluorescence- Cells were fixed for 5 min with 4% paraformaldehyde 
followed by a 30 min block in PBS, 1% BSA, 0.5% Triton (PBSAT). Primary (anti-
CD11 b/c, 1:200 (Pierce, PA1-46162); anti-α tubulin, 1:100 (Sigma, T9026)) and 
secondary antibodies (fluorophore-conjugated, 1:2000 (Jackson 
ImmunoResearch Laboratories)) were added for 1 h at ambient temperature in 
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PBSAT followed by nuclear staining with DAPI (1:300,000; Invitrogen, D1306) 
and mounting with FluorSave reagent (Fisher, D00060).  
 
PREFACE TO CHAPTER III 
Patient peripheral blood mononuclear cells and red blood cells were collected 
and isolated by Diane McKenna-Yasek, Catherine Ward, and Peter Sapp. 
Samples for mass spectrometry analysis were lyophilized and injected into the 
mass spectrometer by Kristin Boggio. Squid axoplasm isolation and perfusion 
was performed by Scott Brady and colleagues. All other work presented in this 
chapter was performed by Melissa S. Rotunno. 
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CHAPTER III: EXPLOITING SOD1 AS A POTENTIAL BIOMARKER 
Introduction 
Finding a reliable biomarker for ALS is critical for patient stratification for 
clinical trials and for early diagnosis. Multiple studies have found a large number 
of proteins that have a unique trend for ALS patients, but are unreliable for 
diagnosis when analyzing data from an individual out of the healthy population 
(reviewed in (Robelin and Gonzalez De Aguilar 2014)). This data, although 
powerful at shedding light on disease mechanism, lacks the clear-cut answer 
required for use as a biomarker. The ALS community would greatly benefit from 
a biomarker that can accurately differentiate ALS from other neurological 
disorders with similar clinical presentations. Early diagnosis is critical for early 
treatment intervention when effective drugs become available and for further 
classification of disease stages in clinical trials. Currently, diagnosis is through 
progression of paralysis, which requires approximately a year of observation from 
symptom onset (Radunovic et al. 2007). This method impedes opportunities for 
early treatment and, in turn, hinders chances of slowing progression, as early 
treatment has proved vital in ALS mouse models (Zhu et al. 2002, Kieran et al. 
2004).  
Misfolded SOD1 is present in end-stage SALS patient spinal cord tissue 
(Bosco et al. 2010, Forsberg et al. 2010, Pokrishevsky et al. 2012), but 
information regarding the extent of SOD1 misfolding in other biofluids and tissues 
as well as the post-translational modifications that induce this misfolding have 
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been lacking. In addition to the spinal cord, we identify and define differentially 
modified forms of SOD1 present in the brain and blood of SALS patients.  The 
findings presented here put forward these differentially modified forms of SOD1 
as a potential biomarker for sporadic ALS. Specifically, we demonstrate elevated 
SOD1 protein in CSF from ALS patients and misfolded SOD1 in a subset of sera 
samples. This study also identifies an over-oxidized SOD1 species in sporadic 
ALS peripheral blood mononuclear cells (PBMCs) that is reduced in controls. 
Further, we found a species of SOD1 present in PBMCs of healthy controls that 
is significantly reduced in SALS patients. Together, these data support a role for 
altered SOD1 homeostasis in SALS, but whether SOD1 is actively involved in 
pathogenesis or is simply a modified bystander has yet to be determined. Either 
way, the differential expression of SOD1 species identified here has the potential 
to serve as a biomarker for ALS. 
Results 
C4F6 ELISA detects misfolded SOD1 
C4F6 is an established tool for identifying misfolded SOD1 in mouse 
models, human tissue and recombinant SOD1 protein (Urushitani et al. 2006, 
Bosco et al. 2010, Prudencio and Borchelt 2011, Brotherton et al. 2012, Pickles 
et al. 2013). Since it is known that C4F6 reports on SOD1 misfolding (See 
Chapter II), we can exploit this antibody for large scale screening of biofluids for 
the presence of misfolded SOD1. The specificity of C4F6 binding to recombinant 
misfolded SOD1 variants (SOD1 G93A, G85R, A4V, and OX) over WT SOD1 in 
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a C4F6-based sandwich ELISA was tested. Briefly, the plates were coated with 
the C4F6 antibody, followed by the addition of the indicated SOD1 variant. Then, 
the plates were incubated with anti-SOD1 and the amount of misfolded SOD1 
present was quantified with an additional HRP-conjugated secondary antibody. 
Consistent with native PAGE and OCTET studies described in Chapter II (Fig. II-
6, Table II-1), SOD1 G93A exhibited the greatest reactivity with C4F6. SOD1ox 
displayed similar reactivity, while SOD1 A4V and G85R were barely differentiated 
from wild-type at concentrations in vivo in humans (200 ng/mL; Fig. III-1A).  
However, it should be noted that the reactivity of SOD1 A4V and G85R with 
C4F6 are easily distinguished from WT SOD1 in this C4F6-ELISA when 
concentrations nearing the apparent Kd  (>2 µg/mL or 0.13 µM) are employed 
(Table II-1, Fig. AII-4).  
To assess the specificity of C4F6 reactivity in a more complex system, 
HEK cells were transiently transfected with either GST-tagged WT SOD1 or 
SOD1 G93A at levels similar to that of endogenous SOD1 (Fig. III-1B). After 24 
hours, the cell lysates were subjected to the C4F6-ELISA (Fig. III-1C). HEK cells 
transfected with WT SOD1 (HEK WT) had no detectable misfolded SOD1, as 
determined by C4F6 reactivity.  Importantly, this data suggests that complex 
protein mixtures, such as cell lysates, do not increase the background inherent in 
the C4F6-ELISA protocol, demonstrating high specificity of C4F6 to misfolded 
SOD1. In contrast, HEK cells transfected with SOD1 G93A had high C4F6 
reactivity confirming misfolded SOD1 can be identified in heterogeneous lysates.  
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Figure III-1. Detection of misfolded SOD1 utilizing the C4F6-based ELISA. 
(A) The C4F6-based ELISA specifically reacts with a subset of ALS-linked SOD1 
(G93A and A4V) and oxidized SOD1 (Ox) over wild-type (WT). Reactivity of ALS-
linked mutant G85R has similar detection to that of WT. The graph is a 
representative of two independent experiments. Error bars represent SEM of a 
technical duplicate. (B) HEK cells were transiently transfected for 24 h with GST-
tagged WT SOD1 or G93A followed by lysis with sonication.  A total of 15 µg of 
lysate was loaded and analyzed by western blot with anti-GST (left) and anti-
SOD1 (right). Both WT and G93A GST-tagged SOD1 were expressed at levels 
similar to endogenous SOD1 (end. SOD1). (C) A total of 150 µg HEK lysate 
described in (B) was analyzed with the C4F6-based ELISA. ALS-linked SOD1 
G93A retains its high C4F6 reactivity when in a lysate (HEK G93A). WT SOD1 is 
not recognized by C4F6 when expressed transiently in HEK cells (HEK WT). 
Error bars represent SEM of technical duplicate. (WT SOD1, recombinant SOD1 
at 100 ng/mL that serves as negative control; No SOD1, buffer control that 
serves as negative control; SOD1 G93A, recombinant protein at 100 ng/mL that 
serves as positive control).  
 
82
SOD1 protein is elevated in the CSF of ALS patients  
Both the C4F6-ELISA and a total-SOD1 ELISA were employed to assess 
the concentration and extent of misfolding of SOD1 in the CSF of ALS subjects. 
First, the sensitivity of the C4F6-ELISA was assessed in the context of CSF. CSF 
samples from i) ALS patients harboring mutations in SOD1 (FALS) and ii) control 
CSF with exogenous recombinant SOD1 G93A (spiked) were tested. The C4F6-
ELISA was unable to detect mutant SOD1 in the SOD1 FALS-derived CSF (Fig. 
III-2A). This is not surprising, as the C4F6 reactivity to the mutations in these 
individuals have either not been established (I113T) or have been shown to be 
similar to WT SOD1 (A4V) at concentrations present in the CSF (200 ng/mL, see 
Fig. III-1A). The SOD1 G93A spiked control, however, is clearly distinguishable 
from that of control CSF, suggesting a subset of misfolded SOD1 species could 
be identified with this technique.  
The C4F6-ELISA was also employed to assess the extent of SOD1 
misfolding in 105 SALS patients, 39 healthy controls (HC), and 27 patients with 
non-ALS neurological disorders (disease controls, DC). The DC cohort included 
multiple sclerosis (n=9), lower motor neuron disease (n=1), peripheral 
neuropathy (n=3), Alzheimer’s disease (n=3), and the remaining 11 were 
characterized as “other” neurological disorder. Despite the fact that exogenous 
recombinant, misfolded ALS-linked SOD1 protein was clearly detected in the 
CSF, no misfolded SOD1 was detected in any of these cohorts (Fig. III-2B). This 
could be due to the detection limit of the assay, as a subset of misfolded SOD1  
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Figure III-2. Quantification of SOD1 in cerebrospinal fluid by ELISA. (A) The 
C4F6-based ELISA is unable to differentiate between CSF samples of SOD1-
FALS patients harboring mutations (A4V, I113T, L9V) from controls (Ctl). 
Recombinant SOD1 G93A exogenously added to control CSF (Ctl+G93A) at 100 
ng/mL is detectable with the C4F6-based ELISA. (B) Misfolded SOD1, as 
determined by the C4F6-based ELISA, is not detectable in CSF of ALS patients 
(SALS, n=105; Healthy Controls, n=39; Disease Controls, n=27. (C) Total SOD1 
was quantified using a sandwich ELISA for samples described in (B). SALS and 
Disease Controls have a ~50% increase in total SOD1 in the CSF (****, 
p<0.0001; ***, p<0.001). No significant difference between SALS and disease 
controls was observed. Error bars indicate the standard error of the mean (SEM). 
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variants are not detectable at concentration levels approaching that of CSF (200 
ng/mL, Fig. III-1A). The total concentration of SOD1, however, in SALS patients 
was significantly elevated to 48% above the mean of the HC group (150 ng/mL, 
HC; 222 ng/mL, SALS, Fig. III-2C). DCs are also elevated by 49%, suggesting 
this could be a general response to the increased level of oxidative stress seen 
among these diseases. These data are consistent with Winer and colleagues 
who found a 30% increase in SOD1 relative to the total protein in both SALS 
patients and other neurological disease controls compared with healthy controls 
in the CSF (Winer et al. 2013).  
 A subset of SALS patients’ sera harbors misfolded SOD1  
The C4F6-ELISA described above was employed to assess the extent of SOD1 
misfolding in sera samples from SALS subjects. To establish the sensitivity of the 
assay in the context of sera, blood collected from FALS patients with an SOD1 
mutation was employed as a positive control. As described above for CSF, we 
were unable to differentiate the FALS-linked SOD1 from the HC sera in this 
assay (Fig. III-3A), likely due to the mutations we were able to obtain (A4V and 
L9V) that are not conducive to binding the C4F6 antibody at concentrations 
present in sera (Fig. III-1A, III-2A). Next, a cohort of SALS sera samples was 
selected for testing in the C4F6-ELISA based on published data demonstrating 
that these samples had elevated levels of anti-oxidized SOD1 antibodies that in 
turn correlated with longer survival (van Blitterswijk et al. 2011). Two out of the 
11 SALS sera samples tested showed misfolded SOD1 elevated from baseline  
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Figure III-3. Quantification of misfolded SOD1 in sera by ELISA. As 
described in Figure III-2 for CSF, the C4F6-based ELISA was employed to 
identify misfolded SOD1 in patient sera. (A) The C4F6-ELISA is unable to 
differentiate sera of SOD1-FALS patients harboring mutations (A4V, L9V) from 
controls (Ctl). (B) Two out of 11 SALS patients’ sera showed C4F6 reactivity 
above baseline compared to 0 out of 9 for the control cases. Error bars indicate 
SEM of the cohort.  (recG93A, positive control; recWT SOD1, negative control). 
 
 
 
 
86
(Fig. III-3B), suggesting sera may be a source of misfolded SOD1 in SALS. In 
contrast, no misfolded SOD1 was detected in control samples. 
SOD1 isolated from SALS patients displays toxic properties   
Previously published data demonstrates that SOD1 isolated from the 
spinal cord of sporadic ALS patients exhibits characteristics of FALS-linked 
mutant SOD1, such as inhibiting axonal transport (Bosco et al. 2010, Morfini G. 
A. et al. 2013). As an alternative approach to the C4F6-ELISA, we aimed to 
investigate whether or not SOD1 misfolding extended beyond the spinal cord of 
sporadic ALS patients using this same axonal transport assay. Briefly, this assay 
is performed by isolating the axoplasm of giant squid (Loligo pealii) and 
measuring fast axonal transport following the addition of SOD1 variants to the 
axoplasm. Previous studies have shown an inhibition of axonal transport in the 
presence of multiple ALS-linked SOD1 variants (Bosco et al. 2010, Morfini G. A. 
et al. 2013, Song et al. 2013).  Here, we assessed the ability of human SOD1 
(hSOD1) isolated from brain tissue to inhibit axonal transport, which would imply 
an aberrant form of SOD1 exists in these tissues. Although hSOD1 derived from 
CNS tissue cannot directly be utilized as a biomarker, determining which tissues 
harbor misfolded SOD1 in ALS patients will help to identify modes of SOD1 
pathogenesis. To test this, hSOD1 was purified from the cortex of frozen post-
mortem tissue. As a positive and negative control, hSOD1 was also purified from 
the spinal cord tissue of SALS patients as well as from healthy controls, 
respectively, in parallel with the purification of SOD1 from brain tissue.  Isolated 
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squid axoplasm was perfused with pooled hSOD1 immunopurified from three 
sporadic ALS patient cortices and monitored using video microscopy. Consistent 
with previous results, SALS-linked hSOD1 isolated from the spinal cord inhibited 
axonal transport, while hSOD1 derived from control spinal cord tissue did not 
(Fig. III-4A,B). Interestingly, SALS-linked hSOD1 isolated from brain tissue also 
inhibited anterograde axonal transport (Fig. III-4C), extending the implications of 
SOD1 misfolding beyond the diseased spinal cord.  
No conformational differences in SOD1 from SALS patients detected by 
limited proteolysis  
Being that hSOD1 purified from spinal cord tissue in SALS, but not 
controls, inhibited axonal transport, we aimed to identify if this toxicity was due to 
an altered conformation of SALS-linked hSOD1 in human tissue. To assess the 
structural integrity of hSOD1 in SALS samples, we employed a limited proteolysis 
experiment with endoproteinase K, as less structured proteins are more 
susceptible to the proteolysis. To establish the limited proteolysis assay, 
recombinant proteins were analyzed after an hour incubation with 
endoproteinase K (0 to 125 ng/µL) followed by western analysis with an anti-
SOD1 antibody. For WT SOD1, the protein bands were further digested with 
increasing enzyme concentrations (Fig. III-5A). For the ALS-linked proteins 
SOD1 G93A and SOD1 A4V, an initial decrease in the protein band is observed 
at the lowest concentration of endoproteinase K, but this protein band remains 
constant   with  increasing  enzyme  concentration.    At  first  glance,   one  might  
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Figure III-4. hSOD1 
immunopurified from 
brain and spinal cord of 
sporadic ALS patients 
inhibits axonal 
transport. Isolated squid 
axoplasm was perfused 
with 1.4 µM of the 
indicated SOD1 protein 
and the rates of vesicles 
transported across the 
axon were manually 
determined. (A) SOD1 
immunopurified from 
control subjects has no 
effect on transport when 
perfused onto the squid 
axoplasm. Conversely, 
SOD1 isolated from both 
sporadic ALS spinal cord 
(B, SC) and brain (C) 
show transport inhibition. 
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Figure III-5. Unaltered digestion patterns of SOD1 purified from SALS and 
control human tissue. (A) A representative western analysis of recombinant 
SOD1 variants digested with endoproteinase K (0 to 125 ng/µL) for 1 h and 
probed with anti-SOD1 (n=2). An enhanced susceptibility to proteolytic digestion 
for both SOD1 G85R and SOD1 OX compared to WT SOD1 suggests a 
decrease in stability. Both SOD1 G93A and A4V have similar digestion patterns 
to WT SOD1. (B) Limited proteolysis analysis, as described in (A), was employed 
to assess the structural integrity of human SOD1 purified from spinal cord tissue 
of SALS (n=11) and Control (n=8) cases.  (C) Quantification of the amount of 
SOD1 digested with endoproteinase K (62.5 ng/µL; B, column 3) normalized to 
undigested (B, column 1).  
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suspect that these mutants have an increased stability compared to WT SOD1, 
but more likely enhanced aggregation of FALS-linked mutant SOD1 is protecting 
the protein from digestion. In support of this hypothesis, limited proteolysis is a 
technique that has been frequently employed for the assessment of protease 
resistant SOD1 aggregates (Furukawa et al. 2010, Chan et al. 2013). For SOD1 
G85R and SOD1ox, the protein is digested at the lowest concentrations of 
endoproteinase K used, 15 ng/µL (Fig. III-5A, column 2), while WT SOD1 
persists. Based on these preliminary experiments, digestion conditions of 0, 15, 
and 62 ng/µL were selected for analysis of SOD1 purified from human tissue.  
SOD1 purified from human spinal cord tissue was assessed with the 
limited proteolysis assay described above to evaluate structural integrity. Grad et 
al. found that treatment with proteinase K of spinal cord homogenates from SALS 
and FALS patients resulted in a decrease of misfolded SOD1.  The misfolded 
SOD1 was quantified by subsequent immunoprecipitation with a misfolded 
SOD1-specific antibody, DSE2 (Table I-1, (Grad et al. 2014)). In the present 
study, we aimed to identify the effects of limited proteolysis on total hSOD1 
purified from spinal cord homogenates. No significant differences, as determined 
by a t-test, in digestion patterns were observed in SALS hSOD1 compared to 
controls (Fig. III-5B,C). Similarly, Grad and colleagues were unable to detect a 
substantial decrease in total SOD1 following proteinase K treatment when 
employing a pan-SOD1 antibody in place of DSE2 (Grad et al. 2014). The reason 
for the discrepancy between pan-SOD1 and misfolded specific SOD1 antibodies 
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is unclear. One possibility is a subpopulation of misfolded hSOD1 that is 
indiscernible when assessing the entire hSOD1 pool. Additionally, the 
endoproteinase K concentration employed in both studies may require further 
optimization. The as-isolated recombinant SOD1 from E. coli used in this study to 
optimize the protease concentration has a lower metal occupancy, which is 
known to decrease the stability of the protein (Fig. II-3, (Hayward et al. 2002, 
Stathopulos et al. 2006)). It is quite possible that a higher concentration of 
enzyme would be required to tease out the differences in total hSOD1 isolated 
from human spinal cords, which are known to be fully metallated in the presence 
of the copper chaperone for SOD1, CCS (Wong P. C. et al. 2000, Rae et al. 
2001, Banci et al. 2012b). In fact, Grad and colleagues found that increasing the 
proteinase K treatment to 20 mg/mL in control spinal cord homogenates had no 
effect on levels of WT SOD1 (Grad et al. 2014). 
A subpopulation of SOD1 is greatly reduced in SALS 
Being that limited proteolysis reveals no conformational differences between 
SALS hSOD1 and controls, we next employed 2D-gel electrophoresis (2D-GE) to 
identify unique modifications that may induce misfolding. SOD1 isolated from 
healthy human erythrocytes has been shown to contain multiple SOD1 species, 
partly due to the long half-life of these cells. These modification include 
deamidation (Shi Y. et al. 2013), phosphorylation (Wilcox et al. 2009), and 
glutathionylation (Wilcox et al. 2009).   Both glutathionylation and deamidation 
enhance the aggregation propensity of WT SOD1 (Wilcox et al. 2009, Redler et 
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al. 2011, Shi Y. et al. 2013). These data suggest a higher abundance of these 
modified species in vivo could be detrimental.  Moreover, an ideal biomarker 
source would be in the blood, as it is relatively non-invasive and simple to obtain. 
In light of this, we aimed to identify differential modifications on SOD1 in red 
blood cells (RBCs) from sporadic ALS patients compared to that of controls. All 
SALS patients included in this study represent earlier stages of disease with ALS 
functional rating scores (ALSFR) above 30 (Table III-1). To identify modifications 
that induce a charge shift in SOD1, we employed 2D-GE on RBC lysates from 
both SALS and controls. 2D-GE separates proteins by both  isoelectric point (pI) 
and molecular weight allowing for an assessment of the charged species present 
in each sample. By doing a western analysis of the 2D-GE probed with anti-
SOD1, we were able to identify multiple species of SOD1 present in RBC lysates 
(Fig. III-6).  The species that migrates at a pI of “5.6” and molecular weight of 16 
kDa likely represents unmodified SOD1, as the theoretical pI of SOD1 is 5.7. As 
illustrated in Figure III-6, modifications on SOD1 from RBCs in both SALS and 
control groups demonstrated high variability. This is likely due to the high amount 
of salts and proteins, such as albumin, present in these samples that may 
interfere with the isoelectric focusing, the first step of 2D-GE. In future studies, it 
will be vital to increase the number of washes and employ harsher pelleting 
strategies to further purify the RBC pellet prior to lysis and analysis by 2D-GE. 
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Figure III-6. Human red blood cells (RBC) contain modified SOD1 protein. A 
total of 300 µg of protein lysate was subjected to 2D-GE western analysis probed 
with anti-SOD1.  SOD1 ran at the expected MW of ~16 kDa. 2D-GE 
demonstrates the presence of multiple differentially charged species of SOD1 in 
both SALS (left) and Control (right) RBC lysates. The number (n) of patients 
pooled for each sample is shown with the estimated pI displayed above. 
*indicates sample subjected to immunoprecipitation and mass spectrometry 
analysis. 
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As an alternative approach, the presence of misfolded SOD1 in RBCs was 
assessed by employing the C4F6-ELISA, as described above for CSF and sera. 
No misfolded SOD1 was detected in control or SALS patient derived RBC lysate 
(data not shown). This data suggests that the misfolded SOD1 detected by C4F6 
is either not present or at concentrations lower than the limit of detection in these 
samples. This does not preclude the possibility that a different misfolded species 
is present, as multiple antibodies have been generated that recognized different 
regions of SOD1 exposed upon misfolding (Table I-1, Fig. I-3 (Jonsson et al. 
2004, Urushitani et al. 2006, Rakhit et al. 2007, Gros-Louis et al. 2010, Kerman 
et al. 2010)). 
To further elucidate the potential differential modifications in SALS and 
control RBCs, immunoprecipitated SOD1 from RBC lysate from SALS (n=2) and 
controls (n=2) was digested with trypsin and analyzed by mass spectrometry. 
Sequence coverage of 100% was observed for both pooled SOD1 samples. 
Consistent with previously published data, deamidation at N26D was present in 
the control group (Fig. III-7A) (Shi Y. et al. 2013), as well as the SALS group 
(data not shown). A novel phosphorylation site at T135 was also observed in 
both groups (Fig. III-7B), but further validation is required as the 
immunoprecipitated SOD1 was washed with phosphate buffered saline (0.01 M  
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Figure III-7. Phosphorylation and deamidation are present on SOD1 isolated 
from RBCs. Immunoprecipitated SOD1 (Fig. III-6, *) was subjected to mass 
spectrometry analysis to identify the modifications present. Two samples were 
pooled for SALS and Ctl cohorts. Representative spectra of modifications 
identified in both SALS pool and Ctl pool are shown. Insets demonstrate ion 
coverage of the indicated modification, allowing for the amino acid assignment. 
Sequence and sequence coverage is displayed above. The monoisotopic peaks 
of y, a, and b-ions assigned to the indicated peptide are illustrated in orange. 
Both SOD1 IP’d from SALS (n=2) and Ctl (n=2) RBCs contained deamidation at 
N26 (DE, A) and phosphorylation at T135 (PH, B).  
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PBS, 0.01% Tween20) which may have induced artificial phosphorylation. 
Phosphorylation has been previously observed at other sites, T2 and T59/S58, 
neither of which were identified in these samples (Wilcox et al. 2009). 
Unfortunately, quantification of phosphorylation by mass spectrometry is highly 
unreliable because of variability in the phosphate bond breaking during ionization 
and further enrichment may be required to identify differential phosphorylation 
(Quan and Liu 2013). 
In addition to RBCs, another source that could harbor misfolded SOD1 
species are peripheral blood mononuclear cells (PBMCs), which can be isolated 
from total blood by centrifugation techniques (see Materials and Methods). 
PBMCs constitute about 1% of the total cells in blood and include multiple white 
blood cells such as monocytes and lymphocytes (Mantovani et al. 2009). PBMCs 
reflect many of the same pathological hallmarks of ALS as seen in other cell 
types such as altered calcium homeostasis, increased nitrative stress, and 
decreased levels of Bcl-2 (Curti et al. 1996, Cova et al. 2006, Nardo et al. 2009). 
To assess the extent of differential modifications of SOD1 in PBMCs isolated 
from SALS and control patients, the same 2D-GE technique was employed as 
described above for RBCs. Blood samples for both RBCs and PBMCs were 
drawn simultaneously from the same cohorts (Table III-1). However, contrary to 
RBCs, the 2D-GE blots of SOD1 from PBMCs had only 3 prominent spots (Fig. 
III-8). Both PBMCs from control (n=9) and SALS (n=9) subjects have an 
abundant  SOD1  species  at  pI  of   ~5.6   (Figure III-8A).  This  SOD1  species,  
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Figure III-8. PBMCs isolated from control cases harbor an SOD1 species 
greatly reduced in SALS. (A) Western analysis probed with anti-SOD1 of 2D-
GE of PBMC lysate from SALS (left) and control (right) isolated from blood. 
Estimated pI, based on the isoelectric focusing strip used, is displayed above. 
The number of patients (n) pooled for each gel sample is shown. (B) A 
representative 2D-GE as described in (A) to demonstrate the method used for 
quantification. (C,D) Quantification of the relative abundance of “Spot 1” and 
“Spot 2” normalized to the total SOD1 (Spot 1 + Spot 2 + Spot 3). “Spot 2” is 
significantly decreased in SALS compared to control (Ctl, p=0.0004). Statistics 
were determined by an unpaired t-test (***, p<0.001; n=9). No significant 
difference for “Spot 1” quantification.  
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Figure III-8 continued. PBMCs isolated from control cases harbor an SOD1 
species greatly reduced in SALS. (E) PBMC lysate was subjected to western 
analysis to determine the relative SOD1 abundance (Tub, α-tubulin). (F) 
Quantification of (E) by densitometry was performed and SOD1 was normalized 
to the loading control, tubulin. These data demonstrate no significant difference 
in the abundance of SOD1 observed between SALS and healthy controls.  
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designated as “Spot 3” (Figure III-8B), signifies the major species of SOD1 
present in PBMCs (90-95% of total SOD1), and likely represents unmodified 
SOD1 with a theoretical pI of 5.7. The SOD1 species at pI 5.0 (Spot 1) appeared 
in a subset of both control and SALS patients, with no significant 
overrepresentation in either cohort (Fig. III-8C). The SOD1 species at pI 5.4 
(Spot 2), however, is significantly overrepresented in control compared to SALS 
subjects and accounts for 8.1 ± 1.1% and 2.7 ± 0.3% of total SOD1, respectively 
(Fig. III-8D). Both Spot 1 and Spot 2 correspond to SOD1 with a modification that 
leads to a net change in charge, either a loss of a positive charge or the gain of a 
negative charge relative to Spot 3. No significant change in the relative levels of 
total SOD1 was observed (Fig. III-8E,F).  
An over-oxidized SOD1 species is present in SALS PBMCs 
Immunoprecipitated SOD1 from pooled PBMCs (n=9 SALS, n=9 Ctl), as 
described above for RBCs, was subjected to mass spectrometry analysis to 
identify Spot 2  that was overrepresented in controls. First, it was vital to confirm 
that Spot 2 was immunoprecipitated by the monoclonal anti-SOD1 antibody 
employed, since we aimed to identify this species by mass spectrometry. As 
illustrated by 2D-GE followed by western blotting (Fig. III-9A), Spot 2 (pI 5.4) is 
immunoprecipitated from Control PBMC lysate. Of note, the antibody used for the 
immunoprecipitation (Pierce) differs from those used to probe SOD1 in the 
western analysis (AbCam and (Taylor et al. 2007)), confirming by 3 independent 
anti-SOD1  antibodies  that  Spot 2 is SOD1 and not cross-reactivity with another  
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Figure III-9. Immunoprecipitated SOD1 from Control PBMCs contains Spot 
2. (A,B) Immunoprecipitation of SOD1 from PBMCs for mass spectrometry 
analysis. (A) 2D-GE probed with anti-SOD1 confirms that the SOD1 species at pI 
5.4 is depleted from the flow-through lysate (FT, top) and present in the 
immunoprecipitated sample (bottom). (B) Immunoprecipitated SOD1 was 
subjected to Coomassie SDS PAGE. SOD1 is seen in anti-SOD1 IP, but not the 
IgG control. This 16 kDa species was excised, digested with trypsin and 
subjected to mass spectrometry.  
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protein.  
The low abundance of Spot 2 precluded our ability to isolate it from total 
SOD1 for mass spectrometry analysis. Instead, to determine protein 
modifications that induce the shift of SOD1 by 2D-GE, total SOD1 was 
immunoprecipitated and subjected to SDS-PAGE followed by Coomassie. The 
16 kDa SOD1 species (Fig. III-9B) was excised, digested with trypsin, and 
analyzed by mass spectrometry. Sequence coverage of 100% was observed for 
SOD1 in both SALS (n=9) and Ctl (n=9) pooled samples. Overall, SALS SOD1 
contained more oxidized amino acid residues than control SOD1. Since oxidative 
stress is a known hallmark of ALS, these results are not surprising (Carri et al. 
2015). The oxidation of Pro13 and Phe20, for example, was only identified in 
SALS SOD1 on the peptide spanning Gly10 to Lys23 (Table III-2). It is also worth 
noting that oxidation of Lys122 was observed only in the SALS SOD1 pool (6.7% 
of Tyr116-Lys128). Lysine oxidation inhibits ubiquitination and, in turn could 
interfere with regulation of protein turnover (Spasser and Brik 2012).   
Moreover, an increase in the total relative abundance of peptides with 
oxidized amino acids (H, W, P, D, N, F, K) was observed (all peptides weighted 
equally; SALS, 3.7%; Ctl, 1.6%; Table III-2). This percentage is calculated by 
weighting all peptides equally. In other words, 100% oxidation would indicate 
every peptide identified by mass spectrometry has at least one oxidized residue 
within it.  This is  a  conservative  calculation  that  does  not consider the relative  
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abundance of individual peptides. For example, 72% of the total oxidation found 
in the Ctl SOD1 pool is attributed to the peptide spanning His80 to Lys91, which 
was uniquely over-oxidized in controls compared to SALS. However, this is 
misleading as the His80 to Lys91 peptide was significantly underrepresented in 
the control SOD1 (Relative Abundance: SALS, 11.3%; Ctl, 0.006%; Table III-2). 
The underrepresentation of this peptide in controls is likely skewing the 
percentage of oxidation present, as His80 to Arg115, a peptide that has the 
His80 to Lys91 sequence within it, contains no sites of oxidation with a much 
greater relative abundance (2.1%). Thus, this suggests that i) there is an 
unidentified modification on His80 to Lys91 in the control pool that is precluding 
its identification or ii) a modification on the terminal lysine is inhibiting the tryptic 
digestion.   
Likewise, the total calculated oxidation present in the SALS pool (3.7%) is 
misleading. Approximately 23.1% of the peptide spanning Glu24 to Lys36 is 
oxidized in the SALS SOD1 pool, while only 0.5% is oxidized in the control pool. 
For the SALS SOD1 pool, Trp32 oxidation (Trp32ox) within Glu24-Lys36 
contributes to more than 90% of the oxidation observed (Table III-2, Fig. III-10). 
Glu24 to Lys36 is the only peptide identified that contains this Trp32 within it, 
suggesting that 21% of the SOD1 population from the SALS pool contains 
Trp32ox. Assuming similar ionization efficiencies between the oxidized and non-
oxidized Glu24-Lys36 peptides, this data implies that 21% of all SOD1 protein 
immunoprecipitated  is  aberrantly  oxidized  at  this  tryptophan residue. Trp32 is  
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Figure III-10. Tryptophan oxidation at residue 32 of SOD1 is elevated in 
SALS PBMCs. Immunoprecipitated SOD1 from both SALS (n=9) and Ctl (n=9) 
PBMCs as described in Fig. III-9, were subjected to mass spectrometry analysis 
to identify protein modifications. (A) Tryptophan is readily oxidized resulting in its 
conversion to hydroxy-tryptophan, among other oxidation products, which 
increases the MW by 16 Da.  (B) The peptide spanning Glu24 to Lys36 contains 
an oxidized tryptophan residue present on SOD1 immunoprecipitated from both 
SALS (≥ 21%) and control (≤ 0.5%) pools. A representative spectrum of the 
oxidation of tryptophan (Trp32) to hydroxy-tryptophan from SALS pooled SOD1 
sample is shown. The sequence coverage is displayed above (OX, oxidized 
tryptophan). The monoisotopic peaks of y, a, and b-ions assigned to the 
indicated peptide are illustrated in orange. 
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implicated in FALS-linked mutant SOD1 pathogenesis, suggesting Trp32ox may 
be the first direct link to a common pathogenic mechanism of SOD1 in both 
SALS and FALS (Zhang H. et al. 2003, Taylor et al. 2007, Grad et al. 2011). 
Whether all 9 SALS samples that were pooled for this analysis contain this 21% 
oxidation or if it is higher in a subset of patients remains to be determined. 
Another interesting differential modification present on SOD1 in PBMCs is 
histidine oxidation to 2-oxo-histidine, a modification induced by metal-catalyzed 
oxidation ((Rakhit et al. 2002, Uchida 2003), Fig III-11A). This modification was 
previously reported to occur in the active site of SOD1 (Uchida and Kawakishi 
1994, Kurahashi et al. 2001, Rakhit et al. 2002). In fact, 2-oxo-histidine was 
observed in both the SOD1 from the control and SALS cohorts (Fig. III-11B). 
Specifically, in the peptide spanning Gly37 to Arg69, oxidation was observed at 
His46 and His48, both of which coordinate Cu(II) in the active site (Selverstone 
Valentine et al. 2005). Since these histidines are in the active site of SOD1, their 
oxidation likely results in inactivation of the protein (Fucci et al. 1983, Smith C. D. 
et al. 1991, Berlett and Stadtman 1997, Selverstone Valentine et al. 2005). 
Further, the percentage of total oxidation of the peptide spanning Gly37 to Arg69 
was enhanced in SALS, as indicated by the relative abundance (SALS, 12.4%; 
Ctl, 5.3%; Table III-2),  with at least 60% of the oxidation attributed to oxidized 
histidine residues.   
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Figure III-11. Histidine oxidation to 2-oxo-histidine is present on PBMCs 
isolated from control and SALS samples. Immunoprecipitated SOD1 from 
both SALS (n=9) and Ctl (n=9) PBMCs as described in Fig. III-9, were subjected 
to mass spectrometry analysis to identify protein modifications. (A) Histidine is 
converted to 2-oxo-histidine in the presence of reactive oxygen species and 
further converted to aspartic acid under prolonged exposure and/or degradation. 
(B) The peptide spanning Gly37 to Arg69 contains multiple oxidized residues 
such as His46 and His48. A representative spectrum of the oxidation of histidine 
(His46) to 2-oxo-histidine from SALS pooled SOD1 sample is shown. His46 
oxidation is present in both SALS and control pooled SOD1 samples. The 
sequence coverage is displayed above (OX, oxidized histidine; CA, 
carbamidomethyl adduct). The monoisotopic peaks of y, a, and b-ions assigned 
to the indicated peptide are illustrated in orange. 
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Within the same peptide discussed above, Gly37 to Arg69, the conversion 
of His46 to aspartic acid, was uniquely observed in SOD1 isolated from controls. 
The conversion of histidine to aspartic acid represents a ring-ruptured form of 2-
oxo-histidine that may be a product of histidine degradation (Fig. III-11A, III-
12,(Dean et al. 1989, Uchida 2003)). The aspartic acid residue at position 46 is 
expected to induce a charge shift like that observed for the SOD1 species at pI 
5.4 (Spot 2) identified in the 2D-GE western analysis (Fig. III-8). In fact, the 
theoretical pI of the histidine to aspartic acid conversion is 5.4. The discrepancy 
in the quantification of Spot 2 by 2D-GE (8.1%) and His46Asp in mass 
spectrometry (0.1% of the total precursor intensity of the peptide) is likely due, at 
least in part, to the decreased ionization efficiency of a peptide with increased 
negative charge.  
 One possibility for why the histidine to aspartic acid conversion is 
observed in controls and not the SALS groups could be the overrepresentation of 
the peptide in the mass spectrometer (i.e. lower concentration could result in loss 
of detection). In fact, the total SOD1 injected into the mass spectrometer was 2-
fold higher in control SOD1 (Ctl, 1.8x1011;SALS, 8.99 x 1010). To address this 
issue, the relative abundance of each peptide was quantified using the total 
intensity of the precursor ion  (Table III-2). The SOD1 peptide Gly37 to Arg69 
was overrepresented in controls compared to SALS (Relative Abundance: Ctl, 
16.325; SALS, 2.113). Nonetheless, if the histidine substitution to aspartic acid 
were  present  at  similar   percentages  in  the  SALS  SOD1,  it  would  likely  be 
109
Figure III-12. Histidine oxidation to aspartic acid is unique to SOD1 in 
PBMCs isolated from controls. (A) The MS/MS spectra of the peptide identified 
as Gly37-Arg69. A carbamidomethyl modification is present in both samples on 
Cys57, which is an artifact of sample preparation (CA). Representative spectra 
with (Ctl, bottom; blue) and without (SALS, top; orange) the His46 to aspartic 
acid conversion are shown. The monoisotopic peaks of y, a, and b-ions assigned 
to the indicated peptide are illustrated in orange and blue, respectively. Note the 
similarity between the two spectra (sequence coverage displayed above).  
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Figure III-12 continued. Histidine oxidation to aspartic acid is unique to 
SOD1 in PBMCs isolated from controls. (B) The conversion of histidine to 
aspartic acid results in a loss of -22.01 Da at His46 (Actual Mass of Gly37-Arg69 
peptide: His46, 3518.62 Da, Asp46, 3496.61 Da; 3518.62-3496.61=-22.01). A 
zoomed in overlay of the spectra with (Ctl, blue) and without (SALS, red) the 
amino acid substitution highlights the peak shifts present on b-ions (b(16), b(17)) 
that include residue 46, the site of histidine conversion to aspartic acid. These 
data demonstrate the change of -22.01 observed with the aspartic acid 
substitution (-22.01/+2)=-11.0).  
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detectable with a total precursor intensity of 106. It was not, however, detectable 
in   the   SALS   SOD1   pool. Repeating the  injection  with   higher 
concentrations of SALS SOD1 or doing a targeted mass spectrometry approach 
is required to confirm these findings.  Moreover, these data represent a single set 
of immunoprecipitated SOD1 from control and SALS pools and a replicate 
analysis with new blood samples will be required to confirm the differences in 
peptide abundance and the differential modifications. 
Discussion 
The structural loosening that results from SOD1 misfolding induced by 
mutations and/or other environmental factors could make SOD1 more 
susceptible to adverse modification(s) (See Chapter II).   Thus, in this study, we 
aimed to devise a mechanism to identify misfolded SOD1 in the context of 
sporadic ALS in order to exploit it as a biomarker. We employed C4F6, a 
misfolded SOD1-specific antibody, to detect misfolded SOD1 in CSF, sera, 
PBMCs and RBCs. Consistent with previous findings, total SOD1 is elevated in 
the CSF of both SALS and neurological controls (Fig. III-2, (Winer et al. 2013)), 
likely due to the oxidative stress found in these neurological disorders (Fig. III-2) 
(Christen 2000, Gilgun-Sherki et al. 2004, Carri et al. 2015). The nonspecific 
increase of SOD1 protein in neurodegenerative diseases renders SOD1 protein 
levels a weak biomarker in the context of ALS.  
 Misfolded SOD1, as detected by the C4F6-ELISA, was found in the sera 
of 2 out of 11 SALS patients selected based on their elevated levels of SOD1ox 
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antibodies. Although this data is intriguing, a larger cohort of both SALS and 
healthy controls is required to quantify the extent of this misfolding in sera and its 
relationship to disease. In contrast, misfolded SOD1 was not identified in RBCs, 
PBMCs (data not shown), or CSF samples from SALS (Fig. III-2). C4F6 may not 
be the optimal misfolded SOD1-specific antibody for detection in complex 
samples. First, the apparent Kd of SOD1 binding to C4F6 is relatively low (Table 
II-1), in the low micromolar range. This suggests that in complex mixtures, C4F6 
will be competing with other SOD1 binding proteins, with C4F6 less favored to 
bind SOD1. Also, at the concentrations of SOD1 present in CSF (100-200 ng/mL) 
and Sera (10-70 ng/mL), C4F6 is reaching its detection limit, as it is unable to 
differentiate a subset of misfolded SOD1 (A4V and G85R) from  WT SOD1 (Fig. 
III-1). Developing antibodies with a higher affinity to misfolded SOD1 will likely 
have greater diagnostic and therapeutic potential. It is also possible that 
misfolded SOD1 is not present in all biofluids and tissues. We have shown that 
toxic SOD1 is in the spinal cord and brain tissue, as indicated by axonal transport 
inhibition, but whether or not this misfolded SOD1 extends to the CSF and RBCs 
is unknown at this time. The presence of an over-oxidized SOD1 species in 
PBMCs, however, supports the presence of misfolded SOD1 in these samples.  
By subjecting spinal cord derived hSOD1 to limited proteolysis with 
endoproteinase k, we aimed to assess the structural integrity of SALS-linked 
hSOD1 compared to controls. In this study, we assessed the susceptibility of the 
entire population of SOD1 to proteolysis and found no difference in digestion 
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patterns between hSOD1 from SALS and healthy controls (Fig. III-5). The fact 
that hSOD1 isolated from the spinal cord demonstrates signs of toxicity through 
axonal transport inhibition, argues for the presence of misfolded SOD1. Whether 
this species is more susceptible to proteolytic digestion is unknown. Previous 
studies demonstrated the susceptibility of a subpopulation of misfolded SOD1, 
immunoprecipitated by DSE2 (Table I-1), to limited proteolysis (Grad et al. 2014). 
In the current study, only the total population of SOD1 was assessed, which does 
not rule out the possibility of a subpopulation of SOD1 present in the spinal cord 
that may be more destabilized in this cohort as well, as suggested by the 
Cashman study (Grad et al. 2014). Another possibility is an enhanced 
aggregation propensity of SALS-purified SOD1, increasing the oligomeric SOD1 
species resulting in proteolytic resistance under the conditions assessed.  
Peripheral blood mononuclear cells (PBMCs) are a vital immune system 
defense and could be a biomarker source for ALS, as they recapitulate many 
aspects of disease. PBMCs isolated from ALS patients, for example, 
demonstrate increased nitrative stress and signs of excitotoxicity such as altered 
calcium homeostasis and glutamate receptor expression (Curti et al. 1996, 
Poulopoulou et al. 2005, Nardo et al. 2009). In fact, when PBMCs are exposed to 
misfolded SOD1, they secrete pro-inflammatory cytokines (Fiala et al. 2010). In 
this study, we identified an SOD1 species at pI 5.4 greatly reduced in SALS 
patients compared to controls in PBMCs. Likely, a modification is present in 
controls that is lacking in the SALS SOD1 causing the shift in pI observed. 
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Another possibility is an additional modification on SALS SOD1 that shifts the 
species back to the “5.6” pI, while the modification originally causing the shift to 
5.4 remains. Alternatively, there could be a slower formation or a more efficient 
clearing of this species of pI 5.4 in SALS patients.  
PBMCs represent a mixed population of white blood cells consisting of 
mainly lymphocytes and monocytes (Ratts and Weng 2012). These cell types 
can be further divided into subclasses with the ratio of cell types varying between 
individuals. One possibility for the lack of this SOD1 species in the SALS 
population could be a PBMC cell type expressing these species that is 
underrepresented in diseased individuals. In fact, SALS patients have 
demonstrated an altered subpopulation of CD3+T lymphocytes, which is the 
major cell type present in PBMCs. Even though the total percentage of CD3+ T 
cells is unchanged, the subpopulations are shifted resulting in an increase in 
CD4+ T helper cells and a decrease in CD8+ T cytotoxic cells relative to controls 
(Mantovani et al. 2009). In this scenario, it remains to be determined if CD8+ T 
cytotoxic cells are the population that express the 5.4 SOD1 species.  
  By analyzing SOD1 immunoprecipitated from both SALS and control 
PBMCs by mass spectrometry, we were able to identify an over-oxidized form of 
SOD1 unique to SALS-linked SOD1. This over-oxidized form of SOD1 would 
likely not induce a pI shift by 2D-GE, as the majority of oxidized residues do not 
reduce the charge of SOD. Additionally, the mass difference of oxidation is too 
small to detect by SDS-PAGE and western analysis. In support of this 
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differentially modified SOD1 species, previously published data identified an 
over-oxidized species of SOD1 in immortalized lymphocytes, the major 
constituents of the PBMC population, derived from SALS patients (Guareschi et 
al. 2012). An increase in protein oxidation that correlates with aging has also 
been observed (Smith C. D. et al. 1991). In fact, aging, oxidative stress, and 
inflammation are implicated in an increased production of reactive oxygen 
species (Berlett and Stadtman 1997) and a decrease in activity of the hydrogen 
peroxide scavenger, catalase (Alper 1998, Tsay et al. 2000). SOD1 is 
responsible for converting the reactive oxygen species, O2-, to oxygen and 
hydrogen peroxide (H2O2). However, in the absence of downstream peroxidases 
to convert H2O2 to non-reactive species, or an overload of produced H2O2, H2O2 
can accumulate and participate in metal-catalyzed oxidation resulting in the 
production of toxic hydroxyl radicals,  OH. These toxic hydroxyl radicals can 
induce histidine oxidation, among many other oxidation products.  
The increase in oxidation of the SALS SOD1 pool has three major 
plausible sources. First, the increase in overall oxidative stress evident in ALS 
(Barber and Shaw 2010, Pollari et al. 2014, Carri et al. 2015) could be inducing 
this over-oxidized state. Second, a decrease in the structural integrity of SOD1 
could enhance susceptibility of the protein to oxidative modifications. As an 
alternative route to limited proteolysis, one could test this by performing H/D 
exchange followed by mass spectrometry on immunopurified SOD1 from PBMCs 
to identify regions of SOD1 with enhanced flexibility. Third, a deficiency in protein 
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turnover could result in the accumulation of over-oxidized SOD1 species. This 
could be tested by pulse-chase radiolabeling of newly synthesized proteins to 
assess the half-life of SOD1 in PBMCs, as PBMCs can be cultured for short 
periods of time (Cova et al. 2006). These theories are not mutually exclusive. 
The amount of protein oxidation is thought to be a balance between the rate of 
protein oxidation and protein turnover. A decrease in protein degradation, for 
example, would likely increase the amount of oxidized species present. 
Supporting this hypothesis, the two major mechanisms involved in protein 
turnover, the ubiquitin proteasome system (UPS) and autophagy, are 
compromised in ALS (Ferrucci et al. 2011). In fact, lysine oxidation, as seen at 
Lys122 in SALS SOD1 from PBMCs, would interfere with SOD1 turnover via the 
UPS and/or autophagy if it functions as a ubiquitination site, as ubiquitination 
would be inhibited (Basso et al. 2006, Kabuta et al. 2006, Spasser and Brik 
2012). Bioinformatics sites have identified Lys122 as a non-ubiquitination site 
(http://www.jci-bioinfo.cn/iUbiq-Lys). Lys122 may still function as a ubiquitination 
site, as consensus sequences for ubiquitination are lacking and Lys136, a known 
ubiquitination site of SOD1, was identified as a non-ubiquitination site as well 
(Basso et al. 2006). Previous studies have demonstrated that even non-
canonical sites of ubiquitination, such as cysteine (Spasser and Brik 2012) are 
oxidized in WT SOD1 in the presence of hydrogen peroxide (Bosco et al. 2010). 
Unfortunately, the extent of oxidation on cysteine residues in PBMC SOD1 was 
unable to be determined because the alkylation and reduction steps employed 
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during sample preparation for mass spectrometry are expected to eliminate the 
presence of these species. Generally, oxidized proteins are degraded more 
rapidly by a ubiquitin-independent proteasome pathway, but the accumulation of 
oxidized SOD1 in SALS PBMCs suggests an impairment of this pathway as well 
(Shringarpure et al. 2003). Together, these data suggest an inefficient/altered 
turnover of SOD1 in sporadic ALS. This does not necessarily translate to an 
increase in the overall level of SOD1 protein, as SOD1 expression is regulated 
by multiple mechanisms (Milani et al. 2011, Milani et al. 2013). In fact,  published 
data suggests a decrease in total SOD1 in PBMCs, although this was not 
observed in the work presented in this chapter (Fig. III-8, (Cova et al. 2006, 
Gagliardi et al. 2010).   
Interestingly, Trp32 was found to be over-oxidized in SOD1 isolated from 
SALS PBMCs compared to controls (Table III-2, Fig. III-10). This tryptophan 
residue is directly implicated in FALS-linked SOD1 pathogenesis. Trp32 is not 
required for toxicity of FALS-linked SOD1 variants as mice expressing mouse 
SOD1 G86R, a model lacking Trp32, develop an ALS-like phenotype, suggesting 
other mechanisms are involved in SOD1 pathogenesis as well (Ripps et al. 
1995). However, multiple studies have suggested the Trp32 residue contributes 
to toxicity and misfolding of human SOD1. For example, oxidation-induced 
aggregation of WT SOD1 requires the presence and oxidation of Trp32 to 
proceed (Zhang H. et al. 2003). In immortalized cell lines, the propagation of 
SOD1 misfolding by FALS-linked SOD1 is prevented when Trp32 is replaced 
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with a serine (Grad et al. 2011).  Moreover, the toxicity due to FALS-linked SOD1 
expression in cultured motor neurons is ameliorated when Trp32 is mutated to a 
phenylalanine (Taylor et al. 2007). The heightened oxidation of Trp32 specifically 
on SOD1 from SALS PBMCs suggests SALS-linked SOD1 may contribute to 
ALS pathogenesis in a similar manner. 
One potential modification responsible for the SOD1 species observed at 
pI 5.4 is the oxidation of His46 to produce aspartic acid. Being that aspartic acid 
is negatively charged, this conversion from histidine induces a reduction in pI like 
that observed for the SOD1 in control samples by 2D-GE (Fig. III-8). Histidine is 
known to be one of the primary targets of metal catalyzed oxidation (Dean et al. 
1989, Schoneich 2000, Uchida 2003), and as such, the oxidation of this amino 
acid is not surprising. In fact, the oxidation of histidine to 2-oxo-histidine that was 
identified in both the SALS and control pooled SOD1 samples has been 
previously identified in SOD1 from bovine and human erythrocytes (Uchida and 
Kawakishi 1994, Rakhit et al. 2002). One can imagine the unique susceptibility of 
histidines in SOD1 to be oxidized, as the majority of the histidines coordinate zinc 
and copper in the active site, which in the presence of H2O2, can participate in 
metal-catalyzed oxidation (Fig. III-11). Further, SOD1 isolated from bovine 
erythrocytes subjected to amino acid composition analysis demonstrated a 
decrease of histidine and an increase in aspartic acid after exposure to H2O2 
(Uchida and Kawakishi 1994). The conversion of histidine to aspartic acid in the 
control SOD1 pool only, however, is surprising especially since an overall 
119
increase in oxidation is seen in the SALS SOD1 pool (Table III-2). One theory is 
that this difference may signify a change in the cellular environment of PBMCs in 
SALS compared to controls. For example, oxidation of SOD1 by other methods 
in vitro, such as CuCl2 and ascorbic acid, results in a decrease in the histidine 
composition, like what is seen for H2O2 induced oxidation, but has no effect on 
aspartic acid composition (Rakhit et al. 2002). These data suggest that the 
oxidized SOD1 products may be indirect evidence of altered oxidative species 
present inside the cell. A second theory is that the ring-ruptured product of 
oxidized histidine, aspartic acid, is an early step in the degradation of SOD1. In 
fact, the ring-opening products of histidine have been proposed to be products of 
degradation as they are downstream events of 2-oxo-histidine (Dean et al. 1989, 
Uchida 2003). Therefore, the conversion of histidine to aspartic acid found 
enriched in SOD1 from control PBMCs could be evidence of a protein 
degradation pathway compromised in SALS. Further, the over-oxidized SOD1 
species present in SALS PBMCs, which is likely misfolded (Rakhit et al. 2002, 
Rakhit et al. 2004), may interfere with protein clearance mechanisms directly by 
triggering ER stress through an interaction with Derlin-1, similar to what is seen 
for FALS-linked SOD1 variants (Nishitoh et al. 2008).  
This is the first study to demonstrate differential species of SOD1 in SALS 
PBMCs compared to controls. The 5.4 SOD1 species identified by 2D-GE 
provides a direct link between altered SOD1 homeostasis and sporadic ALS. 
Future studies aimed at evaluating the SOD1 species in sera and PBMCs of 
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SALS patients over time will help us discover the role of this protein in disease 
progression. Further study is required to identify if this connection is unique to 
ALS, or if it has a more global application with other neurodegenerative and 
inflammatory diseases.  
Materials and Methods 
SOD1 protein expression and purification- See Chapter II, Materials and 
Methods for details on protein purification. 
Sandwich ELISA for misfolded SOD1- A 384-well high binding plate (Greiner, 
#781061) was coated with 12.5 µl/well of C4F6 antibody at 9 µg/ml in phosphate 
buffered saline (PBS) and incubated at 4°C for 16 h. The plate was washed by 
submersion 3x in phosphate buffered saline, tween20 (0.01 M PBS, 0.05% 
tween20) followed by a blocking step with 25 µL/well of 5% BSA in PBS for 1 h at 
room temperature. Following the blocking period, the plate was washed 1x with 
PBST and recombinant SOD1, CSF, sera or lysate were added in a dilution 
series (1, 1:2, 1:4, 1:8) and incubated for 1 h at room temperature. The plate was 
then washed 3x with PBST and the primary antibody, anti-SOD1 (AbCam, 
ab79390), was added at 1:1000 in PBST, incubated for 1 h at room temperature. 
The plate was then washed 3x in PBST and probed with poly HRP-conjugated 
anti-Rabbit (Fisher, PI32260) at 1:10,000 in PBST for 1 h at room temperature. 
After washing 3x with PBST, 25 µL  of TMB substrate (SurModics, TMBS-0100-
01) was added to each well for 30 min. The reaction was quenched by adding 25 
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µL/well of Stop Solution (SurModics, LSTP-0100-01). Absorbance at 450 nm was 
detected with a 384-well plate reader (Safire). 
Sandwich ELISA for total SOD1- For total SOD1 calculations, ELISA was 
performed essentially as described above with the following exceptions. The 
coating antibody was anti-SOD1 at 1: 40 and the detection antibody was HRP 
conjugated anti-SOD1 at 1:1000 (eBioscience, BMS222MST).  
Isolation and lysis of RBCs and PBMCs- All SALS samples were processed 
with a healthy control in parallel. RBCs and PBMCs were processed from the 
same blood draw from the same individual. Blood samples were collected using 
standard venipuncture technique in yellow top tubes containing 22 g/L Trisodium 
Citrate, 8 g/L Citric Acid, 24.5 g/L Dextrose. For RBCs, 8 mL of blood was 
centrifuged in a 15 ml conical tube for 15 min at 300 ruff.  Then, the cells were 
washed with 12 ml of Hank’s Balanced Salt Solution (HBSS; Invitrogen, 
14025076) and spun for 15 min at 300 rcf. Supernatant was removed and the cell 
pellet was resuspended in 500 µL of lysis buffer (25 mM Tris, pH 7.8) and 
sonicated for 5 sec at 10% at 4°C. The lysed RBCs were then centrifuged at 
13,000 rpm for 15 min at 4°C. The supernatant was aliquoted and stored at -
80°C. 
For PBMCs, 4 mL lymphoblast separation solution (Lonza, 17-829F) was 
added to an isolation tube (Greiner, 163290P) and spun at 1000 rcf for 1 min for 
tube priming. Then, 5 ml blood was added slowly to the upper layer of the tube 
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and spun at 1600 rcf for 30 minutes. Immediately following centrifugation, the 
mononuclear cell layer was collected with a Pasteur Pipette and transferred to a 
15 ml conical tube and spun at 300 rcf for 15 min.  Cells were washed with 12 ml 
of HBSS and mixed by inverting tube 5 times. The PBMCs were centrifuged for 
15 minutes at 300 RCF. The supernatant was removed and the cells were 
resuspended in 200 µl of lysis buffer (25 mM Tris, pH 7.8) and sonicated for 5 
sec at 10% at 4°C. The cell lysate was Centrifuged at 13,000 rpm for 15 min at 
4°C. Aliquoted supernatant was stored at -80°C. Lysates were processed within 
one week by 2D-GE analysis. Lysates were processed within one month for 
immunoprecipitation and mass spectrometry analysis. 
Immunoblots- For denaturing western analyses, samples were diluted in 6x 
sample buffer (Boston Bioproducts, BP-111R). Samples were separated by 
PAGE with 15% Tris-acrylamide gels in 1% SDS, 25 mM Tris, 192 mM glycine 
and transferred to PVDF membrane (Millipore) in 25M Tris, 192 mM glycine. 
Membranes were blocked for 1h in Odyssey blocking buffer (LI-COR). Primary 
antibodies were incubated at 4°C overnight at the following dilutions: (pan-
SOD1(Taylor et al. 2007), 1:500; anti-α tubulin (Sigma), 1:5000; anti-SOD1 
(AbCam, ab79390), 1:50,000). The blots were incubated for 1 h with fluorophore-
conjugated secondary antibodies (LI-COR) prior to visualization by the Odyssey 
Infrared Imaging System (LI-COR). The Odyssey infrared imaging software (LI-
COR) was used for densitometry calculations.  
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2-D Gel Electrophoresis- Samples were mixed with rehydration buffer (8 M 
Urea, 1.5% CHAPS, 50 mM DTT, 0.2% Bio-lytes (Bio-Rad, 1632097), trace 
amounts of Bromophenol Blue) and separated by isoelectric focusing on a pH 
strip range 4.7-5.9 (BioRad, 163-2025 (discontinued); suggest 163-2017 as 
alternative). The following parameters were used after a 12 h passive 
rehydration: 
Step 1: 250 V for 15 min 
Step 2: 2000 V hours 
Step 3: 8000 V for 2 hours 
Step 4: 500 V hold 
 
Upon completion of focusing, strips were moved to rehydration trays containing 
500 µl of equilibration buffer (6 M Urea, 2% SDS, 0.375 M Tris, 20% Glycerol, 
150 mM DTT) for 5 min. The strips were then secured in gel with agarose sealing 
solution (1% agarose, 1% SDS, 25 mM Tris, 192 mM glycine) and subjected to 
SDS-PAGE in a 15% Tris-acrylamide gels in 1% SDS, 25 mM Tris, 192 mM 
glycine. Where applicable, the gels were then transferred to a PVDF membrane 
for 16 h at 30 V at 4°C. Membranes were blocked for 1 h in Odyssey blocking 
buffer (LI-COR). Primary antibodies were incubated for 3 h at the following 
dilutions: anti-SOD1(Taylor et al. 2007); anti-SOD1 (AbCam, 1:50,000). The blots 
were incubated for 1 h with fluorophore-conjugated secondary antibodies (LI-
COR) prior to visualization by the Odyssey Infrared Imaging System (LI-COR). 
The Odyssey infrared imaging software (LI-COR) was used for densitometry 
calculations.  
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Mass spectrometry analysis of immunoprecipitated SOD1- Protein G 
Dynabeads (Invitrogen, 10004D) were coated with mouse IgG (Sigma, I5381) for 
preclearing of lysate) and anti-SOD1 (Pierce, LFMA0023) for 
immunoprecipitation. Approximately 1400 µg (RBC) or 350 µg (PBMC) of lysate 
diluted in PBST was added to 50 µL mouse IgG coated beads, rotating at room 
temperature for 1 h. The precleared lysate was removed and added to anti-SOD1 
coated beads for 2 h rotating at room temperature. SOD1 was boiled off the 
beads with 50 µL of 3x SDS Page loading buffer and subjected to SDS-PAGE 
and stained with coomassie. Tryptic (Promega) in-gel digest was performed 
essentially as described (Shevchenko et al. 2006). Extracted peptides were 
lyophilized and resuspended in 16 µL of 5% acetonitrile in 0.1% trifluroacetic acid 
immediately prior to injection on LC/MS/MS.  A 4.0 µL aliquot was directly 
injected onto a custom packed 2cm x 100µm C18 Magic 5µm particle trap 
column.   Peptides were then eluted and sprayed from a custom packed emitter 
(75µm x 25cm C18  Magic 3µm particle) with a linear gradient from 95% solvent A 
(0.1% formic acid in water) to 35% solvent B (0.1% formic acid in acetonitrile) in 
45 minutes at a flow rate of 300 nanoliters per minute on a Waters Nano Acquity 
UPLC system.   Data dependent acquisitions were performed on a Q Exactive 
mass spectrometer (Thermo Scientific) according to an experiment where full MS 
scans from 300-1750 m/z were acquired at a resolution of 70,000 followed by 10 
MS/MS scans acquired under HCD fragmentation at a resolution of 17,500 with 
an isolation width of 1.6 Da.  Raw data files were processed with Proteome 
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Discoverer (version 1.4) with Mascot (Version 2.5, Matrix Science) using the 
human Uniprot database. An error tolerant search was employed to identify 
modifications present on SOD1 peptides. Scaffold was used to quantify the 
modified (oxidation, deamidation, carbidomethylation, N-term acetylation, 
phosphorylation) and unmodified peptides (false discovery rate (FDR), 1.3%) 
identified in the error tolerant search.  
Axonal Transport Assay- Squid axoplasms were isolated and perfused with 
SOD1 essentially as previously described (Morfini G. et al. 2006). The isolated 
axoplasms were perfused with 1.4 µM hSOD1 (pooled from 3 patients) and 
monitored for 50 min using live imaging as described (Morfini G. et al. 2006). 
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PREFACE TO CHAPTER IV: 
 
Parts of this chapter appeared in: 
Rotunno, M.S., Bosco, D.A., “An emerging role for misfolded wild-type SOD1 in 
sporadic ALS pathogenesis.” Frontiers in Cellular Neuroscience. 2013, 7, 253. 
Invited review. 
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CHAPTER IV: DISCUSSION 
 ALS is a devastating disease resulting in motor neuron degeneration, 
muscle atrophy, and paralysis. Although ALS is relatively rare, the lifetime risk is 
estimated at greater than one in 500, as it primarily targets the aged population 
(Alonso et al. 2009, Wijesekera and Leigh 2009). ALS is known to be a multi-
faceted disease with numerous contributing factors such as oxidative stress, 
excitotoxicity, protein aggregation, mitochondrial dysfunction and chronic 
inflammation (Wijesekera and Leigh 2009). The ALS community is starving for an 
effective treatment, as Riluzole, the only FDA approved drug to treat ALS, has 
minimal effects on survival (Miller et al. 2012).  
A large number of mutations in SOD1 result in ALS pathogenesis, but the 
common “toxic” region among these species had not been determined prior to 
this study. Misfolding of ALS-linked mutant SOD1 has been well established 
through both its increased propensity to aggregate (Durham et al. 1997, Bruijn et 
al. 1998, Johnston et al. 2000, Stathopulos et al. 2003, Furukawa et al. 2006, 
Wang Q. et al. 2008, Prudencio et al. 2009) Review: (Chattopadhyay and 
Valentine 2009), in-solution structural analyses (Shipp et al. 2003, Durazo et al. 
2009, Molnar et al. 2009), and through the generation of misfolded SOD1-
specific antibodies (Rakhit et al. 2007, Urushitani et al. 2007, Liu et al. 2009, 
Bosco et al. 2010, Forsberg et al. 2010, Gros-Louis et al. 2010, Grad et al. 2011, 
Brotherton et al. 2012, Fujisawa et al. 2012, Broering et al. 2013).  
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In addition to misfolding of SOD1 induced by ALS-linked mutations, 
aberrant post-translational modifications (PTMs) have been shown to result in 
major structural disturbances, a phenomenon that could result from the 
environmental/genetic factors involved in SALS pathology. Examples of such 
PTMs include oxidation of amino acid side chains (Ezzi et al. 2007, Fujiwara et 
al. 2007, Bosco et al. 2010, Chen X. et al. 2012b, Auclair et al. 2013b), lack of 
metal coordination (Ding and Dokholyan 2008, Banci et al. 2009, Durazo et al. 
2009), and loss of the stabilizing intramolecular disulfide bridge (Chan et al. 
2013).  
The work presented in this dissertation provides preliminary data on 
methods of tracking misfolded and differentially modified forms of SOD1 in 
biofluids as a biomarker strategy for ALS. As discussed in Chapter III, finding a 
reliable biomarker for ALS is vital for patient stratification in clinical trials, early 
diagnosis, tracking patient response to therapeutics and for tracking disease 
progression (Robelin and Gonzalez De Aguilar 2014). With this in mind, it is 
necessary to repeat these preliminary studies with a larger cohort of ALS patients 
to verify the validity and reproducibility of the findings put forth in this dissertation. 
In addition to exploiting SOD1 as a biomarker for ALS, the work presented 
in this dissertation has put forth stabilizing the zinc binding and electrostatic loops 
of misfolded SOD1 as a therapeutic target. Modified forms of SOD1, whether by 
mutations or aberrant post-translational modifications, result in a loosening of the 
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protein structure that further exposes the hydrophobic core (Fig. I-1, IV-1). This 
effect may increase SOD1’s vulnerability to oxidation (Table III-2) and lead to a 
more promiscuous SOD1 protein, engaging in aberrant protein-protein 
interactions and/or tighter binding with normal protein-protein interactions thereby 
altering downstream effects (Fig. I-4). ALS-linked SOD1 has been shown to 
exhibit prion-like properties, similar to those of established prion proteins 
(Polymenidou and Cleveland 2011). In cell culture models, misfolded and 
aggregated SOD1 is secreted and taken up by surrounding cells, inducing 
misfolding and aggregation of endogenous, nonpathogenic SOD1 protein (Grad 
et al. 2011, Munch et al. 2011). Recently, spinal cord homogenates from 
paralyzed SOD1 G93A transgenic mice injected directly into the spinal cord of 
predisposed ALS mouse models have been shown to induce aggregation and 
progressive paralysis (Ayers et al. 2014). Stabilizing SOD1 in its proper fold 
and/or blocking this “toxic” region and inhibiting the exponential process of SOD1 
misfolding could potentially curb disease progression in both sporadic and 
familial forms of ALS. 
SOD1-Based Therapeutics 
Being that SOD1 pathological aggregates are a downstream consequence 
of SOD1 misfolding, the presence of such aggregates in human post-mortem 
tissues and ALS-mice argues for a role of misfolded SOD1 in disease.  As 
discussed earlier, there is evidence for misfolded SOD1 in both sporadic and 
familial   ALS   (see Chapter I).   Strategies   for   neutralizing,  decreasing,   and 
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Figure IV-1. PTM-linked and FALS-linked SOD1 share a common misfolded 
conformation.  We hypothesize that misfolded SOD1 results from both ALS-
linked mutations and aberrant post-translational modifications. The term 
“misfolding” refers to the structural loosening of SOD1 due to a mutation and/or 
altered post-translational modification within a soluble form of the protein.  
Misfolded, soluble SOD1 can engage in aberrant protein-interactions and acquire 
new toxic functions (illustrated in Figure I-4). Misfolded SOD1 can also assemble 
into aggregates. 
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repairing this load of misfolded SOD1 species are being explored as potential 
therapies (Fig. IV-2). 
Immunization Strategies Targeting SOD1 
Studies from van Blitterswijk et al. suggest that longer survival is 
associated with ALS patients harboring antibodies directed at misfolded SOD1 
(van Blitterswijk et al. 2011). In fact, immunization strategies targeting misfolded 
SOD1 species have had therapeutic outcomes in ALS mice. A passive 
immunization strategy with the D3H5 antibody that specifically reacts with 
misfolded SOD1 extended survival in G93A SOD1 transgenic mice (Gros-Louis 
et al. 2010)(Fig I- 3, Table I-1).  A greater therapeutic impact was shown in 
active immunization trials with the SOD1 G37R transgenic mouse model, using 
both recombinant apo-SOD1 G93A (Urushitani et al. 2007) and the SEDI (SOD1 
exposed dimer interface) peptide (Liu et al. 2012) as immunogens.  Use of SEDI 
increased survival and delayed disease onset to a greater extent than the full-
length SOD1 immunogen, likely due to specific targeting of a misfolded toxic 
epitope within mutant-SOD1 (Liu et al. 2009, Liu et al. 2012).  
A more modern approach by Patel et al. demonstrated the effectiveness of 
a “chronic passive immunization” treatment (Patel et al. 2013). This approach 
involves the intrathecal delivery of a viral vector expressing a single chain 
antibody fragment derived from the D3H5 described above.  The result is chronic  
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Figure IV-2. Therapeutic Strategies for SOD1-linked ALS. (A) Immunization 
strategies targeting misfolded SOD1. Passive immunization approaches include 
treatment with misfolded-SOD1 specific antibodies (1) and viral vectors to 
chronically express antibody fragments (2). Active immunization with either 
fragments of (3) or full-length (4) misfolded SOD1 are also being explored. (B) 
Knockdown approaches involving RNAi expressing viral vectors (5), antisense 
oligonucleotides (6, in clinical trials), and siRNA mechanisms (7) are being 
investigated. (C) Small molecules that repair and/or neutralize the load of 
misfolded SOD1 are currently in clinical trials. 
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expression of the variable region of a misfolded SOD1-specific antibody. The 
methodology requires more fine-tuning and optimization to increase consistency, 
but shows great promise as survival in SOD1 G93A transgenic mice was 
extended from 140 to 180 days upon treatment (Patel et al. 2013). These data 
suggest that immunization strategies directly targeting misfolded SOD1 could 
have therapeutic potential.  
While these studies provide a direct correlation between misfolded SOD1 
species and disease in mice, a survival benefit was not realized using humanized 
SOD1 antibodies in SOD1 transgenic mice (Broering et al. 2013).  Going forward, 
immunotherapeutic strategies in humans may require the specific targeting of 
regions within SOD1 that are only exposed upon misfolding.  Moreover, these 
regions should mediate some toxic effect in vivo, so that antibodies have the 
potential to neutralize or otherwise block that “toxic epitope”.  The latter criterion 
is important in light of the fact that not all mutant-specific antibodies have 
produced a therapeutic outcome in SOD1 transgenic mice (Gros-Louis et al. 
2010). 
Decreasing Expression of SOD1 
Studies underway are investigating the possibility of reducing the load of 
total SOD1 protein as a potential therapeutic target. Although the major school of 
thought is the gain-of-toxic function model for SOD1-induced ALS, there is 
increasing evidence that loss-of-function contributes to disease progression as 
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well (reviewed in (Saccon et al. 2013)), which argues against decreasing SOD1 
expression as treatment.  For example, the anti-oxidizing activity, although still 
functional, is decreased in the majority of FALS-linked SOD1 mutations (Borchelt 
et al. 1994, Robberecht et al. 1994).  
Reducing the load of misfolded SOD1 could be a promising avenue, but 
could also increase neuronal susceptibility to degeneration in the absence of 
such a highly abundant anti-oxidizing enzyme. One can imagine in a disease 
such as ALS, where oxidative stress is elevated, that the lack of an abundant 
anti-oxidizing enzyme, like SOD1, could be detrimental. Mice lacking SOD1 
protein, for example, have an increased sensitivity to neuronal injury (Reaume et 
al. 1996). This study implies that when faced with additional neuronal stress, 
which is evident in ALS pathology, SOD1 protein is required as part of the coping 
mechanism. In fact, evidence suggests oxidative stress increases with age 
(Smith C. D. et al. 1991).  Oxidative stress is known to induce destabilization, 
aggregation, and reduced activity of SOD1, which could be one of the reasons 
for the age-related onset of ALS (Smith C. D. et al. 1991, Rakhit et al. 2004, Ezzi 
et al. 2007). 
Altering SOD1 levels has been explored as a novel cancer therapeutic. In 
cell culture systems, SOD1 knockdown results in senescence and therefore has 
the potential to halt tumor growth, and even induces cell death in a cancer cell 
line (Blander et al. 2003). Tumors, however, have evidence of decreased SOD1 
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activity (Sun et al. 1993), which is linked to tumorogenesis. SOD1 deficient mice, 
for example, have a shorter lifespan caused by hepatocellular carcinomas, or 
liver tumors (Elchuri et al. 2005). In fact, overexpression of SOD1 has been 
proposed as a possible cancer treatment, as it has been shown to inhibit tumor 
growth (Bai et al. 1998, Zhang Y. et al. 2002). Hepatocellular carcinoma, one of 
the more common cancers, is likely caused by DNA damage induced by 
oxidative stress (Cardin et al. 2014). The liver has a unique susceptibility to 
spontaneous DNA mutations in SOD1-deficient mice. In contrast, the brain does 
not demonstrate an increase in spontaneous DNA mutations (Busuttil et al. 
2005), which implies a CNS-specific knockdown of SOD1, in the context of ALS, 
might not have the same carcinoma-inducing effect.  
Indeed, several ALS animal models expressing FALS-linked SOD1 have 
demonstrated the protective effects of SOD1 knockdown in vivo (Ralph et al. 
2005, Smith R. A. et al. 2006, Wang L. et al. 2010). It is possible that a more 
selective knockdown in specific cell types could be beneficial while still 
maintaining the protective effect of SOD1 in other parts of the body. More 
specific targeting of SOD1 knockdown in select cell types such as Schwann, 
motoneuron, and astrocytes exhibit protective effects as well (Wang L. et al. 
2012b, Dirren et al. 2015). Ideally, we could identify a method to specifically 
knockdown only the mutant allele, leaving the other allele to express native 
SOD1.  Nevertheless, decreasing SOD1 expression is a therapy worth exploring 
as beneficial effects have been observed. 
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Small Molecules Targeting Misfolded SOD1 
Another potential therapeutic method being explored is to target SOD1 
with small molecules to either stabilize it in its dimeric form or neutralize the toxic 
properties (reviewed in (Limpert et al. 2013)). Being that misfolded SOD1 
engages in multiple aberrant protein-protein interactions (Fig. I-4), high-
throughput screens directed at disrupting them, such as the dynein-SOD1 
interaction, are being explored (Zhang F. et al. 2007, Tang et al. 2012). In fact, 
we identified several small molecules that have the potential to repair misfolded 
SOD1 by employing the misfolded-specific antibody, C4F6 (described in 
Appendix II).   
Monomeric SOD1 is thought to be a precursor to misfolding and 
aggregation. One route of targeting for therapeutics would be to find small 
molecules that can stabilize SOD1 in its dimeric state. Several in silico screens 
have been performed to identify such compounds. In the first in silico study, Ray 
et al.  identified  100 compounds with a predicted high binding affinity to SOD1 
dimer (Ray et al. 2005, Nowak et al. 2010). Of these initial hits, 15 were able to 
prevent dimer loss of mutant SOD1 in vitro. These compounds stabilized SOD1 
as indicated by unfolding studies with guanidine-HCl. In follow-up in vitro studies, 
however, the aggregation of FALS-linked SOD1 was unaltered in the presence of 
these compounds, despite the fact that one of the compounds was found to bind 
SOD1 at an amino acid implicated in SOD1 pathogenesis, Trp32 (Wright et al. 
2013). 
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 Several studies have searched for small molecules that reverse the toxic 
properties of FALS-linked mutant SOD1 in cell culture systems (Benmohamed et 
al. 2011, Yang et al. 2013). Benmohamed et al. identified compounds that 
reduced MG132-induced toxicity and FALS-linked SOD1 aggregation 
(Benmohamed et al. 2011). The benefit of this type of screen over the completely 
in vitro approach with recombinant SOD1 protein is the ability to identify 
compounds that indirectly tweak the cell’s coping mechanisms as opposed to 
only identifying compounds that directly bind SOD1 to interfere with aggregation. 
An aryloxanyl pyrazolone derivative, an optimized version of 1 of the 3 original 
chemical scaffolds identified, extends survival in an ALS mouse model 
(Benmohamed et al. 2011, Chen T. et al. 2012a). These compounds are 
currently being optimized to further enhance the pharmacokinetic properties 
(Zhang Y. et al. 2013) prior to clinical trials.  Preferably, we can identify a 
therapeutic approach specifically targeting the misfolded SOD1 species, leaving 
WT unchanged. This is a challenging endeavor, as SOD1 is a homodimer, and 
dimeric species are likely a mixture of misfolded and normal WT SOD1 (Ganesan 
et al. 2008).  
Other Promising Future Therapeutics 
Multiple small molecules are being explored that target different aspects of 
disease such as decreasing excitotoxicity, conserving mitochondria, increasing 
neuronal survival, decreasing inflammation and increasing muscle function 
(Pandya et al. 2013). A variety of pathways are involved in ALS pathogenesis 
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and, as such, a more effective approach may be therapeutics used in 
combination to enhance the benefits of these compounds. Some of the more 
promising compounds are discussed herein.  
There is ample evidence that excitotoxicity is linked to ALS pathology in 
cell culture models, transgenic models, and patients (Van Den Bosch et al. 
2006). Even Riluzole, the only drug currently available to ALS patients, is thought  
to act as an anti-excitotoxic agent by decreasing extracellular glutamate (Martin 
et al. 1993). Beta-lactam antibiotics act by increasing the expression of glutamate 
transporter, GLT1, which protects against excitotoxicity (Rothstein et al. 2005). 
One clinical trial in progress is testing whether Ceftriaxone, a beta-lactam 
antibiotic, has any promising effects since it indirectly results in a decrease in 
glutamate. Preliminary data shows safety and efficacy, but long-term studies are 
unable to be interpreted, as too many patients left the trial. Therefore, further 
studies are required to determine the effects this treatment has on curbing 
disease progression ((Berry et al. 2013); 
https://clinicaltrials.gov/ct2/show/NCT00349622?term=ALS+ceftriaxone&rank=1). 
Cell replacement therapy is another promising avenue being explored as a  
treatment for ALS (Thomsen et al. 2014). This can be further divided into two 
main approaches. The first is to replenish the depleted motor neurons with 
neuronal progenitor cells. This approach, although potentially very powerful, is 
quite challenging because these cells need to incorporate themselves into an 
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established complex network (Becker and Diez Del Corral 2015). The second 
approach is to deliver cells to serve as a support system for the motor neurons in 
jeopardy. Specifically, mesenchymal stem cells are being explored for this 
purpose and their safety has been established (Mazzini et al. 2009). 
Mesenchymal cells have been shown to promote neurotrophic factors and 
decrease gliosis in ALS mouse models (Vercelli et al. 2008, Sadan et al. 2009). 
Being that neuronal death and lack of muscle stimulation results in progressive 
paralysis in ALS, replacing and/or supporting the motor neurons through cell 
replacement therapy is a promising therapeutic approach. It is, however, 
important to proceed with caution as the chronic immune suppression regimen 
that accompanies these cell replacement therapies can have detrimental side 
effects to ALS patients (Thomsen et al. 2014).  
Directly targeting the toxic properties displayed by ALS-linked neurons is a 
possible treatment for ALS as well. By investigating multiple iPSC-derived motor 
neuron cell lines, Wainger and colleagues demonstrated a hyperexcitability 
unique to ALS patient lines. By using retigabine, an FDA approved 
anticonvulsant for the treatment of epilepsy, a decrease in the hyperexcitability 
was observed. Treatment with retigabine also decreased signs of ER stress, a 
cellular response to unfolded/misfolded protein accumulation, such as reduced 
splicing of XBP1 (Wainger et al. 2014). 
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A generalized increased in heat shock chaperones could prove protective 
in the cytotoxic environment of the CNS. Heat shock proteins represent a known 
coping mechanism of cells in a toxic environment. Arimoclomol, a known inducer 
of heat shock proteins, is currently in Phase III clinical trials for the treatment of 
FALS-linked SOD1 induced ALS
(https://clinicaltrials.gov/ct2/show/NCT00706147?term=Arimoclomol&rank=1).  
Arimoclomol enhances survival in a transgenic mouse model of ALS, even when 
treatment begins after symptom onset (Kieran et al. 2004).  
As discussed below, protein misfolding and aggregation is a hallmark of 
ALS. In theory, the upregulation or enhancement of the cellular system that deal 
with this burden, such as the UPS and autophagy, could be exploited as a 
therapeutic approach. One such autophagy inducer, Tamoxifen, originates as a 
breast cancer drug. A patient with both ALS and breast cancer was prescribed 
Tamoxifen and appeared to a have a milder case of ALS 
(http://www.als.net/ALS-Research/Tamoxifen/ALS-Topics/), launching an 
investigation into this drug as a treatment for motor neuron disease. Tamoxifen 
treatment results in both neuronal protection and a decrease in TDP43 inclusions 
in an FTLD mouse model with TDP43 proteinopathy (Wang I. F. et al. 2012a). 
Now, Tamoxifen has passed phase II clinical trials and is currently recruiting for 
phase III (Traynor et al. 2006, Rubinsztein et al. 2007 ). Hopefully, over the next 
couple of years, a handful of these promising compounds will prove beneficial in 
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the treatment of ALS in patients and slow, halt, or even revert, the process of 
neurodegeneration and paralysis. 
Protein Misfolding and ALS 
Evidence of Altered Protein Homeostasis   
 Multiple mechanisms involved with maintaining protein homeostasis have 
been implicated in ALS. SOD1 is not, by far, the only ALS-associated protein 
incriminating protein misfolding and turnover in pathogenesis.  In fact, the 
majority of FALS-linked mutations translate an aggregation prone form of the 
protein. This is evident in, for example, in vitro studies of SOD1, TDP43, and 
profilin-1, which demonstrate an accumulation of these proteins in the insoluble 
fraction of cellular lysates (Johnson et al. 2009, Prudencio et al. 2009, Wu et al. 
2012). Most ALS-linked proteins, if not all, have been found in end-stage 
aggregates in the spinal cord of patients (reviewed in (Blokhuis et al. 2013)). 
These aggregates are commonly ubiquitinated and contain p62, both of which 
directly implicate the protein clearance mechanisms, UPS and autophagy 
(Seibenhener et al. 2004, Pankiv et al. 2007). Further, two proteins linked to 
inherited ALS, VCP and UBQLN2 are directly involved in protein degradation 
(Wojcik et al. 2006, Lee and Brown 2012). ALS mouse models demonstrate 
signs of both ER stress and proteasome malfunction (Kabashi et al. 2004, Prell 
et al. 2012, Gorrie et al. 2014). In fact, studies support an impairment of the 
proteasome in SALS patient spinal cord (Kabashi et al. 2012). Together, these 
data implicate impaired protein clearance mechanisms in ALS.  
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The Additive Effect of Aging 
ALS is a disease primarily effecting the aging population. This is likely 
because of the breakdown of key systems that are involved with managing 
chronic stress. Aging tips the balance, decreasing the body’s army of defense 
mechanisms, allowing for people who have kept their ALS-inducing factors at bay 
to begin to lose the battle (Fig. IV-3).  
In vitro studies demonstrate a more rapid turnover of ALS-linked misfolded 
proteins, presumably as a coping mechanism (Kabuta et al. 2006, Farr et al. 
2011, Araki et al. 2014), which suggests protein turnover mechanisms are vital to 
combat disease.   In the process of aging under non-diseased conditions, protein 
oxidation is increased which adds to the load of misfolded proteins (Oliver et al. 
1987, Smith C. D. et al. 1991).  This increase in protein oxidation is a contributing 
factor to the decrease in select enzymatic activity, as seen for glutamine 
synthetase (Wolff and Dean 1986) that, mainly expressed in astrocytes, is 
responsible for maintaining extracellular glutamate levels and protecting 
surrounding cells from excitotoxicity (Suarez et al. 2002). The activity of catalase, 
a hydrogen peroxide scavenger, has also been shown to decrease with age 
(Alper 1998, Tsay et al. 2000). In addition to creating an environment that 
promotes protein modifications and misfolding, aging induces a decrease in 
efficiency of mechanisms that are involved in their reparation and degradation 
(Martinez-Vicente et al. 2005, Cuervo 2008). The ability to transcribe 
chaperones, which are required to both repair damaged proteins and/or promote  
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Figure IV-3. Protein misfolding, aging and ALS. Both genetic and 
environmental factors induce ALS-linked protein misfolding. The coping 
mechanisms, autophagy and UPS, counteract this stress by recycling damaged 
proteins. With age, these coping mechanisms decrease in efficiency, resulting in 
a build-up of protein misfolding and subsequently aggregation, both of which 
interfere with cellular homeostasis.  
 
 
 
 
 
 
 
 
 
 
144
their degradation, declines with age (Calderwood et al. 2009). This, in turn, 
increases the load of misfolded proteins in the cell. The effects of this are 
detrimental, particularly in non-dividing cells such as neurons, wherein 
ameliorating this burden of damaged proteins through cell division is not an 
option. Protein clearance mechanisms are also severely compromised in aging 
systems. Chaperone-mediated autophagy, for example, decreases with age in 
both rats and cultured human fibroblasts (Cuervo and Dice 2000).  Moreover, 
proteasome function declines with age (Saez and Vilchez 2014).  One can easily 
imagine a disease, such as ALS, where protein misfolding is rampant, that fully 
functioning protein clearance and repairing pathways are essential for survival.  
By teasing out the mechanism of protein misfolding in the context of ALS, we can 
hope to develop therapeutics that tip the system back to maintaining 
proteostasis.  
 Conclusion 
Since the discovery of the link of SOD1 mutations to ALS in 1993 (Rosen 
et al. 1993), multiple studies have provided insight into disease pathogenesis and 
mechanisms. Studies suggest that SOD1 misfolding extends far beyond the 
inherited form of ALS and targeting this species has great therapeutic potential. 
In fact, SOD1 misfolding is induced by more than simply FALS-linked SOD1 
mutations. Misfolded SOD1 is seen in spinal cord of patients harboring FALS-
linked FUS variants as well as in SALS cases with TDP43 pathology (Bosco et 
al. 2010, Forsberg et al. 2010, Pokrishevsky et al. 2012). Although the direct 
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involvement of SOD1 in ALS pathogenesis remains controversial, the work 
presented in this dissertation supports a causative role for WT SOD1 in disease. 
To test this hypothesis, we need to investigate further the ability of aberrantly 
modified SOD1 species found in SALS to induce an ALS-like phenotype in vivo 
(See Appendix I). If misfolded SOD1 is directly involved in pathogenesis of both 
SALS and FALS, therapeutic targets directed at FALS-linked SOD1 have the 
potential to extend to SALS-linked SOD1 as well.  
We now know protein misfolding, chronic inflammation, mitochondrial 
dysfunction, oxidative stress, impaired axonal transport, excitotoxicity and altered 
RNA metabolism are pathological hallmarks of disease (Barber and Shaw 2010, 
Sreedharan and Brown 2013). Next, we need to identify which of these pathways 
proactively trigger pathogenesis and how they can be exploited for therapeutic 
development.  
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PREFACE TO APPENDIX I 
Alexandra Weiss preformed the surgery wherein osmotic pumps were inserted 
into the mice with a catheter directly inserted into the intrathecal space of the 
spinal cord for protein delivery. Karin Green of the UMass proteomics and Mass 
Spectrometry facility analyzed fluorescently tagged SOD1 by mass spectrometry. 
All other work presented was performed by Melissa S. Rotunno. 
 
 
 
 
 
 
 
 
 
 
 
147
APPENDIX I: Investigating a Causative Role for WT SOD1 in Sporadic ALS 
The primary cause of sporadic ALS, as of now, is unknown.  Since 
multiple neurodegenerative disease-associated proteins have been implicated in 
both familial and sporadic forms of disease, we are testing the hypothesis that 
modified forms of WT SOD1 play a causative role in sporadic ALS.  
Conformation-specific antibodies have been developed that preferentially bind to 
ALS-linked mutant over WT SOD1 (Table I-1, Fig. I-3).  We found that these 
same antibodies recognize an oxidized form of SOD1 (SOD1ox), which exerts a 
mutant-like toxicity in several biological assays. Therefore, SOD1ox and mutant 
SOD1 proteins share a similar “toxic” conformation that is not formed by native 
WT SOD1 (Chapter II).  We are investigating whether misfolded WT SOD1 
proteins that exhibit an aberrant conformation, such as SOD1ox, can induce an 
ALS-like phenotype in mice as observed for FALS-linked SOD1 variants.   The 
difficulty in developing such a model lies in the simple fact that mice cannot be 
transgenically engineered to express proteins with aberrant post-translational 
modifications. To overcome this limitation, we are exploring an alternative 
approach to assess toxicity utilizing osmotic pumps to chronically deliver SOD1 
with aberrant PTMs to the spinal fluid of mice.  
SOD1 variants exhibit prolonged stability in osmotic pumps- Prior to 
inserting osmotic pumps directly into mice, we aimed to assess the efficiency of 
delivery and the stability of SOD1 proteins inside these pumps over time. Being 
that oxidized SOD1 is a misfolded protein, we wanted to confirm the protein was 
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capable of being delivered through the catheter at the concentration expected 
and not lost by adherence to plastic tubing or aggregation.  
Four 28-day osmotic pumps were filled (>100 µl) with filter-sterilized 
protein (WT SOD1 and SOD1ox) at 1 mg/mL. These pumps deliver protein at a 
rate of 0.11 µL/h. Oxidized SOD1 exhibiting various degrees of oxidation induced 
by increasing hydrogen peroxide exposure time (1, 4 and 24 h) were included in 
this analysis (SODox1, 1 h; SODox4, 4 h; SODox24, 24 h). The pumps were 
placed in 50 mL conical tubes containing 15 mL of phosphate buffered saline and 
placed at 37°C. Protein was extracted periodically from the end of the catheter 
and tested for activity and stability. SOD1 activity assays were carried out 
immediately after taking the sample. To assess SOD1 activity, a competition 
assay with cytochrome C was employed (Okado-Matsumoto and Fridovich 
2001). Xanthine oxidase reacts with xanthine to produce superoxide, the natural 
substrate of SOD1. When cytochrome C reacts with xanthine, an increase in 
absorbance at 550 nm is observed. When SOD1 reacts with the superoxide to 
form hydrogen peroxide and water, no change in absorbance is observed 
(Figure AI-1).  
Western blot samples were prepared and placed at -80°C and run 
simultaneously after the completion of the time course. As determined by 
western analysis, an initial decrease in SOD1 was seen for all samples between  
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the initial setup (Day 0) and Day 3. Subsequently, the concentration of SOD1 
remained stable over the 28-day period assessed (Figure AI-2). 
As shown in Figure AI-3, the activity of SOD1 with the superoxide radical 
is maintained with minor fluctuations in the range of 80-100% of SOD1 at the 
start of the experiment. This data supports that the functionality of SOD1 is not 
impaired by a 28 d incubation at 37°C in osmotic pumps. It should be noted, 
however, that oxidized SOD1 dismutase activity is inherently impaired compared 
to WT SOD1 (Fig. AI-4). 
Osmotic pumps effectively deliver SOD1 to the spinal cord of surgically 
implanted mice - Now that the stability of SOD1 has been established over a   
28 d period in osmotic pumps, the next step was to assess the efficiency and 
efficacy of protein delivery to the intrathecal space of these mice.  A pilot study 
was performed with 4 mice surgically implanted with osmotic pumps containing 
fluorescently tagged SOD1 (fluoro488-SOD1, n=3) or PBS (n=1) with the 
catheter directly inserted into the intrathecal space of the lumbar region. 
Fluorescently tagged SOD1 was used to differentiate between the human SOD1 
delivered via osmotic pumps from that of endogenous mouse SOD1. To confirm 
SOD1 was conjugated to the fluorophore, the protein was subjected to mass 
spectrometry analysis (Figure AI-5). Unmodified WT SOD1 and SOD1ox24 have 
a molecular weight of 16,345 Da and 16,405 Da respectively. The modified WT 
SOD1 has molecular weights of  16,861 Da, 17,377 Da and 17,896 Da, which is  
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Figure AI-2. SOD1 proteins are stable for up to 28 days in osmotic pumps. 
Osmotic pumps were filled with the indicated protein (SOD1 WT, SOD1ox-1h, 
SOD1ox-4h, SOD1ox-24h) and placed at 37ºC for 28 days. SOD1 samples were 
taken at the indicated time. The SOD1 was subjected to western analysis to 
assess solubility and stability of SOD1 over time. All SOD1 variants exhibited an 
initial decrease in concentration (compare 0 day to 3 day sample) that was 
maintained over the 28 day period.  
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Figure AI-3. SOD1 proteins retain activity for 28 days in osmotic pumps. 
Osmotic pumps were filled with protein (A, SOD1 WT; B, SOD1ox-1h; C, 
SOD1ox-4h; D, SOD1ox-24h) and placed at 37º for 28 days. Aliquots were taken 
at the indicated times, and tested in the SOD1 activity assay.  All SOD1 variants 
(Sample) were normalized to activity at T=0 (Standard), with the relative activity 
illustrated. Results of assay show that both SOD1 WT and SOD1ox proteins 
retain activity, and thus appear stable, over the 28-day time course. 
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consistent with the addition of 1, 2, and 3 tags, respectively (Figure AI-5A,B). 
Each tag adds 516 Da to available primary amines. Modified SOD1ox has 
molecular weights of 16,923 Da, 17,441 Da, and 17,969 Da, which is also 
consistent with the addition of 1, 2, and 3 tags (Figure AI-5C,D). The mass 
spectrometry results indicate efficient modification of both WT SOD1 and 
SOD1ox with 1-3 modifications per monomer in >80% of the samples. 
To allow for maximum signal, a 3-day pump was employed which delivers 
the solution at a rate of 1 µL/h. After the 3-day period, the mice were sacrificed 
and assessed for protein delivery in the lumbar, thoracic and cervical spinal cord 
regions by immunoblotting and immunofluorescence techniques. The lumbar and 
cervical regions were removed and homogenized, and 12.5 µg and 25 µg of 
lysates, respectively were loaded onto an SDS-PAGE for western analysis. The 
blot was probed with anti- fluoro488 for the detection of fluoro488-SOD1 and 
anti-actin as a loading control. As illustrated in Figure AI-6A, 2 out of the 3 mice 
contained fluoro488-SOD1 in the lumbar spinal cord. Only 1 out of the 3 mice 
contained fluoro488-SOD1 in the cervical spinal cord. The abundance of 
fluoro488-SOD1 in the thoracic region of the spinal cord was not assessed by 
Western analyses. Instead, the thoracic region was sectioned for 
immunofluorescence and fluoro488-SOD1 was detected utilizing the anti-
fluoro488 antibody, which showed fluoro488-SOD1 in 1 out of 3 mice (Fig. AI-
6B).  This data suggests delivery of SOD1 to the spinal cord is possible, but the 
technique requires fine-tuning to increase the efficacy of delivery. 
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Figure AI-5. Mass spectrometry identifies Fluoro488-tagged species of 
SOD1. SOD1 proteins were subjected to LC-MS to identify the number of 
fluorescent tags covalently bound. (A) Analysis of unmodified WT SOD1 revealed 
one predominant species at 16,345 Da that is consistent with the actual mass 
(16,347 Da). This corresponds to the full length WT SOD1 with an additional 
“GPLGS” on the N-terminus that remains from the GST tag employed during 
purification. (B) WT SOD1 conjugated with Fluoro488 revealed 4 predominant 
species, unmodified (16,345 Da), WT SOD1 + 1 Fluoro488 (16,861 Da), WT 
SOD1 + 2 Fluoro488 (17,377 Da) and WT SOD1 + 3 Fluoro488 (17,893 Da). 
(C,D) Same analysis as described in (A) and (B) for unmodified (C) and modified 
(D) 24 h oxidized SOD1 subjected to mass spectrometry  analysis. 
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Figure AI-6. Osmotic pumps effectively deliver SOD1 protein to the spinal 
cord of implanted mice. An osmotic pump delivered SOD1 WT-Fluor488 to 
mice over a 3 day period. After 3 days, the mice were sacrificed and the spinal 
cord sectioned. (A) A Western analysis of homogenized lumbar (left) and cervical 
(right) spinal cord lysates confirmed the delivery of SOD1 WT-Fluor488 into the 
lumbar (mouse 2,3) and cervical (mouse 3) spinal cord.   (B) SOD1 fluorescence 
is detected in thoracic spinal cord tissue sections from mice infused with SOD1 
WT-Fluoro488 (LM=Light Microscopy). 
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Chronic delivery of misfolded SOD1 to mice results in no overt 
phenotype - To test the hypothesis that misfolded SOD1 delivered to the spinal 
cord of mice could result in an ALS-like phenotype, we filled 3 day osmotic 
pumps with SOD1 variants (PBS, n=3; WT SOD1, n=6; SOD1 G93A, n=3; SOD1 
OX, n=8) at a concentration of 1.5 mg/ml. The weight of the mice was monitored 
over time and they were visually inspected for signs of paralysis.  No other 
histological or diagnostic tests were performed. Approximately 9 months after 
surgical implantation of osmotic pumps, the mice revealed no visual signs of an 
ALS-like phenotype. Their weight continued to increase over the period assessed 
and no noticeable impairment was present (Figure AI-7).  
Conclusion 
Providing evidence that oxidized SOD1 can induce an ALS-like phenotype 
would be pivotal for ALS research, as it would demonstrate for the first time the 
ability of modified SOD1 to induce ALS pathology, bridging the gap between 
SALS and FALS. As of now, SOD1ox has been shown to be toxic when 
exogenously added to cultured cells (Ezzi et al. 2007, Rotunno et al. 2014). In 
addition, SOD1ox and WT SOD1 have been shown to be stable in osmotic 
pumps for >28 days and delivery to the spinal cord with these pumps is feasible. 
The chronic exposure of misfolded SOD1 to mice in this preliminary study did not 
elicit any ALS-like phenotype.  This is likely because: 1) Post-translational 
modifications induced by hydrogen peroxide (such as SOD1ox) delivered to the  
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spinal cord of mice is not sufficient to cause disease phenotype or 2) The SOD1 
concentrations assessed were too mild and did not recapitulate that of transgenic 
mouse models vastly overexpressing mutant SOD1 (Rudick et al. 1982, Gurney 
et al. 1994). It is quite likely a higher concentration of SOD1 would be required to 
induce a disease phenotype, as these ALS transgenic mouse models have over 
70 µg of mutant SOD1 present in their spinal cord.  It is vital to determine the 
concentration of recombinant FALS-linked SOD1 variants, such as SOD1 G93A, 
required to induce an ALS-like phenotype using the osmotic pump system to 
develop a baseline to assess aberrantly modified SOD1. As described in 
Chapter II, SOD1ΔIV/ΔVII represents the extreme, artificial case of misfolded 
SOD1, making it an interesting candidate to test for the ability to induce an ALS-
like phenotype in vivo in this pump assay as well. Another avenue to explore 
would be to assess exacerbation of disease onset and progression of an 
established ALS mouse model when delivering SALS-linked SOD1 variants via 
osmotic pumps. As of now, the causative agent of sporadic ALS has not yet been 
established. Obtaining a mouse model would enhance research by providing a 
means to further study the disease mechanism as well as to develop novel 
therapeutic agents to fight SALS.  
Materials and Methods 
SOD1 Activity Assay- SOD1 activity assay was performed essentially as 
previously described (Okado-Matsumoto and Fridovich 2001). Activity Assay 
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Buffer was prepared to reach a final concentration of 50 mM potassium 
phosphate buffer, 230 µM of Xanthine (Sigma, X7375-10G), and 100 µM of 
cytochrome C (Sigma, C2506-100mg). The assay was carried out in a standard 
96-well plate with 100 µl of buffer per well, followed by the addition of the 
specified concentration of protein. Xanthine oxidase (Roche, #10110434001) 
was added to the wells at a concentration of 0.01 units/mL directly preceding the 
absorbance reading. Samples were shaken for 10 seconds prior to measuring 
the absorbance.  Samples were read at 550 nm 12 times over a period of 5 
minutes. 
Preparation of protein for osmotic pumps – GST-tagged protein was purified 
essentially as previously described (Harper and Speicher 2011). The GST-tag 
was cleaved with preScission protease (GE Lifesciences, 27-0843-01). The 
SOD1 protein was concentrated to > 5 mg/mL and buffer exchanged to 0.1 M 
sodium bicarbonate at pH 8.3 for fluorescent tagging. Alexa Fluor 488 5-SDP 
ester was added to a final concentration of 0.5 mg/ml and the SOD1/tag mixture 
was incubated at room temperature for 2 h while rotating. Following the 
incubation, SOD1 was buffer exchanged into PBS. 
Protein delivery with osmotic pumps – All SOD1 proteins were in phosphate 
buffered saline and filter sterilized through a 0.22 µicron (Millipore, SLGV004SL) 
filter prior to usage. The osmotic pumps (Alzet; 1003D, 3 d pumps; 1004, 28 d 
pumps) were filled with approximately 100 µL of SOD1 with a 27G x 0.45” 
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syringe. A mouse intrathecal catheter (Alzet, #0007743) was attached to the top 
of the pump.  
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PREFACE TO APPENDIX II 
The data presented in Figure AII-5 and Table AII-1 was performed by Ye Shang. 
All other work presented was performed by Melissa S. Rotunno. 
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APPENDIX II: Reverting the ALS-linked Misfolded SOD1 to its Non-toxic 
Wild-Type Conformation  
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative 
disease characterized by a loss of voluntary movement over time, typically 
resulting in death within 3-5 years of diagnosis. As of now, there is only weak 
treatment available, extending survival by a mere 3-6 months. Approximately 
10% of ALS cases are inherited or familial (FALS), the majority of which are 
linked to mutations in C9orf72 and SOD1. However, much less is known about 
the cause(s) of sporadic ALS (SALS) that account for 90% of ALS cases. FALS 
and SALS are clinically indistinguishable, suggesting similar mechanisms 
underlie both forms of this disease. SOD1 (Cu,Zn-superoxide dismutase), an 
anti-oxidizing enzyme, represents one factor common to FALS and SALS, 
distinguishing it as a plausible therapeutic target.  Mutations in SOD1 cause ALS 
through a mechanism involving misfolding of the protein. Likewise, aberrant post-
translational modifications can cause non-mutated, wild-type (WT) SOD1 to 
adapt a similar misfolded conformation. A portion of post-mortem SALS spinal 
cord tissues possess misfolded WT SOD1 that, when purified exhibits mutant-like 
neurotoxic properties such as axonal transport inhibition. Together, these 
observations support the hypothesis that WT SOD1 plays a pathogenic role in 
SALS, analogous to the role of mutant-SOD1.   
 A conformation specific antibody, C4F6, preferentially reacts with ALS-
linked SOD1 variants in their native state (see Chapter II). C4F6 also recognizes 
aberrantly modified forms of WT-SOD1 that are present in post-mortem spinal 
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cord tissue from a subset of SALS patients not harboring a genetic mutation in 
SOD1 (Bosco et al. 2010). C4F6 suppresses the axonal transport inhibition 
caused by SOD1 purified from SALS spinal cord tissue, while other anti-SOD1 
antibodies do not. Together, these data suggest the epitope for C4F6 represents 
an exposed pathogenic motif within misfolded SOD1.  
Instead of treating the downstream effects in patients with misfolded 
SOD1, we hypothesize that directly reverting ALS-linked SOD1 to its wild-type 
conformation will attenuate disease progression. Our studies aim to identify small 
molecules to repair misfolded SOD1, as indicated by a loss of C4F6 reactivity. 
Using high-throughput ELISAs, we identified several promising compounds with 
therapeutic potential, the most intriguing of which has been shown to bind and 
decrease SOD1 aggregation in a prior study (Banci et al. 2012a). Currently, we 
are investigating the ability of these compounds to repair SOD1 misfolding and 
curb the toxic properties of ALS-linked SOD1 in hopes of establishing an 
effective therapy for patients suffering from ALS. 
Six small molecules have the potential to revert misfolded SOD1 to 
its WT-like fold. A sandwich ELISA (initial C4F6-ELISA) directed at misfolded 
SOD1 was used to identify compounds that could repair the protein. The C4F6 
reactivity of SOD1 preincubated with compounds was quantified using the initial 
C4F6-ELISA (Fig. AII-1). The compound library (LOPAC®1280, Sigma) consists 
of 1280 compounds that include pharmacologically active compounds and 
diverse chemical structures. Hits were identified as compounds that resulted in a  
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Figure AII-1. Initial small molecule screen, LOPAC®1280, identifies six 
compounds capable of reducing C4F6-ELISA signal. The binding of SOD1 
G93A, a misfolded form of SOD1, to C4F6 in the presence of 1280 different 
compounds was assessed by employing the initial C4F6-ELISA. C4F6 reactivity 
was normalized to SOD1 G93A alone, the negative control. The key to the left 
illustrates the color gradient used in the analyses, where 1 (white) indicates no 
change and 0 (red) indicates a complete loss of C4F6 binding. On the right, all 16 
ELISA plates are illustrated with the color gradient indicating the change in C4F6 
reactivity compared to SOD1 G93A alone.  Each column represents a separate 
96-well plate subjected to the initial C4F6-ELISA. Compounds with greater than 
75% loss in C4F6 binding were considered lead compounds. Six compounds 
from this screen fit this criteria and were selected for additional analyses.  
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>75% reduction in C4F6 binding, when compared to SOD1 G93A reactivity 
alone.  Six compounds were selected for further validation based on this criteria 
(Figure AII-1). 
 Dose-response curve identifies one compound that reproducibly 
results in loss of C4F6 reactivity. The six initial compounds were tested in a 
dose-response curve to determine if the initial results in the screen were 
reproducible. One out of the six compounds, MRS2211 (Drug A, Figure AII-2) 
showed reduction in C4F6-ELISA signal that correlated with increasing drug 
concentration. Being that MRS2211 contains a phosphate group on the 
molecule, one possibility is that the phosphate group is interfering with the 
alkaline phosphatase enzyme, as phosphate inhibits its activity. To eliminate this 
possibility, an identical ELISA was performed with this compound using horse 
radish peroxidase (HRP) conjugated anti-mouse as the secondary antibody 
instead of alkaline phosphatase. The HRP-based ELISA produced similar results 
where increasing concentrations of MRS2211 resulted in a decrease in C4F6 
reactivity suggesting that the signal reduction is not due to interference in the 
alkaline phosphatase enzyme itself (Figure AII-3).  Next, we wanted to test 
whether or not MRS2211 produced a loss of C4F6 reactivity for other SOD1 
variants as well. Dose-response curves with SOD1 G93A and G85R show that 
increasing concentrations of MRS2211 result in loss of ELISA signal (Fig. AII-4). 
Despite the promising data produced by these ELISAs, we were unable to detect 
any  binding   between  SOD1  G93A  and  MRS2211   with  isothermal   titration  
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Figure AII-2. Independent verification of lead compounds with a Dose-
Response analysis. The ability of lead compounds to disrupt C4F6 binding to 
SOD1 G93A in the presence of the six initial lead compounds identified in the 
LOPAC®1280 screen was assessed by C4F6-ELISA with AP-conjugated 
antibody as the detection method (initial C4F6-ELISA). SOD1 G93A was pre-
incubated with the indicated compounds prior to analyses. One (Drug A, 
MRS2211) out of the 6 initial hits demonstrated a reduction in SOD1 G93A 
binding to C4F6.  
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Figure AII-3. Verification of the lead compound, MRS2211, using an 
alternative sandwich ELISA approach. C4F6 reactivity assessed in the 
presence of either WT or SOD1 G93A with increasing concentrations of 
MRS2211. The optimized C4F6-ELISA was employed for verification. SOD1 
G93A pre-incubated with MRS2211 induces a loss of C4F6 binding as 
demonstrated by both the alkaline phosphatase (A) and horseradish peroxidase 
(B) ELISA formats with an EC50 of approximately 10 µM. This loss of C4F6 
reactivity suggests MRS2211 has the potential to revert SOD1 G93A to a “WT-
like” conformation. 
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Figure AII-4. MRS2211 attenuates C4F6 reactivity in all ALS-linked SOD1 
variants tested. The optimized HRP C4F6-ELISA was employed to assess 
C4F6 reactivity of FALS-linked SOD1 variants in the presence of MRS2211. In 
addition to SOD1 G93A, both ALS-linked mutations SOD1 G85R and A4V 
demonstrate a reduction in C4F6 binding when pre-incubated with MRS2211 
([SOD]=0.3 µM). 
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calorimetry experiments (ITC) and, therefore, conclude that the drug was 
interfering with the coating antibody and not binding SOD1 directly. 
Employing an optimized C4F6-ELISA to identify novel compounds with the 
potential to repair misfolded SOD1. The C4F6-ELISA employed in Figure AII-
1 and AII-2 exhibited a high signal to noise ratio. This resulted in huge limitation 
of the initial compound screen to detect promising compounds (Fig. AII-1). The 
sandwich C4F6-ELISA antibodies were further optimized to enhance the signal to 
noise ratio (compare the C4F6 reactivity values from Figure AII-2 (initial C4F6-
ELISA, 0.16) and Figure AII-3 (optimized C4F6-ELISA, 1.0). Also, horseradish 
peroxidase was used as an enzymatic read-out in place of the alkaline 
phosphatase as it demonstrated less well-to-well variability. All told, these 
optimizations increased the signal to noise ration from 2:1 (initial C4F6-ELISA) to 
greater than 10:1 (optimized C4F6-ELISA, Fig. III-1). We repeated the same 
LOPAC screen as discussed above employing the optimized C4F6-ELISA to 
identify potential compounds to repair misfolded SOD1 G93A ([SOD1]=0.04 µM, 
[Drug]=10 µM). As illustrated in Figure AII-5, a significant reduction in overall 
background was observed. The improved screen identified 9 potential candidates 
that resulted in a greater than 50% reduction in C4F6 reactivity (Fig. AII-5). None 
of these 9 hits were identified in the initial compound screen (Fig. AII-1). A dose-
response curve with SOD1 G93A generated from these hits demonstrated a 
reproducible reduction in C4F6 reactivity in 7 out of the 9 compounds tested (Fig. 
AII-5B). To eliminate the compounds that directly interfered with the ELISA  
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Figure AII-5. Optimized C4F6-ELISA identifies 6 potential compounds to 
repair misfolded SOD1. (A) A summary of the LOPAC screen for molecules that 
result in a loss of C4F6 binding (0, complete loss of C4F6 binding; 1, no change). 
All samples were normalized to SOD1 G93A alone, the negative control. “Hits” 
were compounds that resulted in a >50% decrease in signal compared to SOD1 
G93A alone. (B) The initial 9 hits were tested in a dose-response curve with 
SOD1 G93A. Seven out of the 9 initial hits were able to decrease absorbance at 
450 nm, suggesting a loss of C4F6 binding. (C) The confirmed 7 hits were tested 
in an ELISA with SOD1 G93A for total SOD1. Six out of 7 compounds had no 
effect on total SOD1 concentration. One compound resulted in a loss of total 
SOD1, suggesting that it is interfering with the ELISA itself and not repairing the 
SOD1 misfolding.  
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assay, we assessed these 7 compounds in an SOD1 ELISA with WT SOD1 that 
detects total SOD1 using an independent set of antibodies. One out of the 7 
compounds, 13 B04, interfered with the detection of WT SOD1 in a dose-
dependent manner (Fig. AII-5C). In summary, 6 compounds have been identified 
that have the potential to repair misfolded SOD1 but further testing, such as ITC, 
is required to assess the extent of SOD1 binding. 
Discussion 
  In this preliminary study, six compounds have been identified with the 
potential to repair misfolded SOD1 (Table AII-1). With the exception of Cisplatin, 
all compounds contain a benzene ring with at least one hydroxyl group attached, 
suggesting this structural moiety is conducive to binding SOD1.  The structural 
outlier, Cisplatin, is a known binder of SOD1 that interferes with the formation of 
high molecular weight SOD1 aggregates (Banci et al. 2012a). Cisplatin is also a 
common chemotherapy agent. In fact, the resistance of ovarian cancer cells to 
cisplatin-induced apoptosis is linked to an upregulation of the SOD1 protein 
(Brown D. P. et al. 2009, Kim et al. 2010).   
It is important to further validate these compounds since a reduction in 
C4F6 reactivity does not definitively indicate a reparation of SOD1 misfolding. 
The possible reasons for a loss of C4F6 signal include i) binding and stabilizing 
the SOD1 protein thereby decreasing exposure of the C4F6 epitope, ii) binding to  
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Table AII-1. Promising compounds identified in C4F6-ELISA LOPAC Screen 
Compound Rack # C4F6-ELISA Signal Decrease (%) 
Initial Screen Validation 
Aurintricarboxylic acid 
 
 
01 F05 81.2 84.1 
Benserazide hydrochloride 
 
 
03 H04 72.3 64.4 
6-hydroxy-DL-DOPA 
 
 
08 H04 88.4 90.4 
Methyl-3,4-dephostatin 
 
 
11 H02 82.7 79.7 
Cisplatin 
 
 
12 D09 92.7 50.7 
Tyrphostin 47 
 
 
16 C02 51.2 52.9 
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SOD1 and inducing protein precipitation, iii) competing with C4F6 in the 
same binding pocket, with no effect on SOD1 conformation,  iv) competing with 
the detection antibody for the same binding region on SOD1, or v) interfering with 
the coating of C4F6 directly onto the ELISA plate. Future studies are required to 
determine whether or not these compounds have the ability to repair misfolded 
SOD1 directly. Initially, ITC can be performed to determine the kinetics of this 
binding interaction. To test the extent these compounds repair and stabilize the 
fold of SOD1, we could assess the effects of the compounds on aggregation 
propensity, melting temperature, and urea denaturation of SOD1. We can also 
determine whether these compounds reduced the SOD1-induced activation of 
microglia, as described in Chapter II. We can determine if treatment with these 
compounds in in vivo ALS transgenic mouse models alters onset and 
progression of disease. Alternatively, approaches identifying proteins and/or 
genes with the ability to revert misfolded SOD1 to its wild-type conformation 
should be explored. One can imagine that employing siRNA screens for a loss of 
C4F6 binding in cell culture systems could be a powerful tool for identifying 
mechanisms that induce SOD1 misfolding in ALS.  
Materials and Methods 
C4F6-ELISA for initial small molecule screen - The plate was coated with a 
polyclonal anti-SOD1 (Binding Site, PC077). Then SOD1 G93A (0.3 µM) pre-
incubated with small molecules (5 µM) were added to the plate and incubated for 
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1 h. Then C4F6 antibody at 0.6 µg/mL was added to detect misfolded SOD1. 
Alkaline phosphatase (AP) conjugated or HRP-conjugated anti-mouse antibody 
was used to quantify the reaction. Absorbance at 450 nm was recorded.   
C4F6-ELISA for optimized small molecule screen – See Chapter III, Materials 
and Methods for C4F6-ELISA protocol details. The screen was performed with 
SOD1 at a concentration of 0.04 µM and compound at 10 µM. 
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PREFACE TO APPENDIX III 
My contribution to the published work was the purification of human SOD1 
protein from human tissue using immunoprecipitation techniques described 
herein.  
The following is reproduced with permission from: 
 Auclair, J.R., Johnson, J.L., Liu, Q., Salisbury, J.P., Rotunno, M.S., Petsko, 
G.A., Ringe, D., Brown Jr., R.H., Bosco, D.A., Agar, J.N. “Post-translational 
Modification by Cysteine Protects Cu/Zn-Superoxide Dismutase from Oxidative 
Damage.” Biochemistry. 2013, 52, 6137-44.  
 Copyright 2013 American Chemical Society.  
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APPENDIX III: Post-translational modification by cysteine protects Cu/Zn-
superoxide dismutase from oxidative damage. 
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PREFACE TO APPENDIX IV 
All work was performed by Melissa S. Rotunno. 
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APPENDIX IV: Cysteinylation of SOD1 may protect against misfolded SOD1 
As described in detail in Appendix III, cysteinylation of SOD1 may be an in vivo 
mechanism to avoid the presence of misfolded SOD1 induced by oxidation. 
Cysteinylated SOD1 is less likely to be oxidized and demonstrates an increase in 
overall stability of the protein compared to oxidized SOD1 (Auclair et al. 2013a). 
To assess the extent of reparation of the fold of SOD1 induced by cysteinylation, 
SOD1 variants were cysteinylated, run on a native PAGE, and probed with the 
C4F6 antibody. The C4F6 antibody demonstrates a decrease in reactivity in 
SOD1 G93A, G85R, and ΔIV/ΔVII upon cysteinylation (Fig. AIV-1). This supports 
the protective role of cysteinylation in SOD1 folding, described in Appendix III.   
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Figure AIV-1. Cysteinylation of recombinant SOD1 results in a decrease in 
C4F6 reactivity. (A) Recombinant SOD1 variants incubated with 4-fold molar 
excess of cysteine for 16 h were assessed for C4F6 reactivity by Native PAGE 
western analysis. Cysteinylated variants demonstrate a decrease in C4F6 
reactivity. (B) Quantification of analysis described in (A) where each variant is 
normalized to the “no cys” counterpart. 
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